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Chapter 1
General introduction 
and outline of thesis
Adapted from: 
Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJ, Frangioni JV. Image-guided 
cancer surgery using near-infrared fl uorescence, Nat Rev Clin Oncol. 2013 Sep;10(9):507-18
Verbeek FP, van der Vorst JR, Schaafsma BE, Hutteman M, Bonsing BA, van Leeuwen FW, 
Frangioni JV, van de Velde CJ, Swijnenburg RJ, Vahrmeijer AL. Intraoperative near-infrared 
fl uorescence imaging in hepato-pancreatobiliairy surgery, J Hepatobiliary Pancreat Sci. 2012 
Nov;19(6):626-37
Schaafsma BE, Mieog JS, Hutteman M, van der Vorst JR, Kuppen PJ, Löwik CW, Frangioni JV, van 
de Velde CJ, Vahrmeijer AL. The clinical use of indocyanine green as a near-infrared fl uorescent 
contrast agent for image-guided oncologic surgery. 
J Surg Oncol. 2011 Sep 1;104(3):323-32
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Paradigm shifts in surgery arise when surgeons are empowered to perform surgery 
faster, better, and/or less expensively than current standards. For most solid tumors, 
surgical resection remains the only curative treatment. Improvements in preoperative 
imaging techniques have made a meaningful impact on cancer patient care. 
However, the determination of a safe resection margin and the assessment of distant 
metastases during surgery can be challenging since only a limited number of tools are 
available intraoperatively. For certain indications such as colorectal liver metastases, 
intraoperative ultrasound is being used to identify tumors.1 However, during most 
cancer surgeries, the eyes and hands of the surgeon remain the dominant ”imaging 
modalities” used to decide which tissue needs to be resected, i.e., malignant cells, and 
which tissue needs to be avoided, i.e., normal cells. Palpation and visual inspection 
are not always sufficient for discriminating between tissue types, though, leading 
to irradical resections or unnecessary removal of healthy tissue. Unfortunately, this 
results in relatively high occurrence of irradical tumor resections and high recurrence 
rates. In breast cancer, for example, many of which are non-palpable, margin positivity 
rates range from 5 to 49%2,3 and local recurrence rates following breast-conservative 
therapy of 6.7 to 11% are reported.4 Furthermore, the identification of vital structures 
(e.g. nerves, ureters, bile ducts) during surgery, which is imperative to minimize 
comorbidity, can be challenging. These gaps in surgical techniques and surgical 
management of cancer patients show that there is a need for imaging modalities 
that can provide surgeons with real-time visual information during surgery about the 
location of tissues to be resected and tissues to be spared.  
Near-infrared fluorescence optical imaging
Medical imaging is generally based on and also used for obtaining contrast between 
tissues of interest and surrounding tissues. In this perspective, two different contrast 
methods can be distinguished: endogenous and exogenous contrast methods. 
Endogenous contrast methods use natural optical properties of tissue where 
exogenous contrast methods necessitate the administration of contrast agents. A 
typical example of a endogenous contrast method is measuring the oxygenation 
status of tissue by using the absorbing properties of by oxygen saturated hemoglobin 
or using ultrasound waves for the detection of liver metastases. However, with regards 
to tumor imaging or imaging of vital structures, endogenous contrast methods often 
suffer from low sensitivity, specificity and low resolution. For this purpose, exogenous 
contrast methods are more feasible in most cases. 
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 Exogenous methods using fluorescence are based on the administration 
of a contrast agent with fluorescent properties (a fluorophore). Over the past several 
years, intraoperative imaging using invisible near-infrared (NIR) fluorescent light 
has entered the surgical theatre to fill the gap between preoperative imaging and 
intraoperative reality.5-7 Near-infrared (NIR) fluorescence optical imaging is a technique 
that is based on the use of fluorophores and invisible light ranging from 700 to 900 nm 
in wavelength. Whereas visible light penetrates tissue on a micron scale, NIR light (700 
nm - 900 nm) can travel millimeters, up to centimeters, through tissue.8 Because tissue 
exhibits almost no autofluorescence in the NIR spectrum, the signal-to-background 
can be maximized using NIR fluorescent contrast agents, creating “white stars in a 
black sky”.9,10 In addition, it does not use ionizing radiation, making it an inherently 
safe technique provided that attention is paid to laser illumination levels. And, as NIR 
light is invisible to the human eye, it does not alter the look of the surgical field, thus 
minimizing the learning curve. Specialized intraoperative imaging systems for open 
surgery11-17, laparoscopy18,19, thoracoscopy20,21, and robotic surgery22,23 have recently 
become available for clinical trials. Using these systems, NIR fluorescent contrast 
agents can be visualized with acquisition times in the millisecond range, enabling 
real-time guidance during surgery (Figure 1). 
Sentinel lymph node imaging
Sentinel lymph node (SLN) mapping, introduced for the management of cutaneous 
melanoma by Morton et al.24, is nowadays standard-of-care in a variety of cancers, 
including breast cancer and cutaneous melanoma. Currently, most centers perform 
SLN mapping using a radioactive tracer, a visible blue dye such as isosulfan blue 
or patent blue, or a combination of the two. Although in most cases acceptable 
results are obtained using these methods, they both have some drawbacks. 
Visible blue dyes stain the patient and the surgical field and cannot be visualized 
below the surface of tissue. Thereby, tattooing of the skin can last for months after 
surgery. Radioactive tracers expose patients and caregivers to ionizing radiation, 
are expensive, and imaging suffers from poor spatial and temporal resolution. For 
SLN mapping using NIR fluorescence imaging, contrast agents are injected at a low 
concentration with no staining of the surgical field, no ionizing radiation is used, 
and an improvement is observed over blue dyes in terms of depth sensitivity. 
























Figure 1 - The mechanics of NIR fl uorescence imaging
The mechanics of NIR fl uorescence imaging. NIR fl uorescent contrast agents are administered intravenously, 
topically or intraparenchymally. During surgery, the agent is visualized using an NIR fl uorescence imaging 
system of the desired form factor (above the surgical fi eld for open surgery, or encased within a fi berscope 
for minimally-invasive and robotic surgery). All systems must have adequate NIR excitation light, collection 
optics, fi ltration and a camera sensitive to NIR fl uorescence emission light. An optimal imaging system 
includes simultaneous visible (white) light illumination of the surgical fi eld, which can be merged with the 
generated NIR fl uorescence images. The surgeon’s display can be one of several form factors, including a 
standard computer monitor, goggles or a wall projector. Current imaging systems operate at a suffi  cient 
working distance that enables the surgeon to operate and illuminates a sizable surgical fi eld. Abbreviations: 
LED, light-emitting diode; NIR, near-infrared. 
 For SLN mapping, targeted contrast agents are not necessary. Since 
indocyanine green (ICG) is the only 800 nm NIR fl uorescent contrast agent that is 
approved for sentinel lymph node mapping by the Food and Drug Administration 
(FDA) or the European Medicines Agency (EMA), many SLN studies were undertaken 
as soon as the fi rst intraoperative imaging systems became available. Numerous 
clinical studies have shown feasibility of NIR fl uorescence imaging using ICG for the 
SLN procedure in breast cancer15,25, gastrointestinal cancers26,27, prostate cancer 19 and 
other tumor types28. A few research groups premixed ICG with human serum albumin 
(HSA; complex is ICG:HSA) to improve retention in the fi rst draining lymph node and 
to increase fl uorescence. However, no advantage of using ICG:HSA over ICG alone 
was shown in breast cancer25, cervical cancer29 and vulvar cancer30. Another approach 
is the combined use of radioactive nanocolloids and ICG.  This combination permits 
preoperative planning and intraoperative localization of deeply located SLNs with 
direct optical guidance by a single lymphatic tracer. Several proof of principle studies 
showed the feasibility of using the ICG-99mTc-nanocolloid19,28,31.




One of the key applications in cancer surgery is intraoperative tumor visualization. 
In order to visualize tumors using NIR fluorescence imaging, a contrast agent should 
accumulate in or around a tumor. To date, NIR fluorescent contrast agents specific for 
many different targets have been developed, including agents for cancer cells32-34, 
sentinel lymph nodes28,35,36, neurological diseases37,38, cardiovascular diseases39,40, 
skeletal processes41, renally cleared agents for ureter imaging42, and hepatically 
cleared agents for bile duct imaging43,44. Optically-active nerve cell agents have 
also been described, but are yet to achieve NIR wavelengths.45,46 Although a variety 
of tumor specific NIR fluorescent contrast agents have been applied preclinically, 
none of these has obtained full clinical approval by either the FDA or EMA. 
Intraoperative NIR fluorescence imaging depends on the availability of a NIR 
fluorescent contrast agent and an intraoperative imaging system to visualize the 
otherwise invisible contrast agent during surgery.7 As stated before, ICG is the 
only 800 nm NIR fluorescent contrast agent that is approved for near-infrared 
fluorescence imaging. Methylene blue (MB) has been applied clinically for many 
years as a visible (dark blue) contrast agent. As MB was introduced into clinical 
practice in an era were no formal approval was needed, no evaluation by the 
FDA, EMA, or comparable authorities has been performed, but it remains widely 
used. When sufficiently diluted, MB acts as a 700 nm fluorophore. ICG is clinically 
used to test the clearance capacity of the liver and MB is used for the macroscopic 
identification of ureters and parathyroid glands. These agents can be successfully 
deployed using naturally occurring mechanisms of the human body, which result 
in accumulation of the agent. Using ICG and MB first-in-human intraoperative 
tumor imaging studies have been published in various cancer types.47-51 A 
disadvantage of both fluorophores however is the inability to conjugate them to 
tissue-specific ligands such as an antibody or peptide. Novel NIR fluorophores have 
been developed which can be easily conjugated to targeting ligands (antibodies, 
nanobodies, peptides) using straightforward chemistry techniques and have 
optimized fluorescent properties.  Using these ‘targeting’ fluorophores, several 
preclinical studies have been performed to identify tumors during surgery. 
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OUTLINE OF THE THESIS
This thesis is divided in three parts; Part I focuses on preclinical validation of NIR 
fluorescence imaging of solid tumors and tumor metastases, Part II describes the clinical 
use and optimization of NIR fluorescence for the sentinel lymph node procedure and 
Part III describes the clinical introduction of NIR fluorescent imaging of solid tumors.
Part I, chapter 2 describes the intraoperative use of indocyanine green 
(ICG) administered at different time-points in different doses for NIR fluorescence 
imaging of colorectal liver metastases in an experimental rat model. Chapter 3 
describes the use of a NIR fluorescent nanobody targeting the EGF-receptor in 
an experimental orthotopic tongue tumor mouse model. Chapter 4 shows the 
successful use of the novel cRGD-ZW800-1 probe in a subcutaneous and orthotopic 
colon cancer mouse model. 
 Part II shows the use of NIR fluorescence imaging and ICG premixed with 
human serum albumin (complex: ICG:HSA) for SLN mapping in vulvar cancer in 
chapter 5 and cervical cancer in chapter 6. A randomized comparison of ICG with 
or without premixing with HSA in cervical cancer patients was reported in chapter 
7. Chapter 8 demonstrates the use of ICG:HSA and NIR fluorescence in melanoma 
patients. Chapter 9 shows the use of NIR fluorescence imaging for SLN mapping in 
head and neck cancer patients. Chapter 10 demonstrates a randomized comparison 
of using ICG with or without patent blue for SLN mapping in breast cancer patients. 
Part III, chapter 11 reports the clinical use of NIR fluorescence imaging and 
ICG to identify occult otherwise missed colorectal liver metastases during surgery. 
Chapter 12 demonstrates the attempt to intraoperatively visualize pancreatic 
tumors after an intravenous injection of ICG. Besides, NIR fluorescence imaging 
of bile ducts was explored. Chapter 13 describes the use of NIR fluorescence and 
methylene blue for the intraoperative identification of parathyroid adenomas. 
Chapter 14 describes a patient suffering from a solitary fibrous tumor of the 
pancreas, which was intraoperatively clearly visualized using NIR fluorescence and 
methylene blue for the first time in literature. 
Finally, all results are summarized and discussed and future perspectives 
are given in chapter 15.
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Chapter 2
Near-Infrared fl uorescence imaging 
of liver metastases in rats using 
indocyanine green 
van der Vorst JR, Hutteman M, Mieog JS, de Rooij KE, Kaijzel EL, Lowik CW, 
Putter H, Kuppen PJ, Frangioni JV, van de Velde CJ  and Vahrmeijer AL
J Surg Res. 2012 May 15;174(2):266-71





Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) is a 
promising technique to obtain real-time assessment of the extent and number 
of colorectal liver metastases during surgery. The current study aims to optimize 
dosage and timing of ICG administration. 
Material and methods
Liver tumors were induced in 18 male WAG/Rij rats by subcapsular inoculation of 
CC531 rat colorectal cancer cells into three distinct liver lobes. Rats were divided 
in 2 groups: imaging after 24 and 48 hours or 72 and 96 hours after intravenous 
ICG administration. In each time group, rats were allocated to three dose groups: 
0.04, 0.08, or 0.16 mg ICG. Intraoperative imaging and ex vivo measurements 
were performed using Mini-FLARETM and confirmed by fluorescence microscopy. 
Fluorescence intensity was quantified using the Mini-FLARE software and the 
difference between tumor signal and liver signal (tumor-to-liver ratio; TLR) was 
calculated.
Results
In all 18 rats, all colorectal liver metastases (N = 34), some as small as 1.2 mm, were 
identified using ICG and the Mini-FLARETM imaging system. Average tumor-to-liver 
ratio (TLR) over all groups was 3.0 ± 1.2. TLR was significantly higher in the 72 h time 
group compared to other time points. ICG dose did not significantly influence TLR, 
but a trend was found favoring the 0.08 mg dose group. Fluorescence microscopy 
demonstrated a clear fluorescent rim around the tumor. 
Conclusions
This study demonstrates that colorectal cancer liver metastases can be clearly 
identified during surgery using ICG and the Mini-FLARETM imaging system, with 
optimal timing of 72 h post-injection and an optimal dose of 0.08 mg (0.25 mg/
kg) ICG. NIR fluorescence imaging has the potential to improve intraoperative 
detection of micrometastases and thus the completeness of resection. 
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INTRODUCTION
With a worldwide annual incidence of approximately 1 million cases and an annual 
mortality of over 500.000 cases, colorectal cancer is the second cause of cancer 
death worldwide.1 The survival of patients with colorectal carcinoma is mostly 
determined by the occurrence of distance metastases. Approximately 30% of 
patients with CRC eventually develop liver metastases.2,3 When metastases are 
confined to the liver and are resectable, surgical resection can offer a 5-year survival 
rate of 35-40%.3,4 Despite improved surgical techniques, preoperative imaging 
modalities and improved chemotherapy regimens, intrahepatic recurrence rates 
vary from 11-26%.5-8 This is possibly due to an inadequate assessment of the extent 
of disease before and during liver surgery. Currently, the most frequently used 
imaging modalities to make this assessment are computed tomography (CT) and 
intraoperative ultrasonography (IOUS). However, even with the combined use of 
these modalities, 6-20 % of liver metastases can not be identified.9-11 In particular, 
the detection of small (< 5 mm) liver metastases and superficially located liver 
metastases appears to be difficult.11 New imaging modalities are necessary to 
facilitate a more complete assessment of the extent of disease. 
Near-infrared (NIR) fluorescence imaging is a promising technique to 
intraoperatively assess the extent of colorectal liver metastases. Recently, Ishizawa 
and colleagues12 have shown that primary hepatocellular carcinoma and colorectal 
liver metastases could be identified using NIR fluorescence imaging and the NIR 
fluorescent agent indocyanine green (ICG). Colorectal liver metastases could be 
identified by a fluorescent rim around the metastases. They hypothesized that this 
distinct fluorescent pattern is probably based on biliary excretion disorders in the 
surrounding normal liver tissue that is compressed by expanding pressure of the 
tumor. In their study of 49 patients, a fixed dose of 0.5 mg/kg ICG was administered 
preoperatively as part of a routine ICG clearance test, which is commonly used in 
Asia to plan the safe extent of hepatectomy. The interval between administration 
of ICG and surgery varied between 1 to 7 days. Consequently, the optimal dose of 
ICG and time of administration before surgery remain unclear. 
The goal of our study was to determine the optimal ICG dose and 
administration time before surgery, using a syngeneic rat model of colorectal 
cancer metastases in conjunction with the Mini-FLARETM image-guided surgery 
system. 





The colorectal cancer rat CC531 cell line was used for this study. The cell line and the 
induction of liver metastases have been described previously.13 In short, cells were 
cultured in RPMI 1640 supplemented with 2 mM L-glutamine (Gibco, Invitrogen Ltd, 
Carlsbad, USA), 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 0.1 
mg/ml streptomycin sulfate. In order to induce liver metastases, CC531-syngeneic 
male WAG/Rij rats (Harlan, Horst, the Netherlands) weighing approximately 300-
350 g underwent median laparotomy and the liver was mobilized and exposed. 
Subsequently, 125,000 CC531 cells (in 50 µl PBS) were subcapsularly inoculated into 
the left and right main liver lobes and the right accessory liver lobe.13 Four weeks after 
inoculation, metastases ranging from 1.2 to 13.4 mm in size had originated in the liver. 
The weight of the animals was followed throughout the experiment to 
monitor their general health state. Throughout tumor inoculation, injection of 
ICG and imaging, the animals were anesthetized with 5% isoflurane for induction 
and 2% isoflurane for maintenance in oxygen with a flow of 0.8 L/min. During 
anesthesia, the respiration rate was constantly monitored. For postoperative 
analgesia, the analgesic buprenorphine (0.1 mg / kg) was used.  The Animal Welfare 
Committee of the Leiden University Medical Center approved the experiments. 
All animals were housed in the animal facility of the Leiden University Medical 
Center. Pellet food and fresh tap water were provided ad libitum.
NIR fluorescent contrast agent
The clinically available NIR fluorescent contrast agent ICG (Pulsion Medical Systems, 
Munich, Germany) was used. Three ICG dose groups were tested: 0.04, 0.08 and 0.16 
mg. Before injection, ICG powder was resuspended in 200 µL sterile water. 
Intraoperative NIR fluorescence imaging system
Imaging of liver metastases was performed using the Mini-FLARETM imaging system 
(Troyan et al., manuscript under review), which is a miniaturized version of the 
FLARE™ imaging system.14 Briefly, the system consists of two wavelength-isolated 
light sources: a “white” light source, generating 26,600 lx of 400-650 nm light and a 
“near infrared” light source, generating 7.7 mW/cm2 of 760 nm light. Color video and 
NIR fluorescence images are simultaneously acquired and displayed in real-time 
using custom optics and software that separate the color video and NIR fluorescence 
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images. A pseudo-colored (lime green) merged image of the color video and NIR 
fluorescence images is also displayed. The imaging head is attached to a flexible 
gooseneck arm, which permits positioning of the imaging head virtually anywhere 
over the surgical field, and at extreme angles. 
Experimental design
In a time-dependent and dose-dependent experiment, NIR fluorescence imaging 
was performed in 18 tumor-bearing rats. To minimize surgery-related trauma 
and distress, rats were divided in two groups: imaging after 24 and 48 hours, and 
imaging after 72 and 96 hours of ICG administration. In each time group, rats were 
allocated to three dose groups of 0.04, 0.08, or 0.16 mg ICG, which was administered 
intravenously via the penile vein. Each dose group contained 3 rats. ICG dose 
levels were chosen based on clinically relevant doses using human body weight 
and correspond to doses of 10, 20 and 40 mg of ICG. The imaging time-points 
were chosen based on Ishizawa et al. 12 who reported NIR fluorescence imaging 
is preferably performed at least 24 hours after ICG administration. Furthermore, 
for clinical translation, these time-points must be logistically acceptable to use in 
a clinical setting. For intraoperative imaging, the liver and other intra-abdominal 
organs were exposed after median laparotomy. After the first intraoperative imaging 
session (24 or 72 hours after ICG administration), the abdomen was closed in two 
layers and the animal was imaged again 24 hours later. At all time-points, tumor 
fluorescence and fluorescence of abdominal organs was measured.
Data analysis
NIR fluorescence data generated with the Mini-FLARETM system were analyzed using 
the Mini-FLARETM software package. Regions-of-interest were drawn on the outline 
of the tumor, liver, kidney, spleen, stomach, small bowel, colon and bladder as traced 
manually by visual interpretation on the white light image. Subsequently, fluorescence 
intensity was automatically calculated and exported to statistical analysis software. 
Fluorescence microscopy
After intraoperative imaging experiments at 48 or 96 hours, the liver was excised 
completely for ex vivo fluorescence measurements. Subsequently, liver tumors 
were sliced in two to examine internal fluorescent patterns using the Mini-FLARETM 
system. Excised tumor slices were snap-frozen on dry ice and stored at -80ºC or were 
fixed in 10% buffered formalin overnight, washed in 70% ethanol and subsequently 
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embedded in paraffin. Frozen tissue sections were measured for fluorescence 
using the Nuance multispectral imager (CRi, Woburn, MA) mounted on a Leica 
DM IRE2 inverted microscope (Leica, Wetzlar, Germany) and subsequently stained 
with hematoxylin and eosin. White light images where created using the same 
microscope and subsequently merged with fluorescence images.
Statistical analysis
Statistical analysis and generation of graphs were performed using GraphPad Prism 
Software (version 5.01, La Jolla, USA) and SPSS (version 17.0). Fluorescence intensity 
and tumor size were reported as mean and standard deviation. To test differences 
between dose groups and time groups, repeated measures ANOVA was used 
with rat as random factor and dose, time, and dose by time interaction as fixed 
effects. When the dose by time interaction was not significant, it was subsequently 
removed from the model. Comparisons between doses and between time points 
were performed using least square difference (LSD) adjustment for multiple testing. 
Statistical tests were two-tailed and p < 0.05 was considered significant.
RESULTS
Intraoperative detection of colorectal liver metastases
In 18 rats, syngeneic colorectal liver metastases were induced using the colorectal 
cancer rat cell line CC531. The mean number of metastases per rat was 1.8 ± 0.8 
(range 1 – 3). The mean size of the liver metastases was 5.2 ± 0.3 mm (range 1.2 – 
13.4 mm). In all 18 rats, all colorectal liver metastases (N = 34) were identified using 
ICG and the Mini-FLARETM imaging system (Fig. 1). 
Dose of ICG and time of intraoperative imaging
To determine the influence of ICG dosage and time of imaging, rats were allocated 
to three dose groups and imaged at four time points and tumor-to-liver ratios (TLRs) 
were calculated. At all time-points (24, 48, 72 and 96 hours) and in all dose groups 
(0.04, 0.08 and 0.16 mg), fluorescence intensity of liver metastases was significantly 
higher than the fluorescent intensity of normal liver tissue (P < 0.001). Average TLR 
over all groups was 3.0 ± 1.2. The highest average TLR (4.3 ± 1.8) was reached in the 
0.08 mg dose group and 72 h after intravenous administration (Fig. 2C). 
 Repeated measures ANOVA was used to test for differences in TLR 
between dose and time groups. There was a significant effect of time (P < 0.001), 
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but the effects of dose (P = 0.12) and dose by time interaction (P = 0.91) were 
not significant. Dose by time interaction was therefore removed from the model. 
Consequently, the model included rat as random factor and dose and time as 
fixed effects. This model showed that the TLR was significantly higher in the 72 h 
time group compared to the 24 h (P < 0.001), 48 h (P = 0.001) and 96 h (P = 0.004) 
time groups (Fig. 2D). Also, the TLR was significantly higher in the 96 h time group 
compared to the 24 h group (P = 0.049). ICG dose did not significantly influence 
TLRs, but a trend was found favoring the 0.08 mg dose group (0.08 vs. 0.04, P = 
0.06; 0.08 vs. 0.16, P = 0.09). 
Biodistribution of Indocyanine Green
Fluorescent intensity of the metastases, liver, kidney, stomach, spleen, small bowel, 
colon and bladder was measured at all time points and in all dose groups (data 
not shown). 
 Repeated measures ANOVA was used to test for differences in fluorescent 
intensity of the liver (Fig. 2A) and liver metastases (Fig. 2B) between dose and time 
groups. Dose by time interaction did not significantly effect liver signal (P = 0.1) and 
metastases signal (P = 0.125) and was therefore removed from the model. There was 
a significant effect of time on both liver signal (P < 0.001) and liver metastases signal 
(P < 0.001). No significant effect of dose was found on liver signal (P = 0.061) and 
metastases signal (P = 0.152). This model showed that liver signal and metastases 
signal were both significantly higher in the 24 h group compared to all other time-
points (P < 0.001). 
NIR fluorescence intensity of all organs except for the stomach, colon and the small 
bowel, was lower or equal to the liver signal. Fluorescence intensity of the stomach, 
colon and small bowel was significantly higher compared to other organs and had 
a maximum at 48 and 72 hours.
Microscopic distribution of ICG in liver metastases
To determine the precise location of ICG in the vicinity of the tumor, sliced liver metastases 
were examined for internal fluorescent patterns using the Mini-FLARETM system. In all 
liver metastases a clear fluorescent rim around the tumor was found. Frozen tissue 
sections were examined using the Nuance multispectral imager (CRi, Woburn, MA) 
mounted on a Leica DM IRE2 inverted microscope (Leica, Wetzlar, Germany). A clear 
fluorescent rim was found in stromal tissue in the transition area between tumor and 
normal liver tissue in all liver metastases. In this area, multiple cell types that are involved 
in tissue inflammation (e.g. granulocytes, lymphocytes) were found (Fig 3).
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Figure 1 – Intraoperative detection of colorectal liver metastases using NIR fluorescence 
Shown are a color image (left), a NIR fluorescence image (middle) and a  pseudo-colored green merge (right) 
of two CC531 colorectal liver metastases intraoperatively detected using NIR fluorescence in a male rat 72 h 
after injection of 0.08 mg indocyanine green. 
Figure 2 - Dose of ICG and timing of intraoperative imaging 
A. Fluorescent intensity of the liver in 18 rats injected with 0.04, 0.08 or 0.16 after 24, 48, 72 and 96 h.
B. Fluorescent intensity of all liver tumors (N = 34) in 18 rats injected with 0.04, 0.08 or 0.16 mg ICG after 24, 
48, 72 and 96 h.
C. Average tumor-to-liver ratios and standard deviations are plotted for all liver metastases (N = 34) in 18 rats 
injected with 0.04, 0.08 or 0.16 mg ICG after 24, 48, 72 and 96 h. 
D. Estimated marginal means of tumor-to-liver ratio for rats injected with 0.04, 0.08 or 0.16 mg ICG after 24, 
48, 72 and 96 h using the repeated measures ANOVA and least square difference (LSD) adjustment for 
multiple testing. This model showed that the tumor-to-liver ratio was significantly higher in the 72 h time 
group compared to the 24 h (P < 0.001), 48 h (P = 0.001) and 96 h (P = 0.004) time groups. ICG dose did not 
significantly influence tumor-to-liver ratios, but a trend was found favoring the 0.08 mg dose group (0.08 vs. 
0.04, P = 0.06; 0.08 vs. 0.16, P = 0.09). 
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Figure 3 – Fluorescent microscopy of a colorectal liver metastasis 
Shown are a hematoxylin and eosin staining (top left), a pseudo-colored green NIR fluorescence image (top 
middle) and pseudo-colored green merge (top right) of a 20 µm frozen tissue section of a colorectal liver 
metastasis. Furthermore, a phase image (bottom left), a pseudo-colored red NIR fluorescence image (bottom 
middle) and a pseudo-colored red merge (bottom right) of a 20 µm frozen tissue section of a colorectal liver 
metastasis is shown. The fluorescent rim in stromal tissue in the transition area between tumor and normal 
liver tissue can be clearly identified.
DISCUSSION
In the present study, significant differences in TLR were shown between four 
different time points after ICG administration, with an optimal time of imaging of 
72 h after ICG administration. No significant effects were found with regard to dose 
level; however, a trend was shown favoring 0.08 mg. Moreover, all liver metastases, 
even as small as 1.2 mm, could be clearly identified during liver surgery using 
clinically available ICG and the Mini-FLARETM system in this syngeneic rat model.
 Highest TLRs were reached 72 h after ICG administration. Fluorescence 
intensity of the liver and the liver metastases were also examined separately. 
Fluorescent intensity of the liver decreased strongly after 24 h and was not dose 
dependent. Fluorescent intensity of the liver metastases also decreased strongly at 48 
h, but a small, non-significant peak was found at 72 h. This small peak can be explained 
by the re-uptake of ICG in the small bowel as part of the enterohepatic circulation and 
subsequent passage through the bowel tract, hence the highest TLR at 72 h. 
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 Regarding ICG dosage, a trend was found favoring the 0.08 mg ICG group. 
Extrapolating to human body weight, this dose corresponds to a dose of 20 mg ICG, 
which is frequently used in a clinical setting. To optimize this technique in clinical 
practice, a dose-finding study is imperative. As ICG is already clinically available and 
FDA-approved, a straightforward translation of our results to the clinic can be made.
 It is known that a substantial part of liver metastases, mainly the small (< 
5 mm) and superficially located, can not be identified using conventional imaging 
modalities such as CT or IOUS. Size of metastases in the present study varied from 
1.2 to 13.4 mm of which 50 % were smaller than 5 mm.  This emphasizes that ICG 
fluorescence in liver surgery might be of great value in detecting small colorectal 
liver metastases. As the currently used preclinical animal model only generated 
colorectal liver metastases, future clinical studies will have to determine the ability 
of this technique to discriminate between malignant and benign lesions of the 
liver.
 Since maximum penetration depth of NIR fluorescence is currently up 
to 1 cm, identification of non-superficially situated liver metastases will be more 
challenging.  Therefore, intraoperative ICG fluorescence must be regarded as a 
complement on currently used conventional imaging modalities as IOUS and CT. 
Improvements in imaging systems, NIR fluorescence contrast agents and software 
and reduction in background fluorescence may facilitate NIR fluorescence imaging 
of deeper located metastases.
 The currently used technique to detect liver metastases using NIR 
fluorescence and ICG is based on the clearance capacity of the liver. It has been 
described that in patients with a cirrhotic liver, or in patients pretreated with 
chemotherapy, the liver function and clearing capacity can be reduced. A reduced 
liver function could also affect the clearance of ICG, which can result in a higher 
background signal and therefore lower contrast. However, it has been shown 
that even cirrhotic livers have an extensive clearance capacity.15 This implies that 
the currently used technique can probably be used in subjects with a reduced 
liver function. Though, in these patients, the optimal time interval between 
ICG administration and imaging could be longer. Future clinical studies have to 
elaborate on this topic. 
 A recent development in liver surgery is the introduction of laparoscopic 
surgery. NIR fluorescence can be of great value, also in laparoscopic surgery, 
since palpation of the liver is not possible and the surgeon can only rely on 
visual inspection and preoperative imaging. To anticipate on this potential new 
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application, laparoscopic NIR fluorescence camera systems are presently being 
developed and tested.16,17 
 In summary, this study demonstrates clear identification of colorectal liver 
metastases during surgery using the clinically available NIR fluorescent agent ICG 
and the Mini-FLARETM system. Imaging 72 h after administration of 0.08 mg ICG 
provided the highest TLRs. In particular, the ability to detect small (< 5 mm) and 
superficially located metastases can be of great value during liver surgery. When the 
current intraoperative identification of colorectal liver metastases can be improved 
using this technique, the resection can potentially be performed more accurately 
and preoperatively missed metastases can be involved in surgical decision making.
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Intraoperative near-infrared (NIR) fluorescence imaging is a technology with high 
potential to provide the surgeon with real-time visualization of tumors during 
surgery. This study explores the feasibility for clinical translation of an epidermal 
growth factor receptor (EGFR) targeting nanobody for intraoperative imaging and 
resection of orthotopic tongue tumors and cervical lymph node metastases. 
Material and Methods
The anti-EGFR nanobody 7D12 and the negative control nanobody R2 were 
conjugated to the NIR fluorophore IRDye800CW (7D12-800CW and R2-800CW). 
Orthotopic tongue tumors were induced in nude mice using the OSC-19-luc2-cGFP 
cell line. Tumor bearing mice were injected with 25µg 7D12-800CW, R2-800CW or 
11µg  800CW. Subsequently, other mice were injected with 50 µg or 75 µg of 7D12-
800CW. The FLARE imaging system and the IVIS spectrum were used to identify, 
delineate and resect the primary tumor and cervical lymph node metastases. 
Results
All tumors could be clearly identified using 7D12-800CW. A significantly higher 
tumor-to-background ratio (TBR) was observed in mice injected with 7D12-800CW 
compared to mice injected with R2-800CW and 800CW. The highest average TBR 
(2.00 ± 0.34 and 2.72 ± 0.17 for FLARE and IVIS spectrum, respectively) was observed 
24 hours after administration of the EGFR-specific nanobody. After injection of 
75 µg 7D12-800CW cervical lymph node metastases could be clearly detected. 
Orthotopic tongue tumors and cervical lymph node metastases in a mouse model 
were clearly identified intraoperatively using a recently developed fluorescent 
EGFR targeting nanobody. 
Conclusion
Translation of this approach to the clinic would potentially improve the rate of 
radical surgical resections. 
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INTRODUCTION
 In oncology, a range of noninvasive imaging modalities, including X-ray, 
ultrasonography, computed tomography (CT) and magnetic resonance imaging 
(MRI), enable early detection, staging, and treatment evaluation of cancer. However, 
in most cases surgeons still discriminate healthy tissue from cancerous tissue 
by means of visual inspection and palpation during surgery. Given the fact that 
adequate tumor free margins are of paramount importance for patient prognosis 
and outcome, and that irradical resections still frequently occur, novel imaging 
modalities are needed. Despite the primary objective of achieving macroscopic 
clearance of 1 cm in the surgical management of oropharyngeal or oral squamous 
cell carcinoma (OSCC), the presence of tumor positive margins has been reported 
in 16% of patients.1 Numerous reports have indicated that involved margins imply 
deteriorated prognoses.2 On the other hand, applying wider surgical margins will 
result in functional impairment in most cases.3,4 Therefore, clearer delineation of 
the tumor during surgery may improve the number of radical resections, thus 
increasing patients’ survival rates while maintaining postoperative functionality. 
 Near-infrared (NIR) fluorescence imaging is a novel imaging technique 
that provides the surgeon with real-time visualization of tumors during surgery.5-7 
In the NIR region (650 – 800 nm), less absorption of light by tissue components 
allows much deeper penetration of light. Furthermore, lower fluorescence from 
endogenous fluorophores decreases the non-specific background signal. As the 
human eye is not sensitive to NIR fluorescent light, a specific NIR fluorescence 
imaging system is needed to visualize the fluorescence signal. At the same time, 
since NIR light is invisible to the human eye, it will not alter the surgical field.8 
 One of the main challenges in intraoperative fluorescence imaging 
lies in the development, validation and clinical introduction of a tumor specific 
agent. Being widely overexpressed in OSCC, the epidermal growth factor receptor 
(EGFR) serves as an interesting target for intraoperative fluorescence imaging.9,10 
The EGFR is a transmembrane glycoprotein that is involved in DNA synthesis and 
cell proliferation. Overexpression contributes to oncogenesis by proliferation, 
dedifferentiation, inhibition of apoptosis, invasiveness and lack of adhesion 
dependence.11 Furthermore, EGFR overexpression is often associated with a poor 
prognosis for patients with OSCC.12 
 For tumor targeting using molecular imaging techniques, antibodies 
are promising as they can be raised specifically against practically any molecular 
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target. Nevertheless, due to their large hydrodynamic diameter, intact antibodies 
accumulate in the liver. Moreover, long half-life in the bloodstream and slow 
blood clearance via the liver results in high contrast images only several days after 
injection. A very appealing alternative is the use of nanobodies.13 Nanobodies 
are the smallest functional antigen-binding fragments derived from naturally-
occurring heavy-chain only antibodies.14 They show very specific binding to their 
targets and their size of approximately 15 kDa ensures efficient distribution and 
tissue penetration, as well as rapid clearance from the body.15-17 
 This study assesses the feasibility of intraoperative fluorescence delineation 
of orthotopic OSCC and microscopic lymph node metastases, using an anti-EGFR 
nanobody and a clinically available fluorescence camera system. For this, the anti-
EGFR nanobody 7D12 was conjugated to the NIR fluorophore IRDye800CW.18 , as 
previously described by Oliveira et al.17.  Tumor accumulation and specificity of 
7D12-800CW was compared to the negative control nanobody R2-800CW and to 
800CW alone.
MATERIAL and METHODS
Cell lines and culture
Two human cell lines were used. For the animal studies, the metastatic oral squamous 
cell carcinoma (OSCC) line OSC-19 was used. The OSC19 cell line was established in 
Japan with cells from a patient with a well-differentiated squamous cell carcinoma 
of the tongue that metastasized to a cervical lymph node.19 Luc2 luciferase from 
pGL4.10 plasmid (Promega, Madison, WI, USA) was cloned into the multiple cloning 
site (MCS) of the lentiviral vector pCDH-EF1-MCS-T2A-copGFP (Biocat, Heidelberg, 
Germany) using specific primers with the corresponding restriction sites. OSC-19 
cells were transduced by self-inactivating lentiviral vectors as previously described20 
and positive cell clones selected by limit dilution to create a stable luciferase 2 (luc2) 
and green fluorescent protein (GFP) expressing OSC-19-Luc2-copGFP cell line. The 
cells were grown in vitro in Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen, 
Carlsbad, CA, USA) containing 4.5 g D-Glucose/L, 110 mg sodium pyruvate/L, 580 mg 
L-glutamine/L supplemented with 10% fetal bovine serum (FCS; Lonza, Basel, Swiss), 
100 IU/mL penicillin, 100 μg/mL streptomycin (Invitrogen), 1x Minimal Essential 
Medium (MEM) Non-Essential Amino Acids solution and 1x MEM vitamin solution 
(Invitrogen). The human colorectal cancer cell line SW620 was used as an EGFR 
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negative control. This cell line was cultured in Leibovitz’s L-15 medium (Invitrogen) 
containing 300 mg L-glutamine/L supplemented with 10% FetalClone II (Hyclone, 
Logan, UT, USA) 100 IU/mL penicillin, 100 μg/mL streptomycin (Invitrogen) and 20 
mM HEPES (Invitrogen). All cell lines were grown in a humidified incubator at 37°C 
and 5% CO
2
. Cells were regularly checked for Mycoplasma infection by PCR. 
Nanobodies and Conjugation to IRDye800CW
Two nanobodies were used: 7D12 and R2. The EGFR specific nanobody 7D12 binds 
to the ectodomain of the EGFR.18,21 EGFR specificity of 7D12-800CW in vitro and 
in vivo was reported earlier.17 The nanobody R2 was used as a non-EGFR specific 
control.22,23 Both nanobodies have a molecular weight of approximately 15 kDa 
and show similar in vivo biodistribution.17,18,24 The generation of the nanobodies 
7D12 and R2 was described previously.18,23 Induction of protein expression and 
purification of nanobodies from the periplasmic space of Escherichia coli were 
performed as described by Roovers et al.25 Conjugation of both nanobodies to the 
NIR fluorophore IRDye800CW was performed as described by Oliveira et al.17 Briefly, 
the IRDye800CW N-hydroxysuccinimide ester (LI-COR, Lincoln, NE, USA) was added 
to the protein in a 4-fold molar excess and was incubated for two hours at room 
temperature. Removal of the unconjugated fluorophore was accomplished by 
using two Zeba Spin Desalting columns (Thermo Fisher Scientific, Perbio Science 
Nederland B.B., Ettenleur, the Netherlands) per protein in two sequential steps. 
The fluorescent nanobodies, i.e. 7D12-800CW and R2-800CW, were characterized 
as previously described17, namely for their conjugation efficiency and these 
parameters were in agreement with previous values, i.e. 0.5 and 1.1, respectively.   
EGFR expression
OSC-19 and SW620 cells were cultured until subconfluence. Cells were detached with 
trypsin and adjusted at 1 x 105 cells/tube in ice cold PBS, 10% FCS (Lonza, Basel, Swiss) 
and 1% sodium azide. The anti-EGFR monoclonal antibody sc-120 alexa fluor 647 (Santa 
Cruz biotechnology, Santa Cruz, CA, USA) or non-specific normal mouse IgG
2a
 alexa fluor 
647 (Santa Cruz) were added and cells were incubated in the dark on ice for 30 minutes. 
After incubation, cells were washed three times in ice cold PBS and resuspended in ice 
cold PBS, containing 10% FCS (Lonza) and 1% sodium azide. Flow cytometry of alexa 
fluor 647 labeled cells was performed using the BD LSR II (BD biosciences, San Jose, CA, 
USA). EGFR expression was estimated as the geometric mean of fluorescence intensity 
measured in 10.000 viable cells. The experiment was performed in duplicate. 




A binding assay was performed to confirm the specificity of the EGFR binding of 
7D12-800CW. A black 96-well plate (Greiner bio-one, Frickenhausen, Deutschland) 
was used in which 20.000 OSC-19-luc2-cGFP and SW620 cells were seeded per 
well. After one day, cells were washed with binding medium (DMEM supplemented 
with 25 mM Hepes and 1% BSA, at pH 7.2). 7D12-800CW (7D12), R2-800CW (R2) 
and IRDye800CW carboxylate (800CW, LI-COR, Lincoln, NE, USA) were added in 
triplicate in a concentration range of 0 to 50 nM. R2-800CW and IRDye800CW 
carboxylate were used as negative controls. The cells were incubated for 2 hours 
in the dark on a rocker at 4°C and afterwards washed two times with binding 
medium. Bound proteins were directly observed with the Odyssey scanner (LI-
COR), scanning at 800 nm. Directly after these measurements cells were fixed with 
4% paraformaldehyde and incubated with TO-PRO-3 (Invitrogen) at 1:5000 for 15 
minutes. Again cells were washed twice and the plate was imaged using the 700nm 
channel of the Odyssey (LI-COR) to detect TO-PRO3 fluorescence. Nucleus staining 
was performed to correct the fluorescence signal for the amount of cells enabling 
direct comparison of fluorescence signal of both cell lines. 
Fluorescence imaging systems
Real-time fluorescence imaging of primary tumor and lymph node metastases was 
performed using the FLARE imaging system.26 Briefly, This imaging system consists 
of three wavelength-isolated light sources: a 400-650 nm light source generating 
40.000 lux (white light), a 656-678 nm light source generating 4 mW/cm2 (700 nm) 
and a 745 – 779 nm light source generating 14 mW/cm2 (800 nm). The imaging 
head, attached to a flexible gooseneck arm, enables real-time image acquisition 
from all three cameras. Color, NIR fluorescence and pseudo-colored (lime green) 
merged images are displayed in real time. Next to the FLARE imaging system, the 
IVIS spectrum (Caliper Life Science, Hopkinton, MA, USA) was used to visualize 
primary tumors and metastases. Data analysis of FLARE and IVIS spectrum data 
was performed using image J and the Living Image software from xenogen version 
3.2 (Caliper LS) respectively. Multiple regions of interest (ROI) were drawn in the 
tumor and in adjacent normal tissue of the tongue and divided by each other to 
calculate TBRs.
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Animal model
Nude Balb/c female mice (Charles River laboratories, l’Arbresle, France), aged 4 – 6 
weeks, were housed in individually ventilated cages and provided with food and 
sterilized water ad libitum. Animal experiments were approved by the local animal 
welfare committee of the Leiden University Medical Center. 
Orthotopic tongue tumors were submucosally induced in the tip of the tongue 
through injection of 40.000 OSC-19-luc2-cGFP cells, diluted in 20 μL phosphate-
buffered saline (PBS). Mice body weight was monitored twice a week and tumor 
growth was monitored twice a week by bioluminescence (BLI) measurements 
and visual inspection of the tongue. BLI signal, being the most sensitive imaging 
method for the detection of tumor cells27, served as an in vivo control for the tumor 
specific fluorescence of the nanobodies. Imaging procedures were performed 
under isoflurane gas anesthesia. Weight measurements and tongue inspections 
were performed to monitor general health during the experiments. Mice were 
sacrificed by injection of high doses ketamine/xylazine.
Fluorescence measurements
Twenty days after injection of tumor cells, mice (n = 9) were randomly divided into 
three groups and received a systemic injection of 25 μg 7D12-800CW (1.6 nmol, 64 
nmol/kg), 25 μg R2-800CW (1.5 nmol, 60 nmol/kg) or 11 μg 800CW carboxylate (1 
nmol, 40 nmol/kg, LI-COR). For the two nanobodies, a previous study reported 25 
μg to be the optimal dose.17 Fluorescent images were acquired at 0.5, 1, 2, 4, 8, 24 
and 48 hours after injection. 
For the detection of microscopic cervical lymph node metastases two additional 
concentrations of 50 and 75 μg 7D12-800CW were injected (n = 4). Mice were 
sacrificed at 24 hours after injection and overlying skin of the cervical region was 
removed for gross examination. Whole-body fluorescence imaging was performed 
and the tongue and cervical lymph nodes were subsequently resected. 
Histology and fluorescence microscopy
After ex vivo fluorescent measurements, the resected tongues were cut in two. 
One half was frozen on dry ice, the other half fixed in 4% formalin overnight and 
embedded in paraffin blocks. Cervical lymph nodes on both sides were resected. 
The left lymph node was frozen on dry ice, the right lymph node paraffin embedded 
and fixed in 4% formalin overnight. Tissue was sectioned at 10 μm and imaged 
using the Odyssey (LI-COR). All images were acquired using the same settings but 
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the images (i.e. brightness and contrast) of the control probes were altered to show 
any fluorescence and emphasize the difference in localization between specific 
and non-specific probes. To confirm the presence of tumor cells, fluorescence 
microscopy (Nikon eclipse e800, Nikon, Amsterdam, the Netherlands) of the GFP 
fluorescence signal emitted by OSC-19-luc2-cGFP cells was performed on frozen 
tissue slices. Histologic sections were stained with standard hematoxylin-eosin stain 
(HE). As expected, fluorescence of GFP could not be detected in paraffin embedded 
sections. Therefore, the presence of smaller cervical lymph node metastases in 
paraffin sections was confirmed by staining the cervical lymph node sections with 
anti-human wide-spectrum cytokeratin staining (Abcam inc., Cambridge, MA, USA).
Statistical analysis
For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, IL) 
was used. TBR’s were calculated by dividing the fluorescent signal of the tumor by 
fluorescent signal of surrounding tissue. TBR was reported in mean and standard 
deviation. To compare TBR between dose groups and time points, and to assess 
the relation between dose and time, a mixed model analysis was used. When 
a significant difference was detected, a one-way ANOVA was used to post-test 
for differences between separate dose groups and/or time points. The one-way 
ANOVA was corrected using the Bonferroni correction.  P < 0.05 was considered 
significant. Differences between the FLARE and IVIS imaging systems were tested 
with an unpaired T-test. 
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The specificity of the EGFR targeting nanobody for the squamous cell carcinoma of 
the tongue, that metastasizes to cervical lymph nodes, was first validated in vitro. For 
that purpose, we started with the evaluation of the EGFR expression in the OSC-19-
luc2-cGFP cell line. Direct staining of the cell surface epitope of the EGFR of OSC-19-
luc2-cGFP cells caused an increase in fluorescence intensity, as shown by a shift to 
the right through flow cytometry analyses, compared to the non-specific antibody 
(Fig 1A). Next, as a control to the EGFR overexpressing OSC-19-luc2-cGFP cell line, 
we assessed the EGFR expression in the human colon carcinoma cell line SW620, 
a cell line that has no overexpression of the EGFR. In contrast to OSC-19-luc2-cGFP, 
the FACS data of this cell line revealed no increase in fluorescence intensity, thus 
confirming the absence of EGFR expression in the SW620 cell line (Fig 1B). 
 Both these cell lines were employed to confirm the specificity of the EGFR 
targeting nanobody 7D12-800CW, which was compared to the non-EGFR specific 
nanobody R2-800CW and to 800CW alone. The IRDye800CW-conjugated probes 
were produced and characterized as described by Oliveira et al.17 Consistently, after 
purification of the conjugates through removal of unconjugated fluorophores, a 
small percentage of the 800CW unconjugated fluorophore (less than 7.5 % of the 
800CW conjugated fraction) was still present (data not shown) and the fluorophore 
to protein molar ratio of 7D12-800CW and R2-800CW after random conjugation 
was 0.5 and 1.1 respectively.
 The cell assay, performed at 4C to prevent internalization and investigate 
binding only,clearly demonstrated an EGFR specific binding of 7D12-800CW in 
OSC-19-luc2-cGFP cells that proved to be concentration dependent (Fig 1C). With 
R2-800CW and 800CW, although slightly concentration dependent, significantly 
less fluorescence intensity was observed (Fig 1C). In the EGFR negative cell line 
no significant differences in fluorescence intensity between 7D12-800CW and R2-
800CW were observed. Altogether, these results confirm the specificity of 7D12-
800CW for binding to EGFR and show that both the negative control R2-800CW 
and the 800CW alone do not associate with these cells (Fig 1C and 1D). 
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Figure 1 – EGFR expression and binding assay: Flow cytometry was performed using OSC-19-luc2-cGFP 
and SW620 without antibody (green), with an EGFR specific antibody conjugated to alexa fluor 647 (blue) 
and with an isotype control normal mouse IgG2a conjugated to alexa fluor 647 (red). 7D12-800CW binds to 
human epidermal growth factor receptor expressed on OSC19-luc2-cGFP cells.
A. The EGFR is highly expressed on the surface of OSC-19-luc2-cGFP cells. 
B. No expression of EGFR was found on the surface of SW620 cells. 
C. The human EGFR expressing OSC cells and EGFR negative SW620 cells were incubated with different 
concentrations of 7D12-800CW, R2-800CW and 800CW. The ratio of the fluorophore bound protein and the 
fluorescence intensity of TO-PRO-3 was plotted to correct for the amount of cells. Every concentration was 
performed in triplicate. Error bars indicate the standard deviation.
D. Images were acquired with the Odyssey Scanner (LICOR). OSC and SW620 cells were incubated with 50 
nM 7D12, R2 and 800CW. OSC = OSC-19-luc2-cGFP. 
Animal model
Within three weeks after orthotopic inoculation of OSC-19-luc2-cGFP cells in the tip 
of the tongue, all mice developed a primary tongue tumor and cervical lymph node 
metastases (a typical example is shown in Fig 2A), observed during regular visual 
inspection and confirmed by the increase in mean bioluminescence signal (Fig 2B) 
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Figure 2  - Tumor growth followed by imaging bioluminescence: 
A. Bioluminescent image after injection of OSC-19-luc2-cGFP cells. Primary tongue tumor and lymph node 
metastasis are shown. 
B. Increase of tumor growth (measured in bioluminescence signal) as a function of time.
In vivo NIR Fluorescence Imaging of primary tumors
Three weeks after tumor cell inoculation, mice were injected intravenously with 
25 μg of 7D12-800CW, R2-800CW or 11 μg 800CW (for equivalent fluorescence to 
7D12-800CW). To assess the feasibility of a possible clinical translation, fluorescence 
images were taken with both the preclinical, highly sensitive IVIS spectrum camera 
as well as with the FLARE intraoperative imaging system. As demonstrated in Figure 
3A, all tumors of the animals that were injected with 7D12-800CW could be clearly 
identified through NIR fluorescence using both imaging modalities. No adequate 
tumor-to-background ratios were observed in the control mice injected with 
R2-800CW or 800CW (Fig 3B), which is in agreement with the results obtained 
in vitro (Fig 1). Using the IVIS imaging system, a mixed model showed significant 
differences in TBRs between three study groups and between time points (p < 
0.0001 and p < 0.0001, respectively) (Fig 4A). Post-testing using a one-way ANOVA 
showed significant differences between the 7D12-800CW and the R2-800CW (p < 
0.0001) study groups and between the 7D12-800CW and 800CW (p < 0.0001) study 
groups. No significant difference was found between R2-800CW and 800CW (p > 
0.999). The highest TBR (2.72 ± 0.17) was measured at 24 hours after administration 
of 7D12-800CW. Using the FLARE imaging system, a mixed model showed 
significant differences in TBRs between the three study groups and between time 
points (p = 0.041 and p < 0.0001, respectively) (Fig 4B). Post-testing using a one-
way ANOVA showed significant differences between the 7D12-800CW and the R2-
800CW study groups (p = 0.05) and between the 7D12-800CW and 800CW study 
groups (p = 0.002). No significant difference was found between R2-800CW and 
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800CW (p = 0.77). The highest TBR (2.00 ± 0.34) was measured at 24 hours after 
administration of 7D12-800CW.  The highest TBR measured with the IVIS imaging 
system was significantly higher compared to the highest TBR measured with the 
FLARE imaging system (p = 0.03). 
Figure 4 - Intraoperative tumor to background ratios over time: The tumor to background ratio of 7D12-
800CW is significantly higher compared to those of R2-800CW and 800CW. Tumor to background ratios were 
calculated from 0.5 hours to 48 hours after injection. Error bars indicate the standard deviation. Tumor to 
background ratios were plotted for the IVIS-Spectrum (A) and the FLARE imaging system (B).
Ex vivo fluorescence imaging and histology of primary tumors
In cryo sections, fluorescent imaging of the GFP that was transduced in the OSC-19 
cells confirmed the presence of tumor cells in the tongue (Fig 5). After fluorescent 
imaging (GFP and NIR fluorescence), sections were stained with HE. Even sub-
millimeter islands of tumor cells, confirmed with GFP fluorescence, co-localized 
with the fluorescence of 7D12-800CW, as measured with the Odyssey Scanner (Fig 
5). No co-localization was observed in the tongue specimens of mice injected with 
R2-800CW or 800CW, which is in agreement with our observations in vivo (Fig 3B). 
In vivo and ex vivo fluorescence imaging and histology of cervical lymph nodes
In contrast to the primary tumor, microscopic cervical lymph node metastases 
were not grossly visible. In fact, a dose of 75 μg of 7D12-800CW only gave a weak 
fluorescence signal through the skin using the IVIS, but, importantly, a strong 
fluorescence with both imaging systems could be detected when the skin was 
removed (Fig 6). This highlights the potential of this imaging modality in the 
intraoperative context. 
During ex vivo imaging, the fluorescence of GFP that was transfected in the OSC-
19-luc2-cGFP cells confirmed the presence of cervical lymph node metastases in 
the tissue specimen and could be colocalized to the fluorescent signal of 7D12-
800CW. As expected, due to bleaching and the washing steps, no GFP fluorescence 
was found in the paraffin sections of the cervical lymph nodes. Nevertheless, 
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immunohistochemical analysis, using a wide spectrum anti-cytokeratin staining, 
confirmed the presence of tumor cells. As shown in Figure 6, the fluorescence 
signal of 7D12-800CW co-localizes with the tumor cells in the cervical lymph node. 
DISCUSSION 
 In the present study, the EGFR targeting nanobody conjugated to 800CW 
was used to delineate orthotopic OSCC tumor margins during surgery. After 2 
hours post injection tumors could already be clearly delineated. The highest TBR 
was obtained 24 hours after injection. Furthermore, a significant difference in TBR 
was observed between mice injected with 7D12-800CW, and mice injected with 
the control nanobodyR2-800CW or with 800CW alone.  
 NIR fluorescent optical imaging is an imaging technique with high 
potential to obtain real-time information about the presence, location and 
dimensions of tumor tissue so that adequate tumor free margins can be obtained 
after resection.28-30 Although the first clinical trial has recently been performed29, it 
remains challenging to find a suitable fluorescent probe which can be detected 
with a sensitive NIR-fluorescent imaging system. 
 The first challenge to NIR fluorescence imaging is the optimal fluorescent 
probe. An ideal fluorescent probe should distribute well, have a high affinity 
towards its target and a fast clearance from the bloodstream, to allow efficient 
accumulation at the tumor and rapid acquisition of images with high contrast. 
Furthermore, no accumulation in the liver is desirable and the ability to adequately 
penetrate the tissue of interest is of great importance. The EGFR serves as a very 
interesting target in head and neck cancer as the majority of these cancers 
overexpress this receptor.10,31 In a previous study we used recombinant human 
EGFR ligands conjugated to 800CW to target head and neck tumors.32 Although 
efficient in targeting head and neck tumors, recombinant human EGFR ligands 
can potentially activate this receptor, which promotes its malignant phenotype. 
In other studies, cetuximab conjugated to Cy5.5 and panitumumab conjugated 
to 800CW are used to image head and neck tumors.9,33 Conventional antibodies, 
however, show slower blood clearance (up to several days), higher accumulation 
in the liver and limited tumor penetration compared to nanobodies.17 For these 
reasons, we have selected a nanobody as our probe for this study. 
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Figure 5 - Histology and fluorescence imaging of orthotopic primary tongue tumors: Shown are 
hematoxylin and eosin (HE) stainings, HE and GFP fluorescence overlays, HE and NIR fluorescence overlays 
and HE, NIR and GFP fluorescence overlays. In the 7D12-800CW tissue specimen, a clear overlap between 
NIR and GFP (indicating tumor cells) fluorescence was observed. In the R2-800CW and 800CW specimens, 
no overlap between NIR and GFP fluorescence was observed. Brightness and contrast of the images of R2-
800CW and 800CW was altered to show fluorescence and emphasize the localization in tissue.
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Figure 3 – Multimodal in vivo and ex vivo imaging of an orthotopic tongue tumor: 7D12 is specifically 
taken up in the oral squamous cell carcinoma of the tongue. Mice bearing OSC-19-luc2-cGFP human 
xenografts were intravenously injected with 25µg of 7D12, R2 and 800CW. After 24 hours fluorescent images 
were obtained with the IVIS spectrum and the intraoperative camera system (FLARE). 
A. In vivo: bioluminescence brightfield merge image (left), NIR fluorescence brightfield merge IVIS image of 
7D12-800CW  (middle) and NIR fluorescence color merge FLARE image (right) Ex vivo: GFP brightfield merge 
image (left), NIR fluorescence brightfield merge IVIS image of 7D12-800CW  (middle) and NIR fluorescence 
color merge FLARE image (right)
B. In vivo: Fluorescent imaging of a tongue tumor 24 hours after administration of 7D12-800CW (left), R2-
800CW (middle) and 800CW (right). Ex vivo: Fluorescent imaging of a tongue tumor 24 hours after 
administration of 7D12-800CW (left), R2-800CW (middle) and 800CW (right). Images were obtained with the 
intraoperative camera system (FLARE)
 
Figure 6 – In vivo, ex vivo and histological fluorescence imaging of cervical lymph nodes:
In vivo: bioluminescence brightfield merge image (left), NIR fluorescence brightfield merge IVIS image of 
7D12-800CW  (middle) and NIR fluorescence color merge FLARE image (right) 
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Ex vivo: GFP brightfield merge image (left), NIR fluorescence brightfield merge IVIS image of 7D12-800CW 
(middle) and NIR fluorescence color merge FLARE image (right)
Histology: Shown are a hematoxylin and eosin (HE) staining combined with a cytokeratin staining (left) and 
NIR fluorescence image (right) of a cervical lymph node of a mice injected with 7D12-800CW. A clear overlap 
between NIR fluorescence and the brown cytokeratin staining (indicating tumor cells) was observed. 
 Next to the ideal probe, the extent to which a tumor can be visualized 
during surgery is highly depending on the NIR fluorescent imaging system. Gioux 
et al.34 have reviewed the technical requirements for an intraoperative imaging 
system. To assess the feasibility of translating our results into clinical experiments, 
we used the clinically available FLARETM imaging system. This system is able to 
adequately detect microscopic disease intraoperatively and has proven its clinical 
use in over 25 clinical trials.26,35  Using the IVIS spectrum we were able to measure 
bioluminescence and confirm the presence of tumor cells ex vivo, by imaging GFP 
fluorescence of the transfected OSC-19-luc2-cGFP cells. Furthermore, fluorescence 
measurements obtained with the IVIS spectrum, i.e. a closed (‘black box’) preclinical 
imaging system, were compared with the measurements of the clinically available 
FLARETM imaging system. This comparison showed a significant difference in TBR 
favoring the IVIS spectrum on the optimal imaging time point (24hr post injection). 
This difference can be explained by the fact that the IVIS spectrum is, in contrary to 
the FLARE imaging system, a ‘black box’ imager with less daylight interfering and 
subsequently less background fluorescence. However, since this device obviously 
cannot be used intraoperatively, the FLARE imaging system is an adequate 
alternative as the average TBR was over 2. 
 In previous studies, we used the EGFR targeted nanobody 7D12 conjugated 
to 800CW to image subcutaneous A431 tumor xenografts, which have high EGFR 
expression.17 Undoubtedly, the host microenvironment has great influence on 
tumor biology that affects parameters such as angiogenesis, growth, invasion, 
metastasis and lymphangiogenesis. Therefore, an orthotopic model is clinically a 
more relevant model with great importance to assess the ability of a probe for 
fluorescence delineation of tumors and its possible translation to the clinic. In 
this study, we successfully tested the potentiality of intraoperative fluorescence 
delineation of orthotopic OSCC and microscopic lymph node metastases using 
a clinically available fluorescence imaging system. Based on these results we 
conclude that clinical translation of 7D12-800CW may be possible, using the FLARE 
imaging system in the intraoperative set-up. 
 A sufficient TBR is required to distinguish tumor from normal tissue30 The 
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small molecular weight of 7D12 allows fast detection of the tumor due to rapid 
distribution and fast clearance of unbound molecules. Oliveira et al.17 reported 
tumor detection from 30 minutes after injection onwards. In the present study, 
using both the FLARE and IVIS spectrum, the tumor could be sufficiently detected 
2 hours post injection. The use of an orthotopic model in the tongue that differs 
in angiogenesis, lymphangiogenesis and interstitial pressure from a subcutaneous 
A431 tumor, could perhaps explain these variations. Nevertheless, the highest 
average tumor to background ratio (2.72 IVIS spectrum vs 2.0 FLARE) was obtained 
24 hours after injection, which is in agreement with what was previously reported 
in the subcutaneous tumor model.17 Although nanobodies distribute and bind to 
their targets very rapidly, the background signal is relatively high during the first 
hours. Monovalent nanobodies are not efficiently internalized and therefore bound 
nanobody can un-bind over a certain period of time.36 The 7D12-800CW washout 
from normal tissue occurs faster than the release from its receptor in the tumor. As 
a result the TBR will increase over time until an optimal TBR is reached. After that, 
release of nanobody from its receptor will result in a decrease in TBR. A decreased 
TBR in our study was seen after 48 hours. 
 Cryosections of the tongue confirmed the tumor specific fluorescence 
by colocalization of the fluorescent signal of 7D12-800CW and the fluorescence 
of the GFP transfected OSC-19 cells. In the cryosections of mice injected with R2-
800CW some fluorescence was detected, but there was no colocalization of NIR 
and GFP fluorescence. R2-800CW fluorescence mainly originated from the area 
surrounding the tumor. A possible explanation for the non-EGFR specific presence 
of R2-800CW could be the enhanced permeability and retention that is seen in 
many tumors.37 Fluorescence could not be detected in the cryo sections of tongues 
of mice injected with 800CW alone. 
 When translating 7D12-800CW to the clinic, the specific binding of the 
nanobody to human EGFR could result in higher background fluorescence and 
therefore lower contrast. Importantly, Oliveira et al.17 demonstrated the ability of 
7D12-800CW to distinguish between different expression levels of EGFR in vitro. 
This implies that 7D12 could differentiate tumor tissue with high EGFR expression 
from normal tissue without overexpression of EGFR. 
 The prognosis of patients with head and neck cancer is largely dependent 
on lymph node involvement.38,39 A sentinel lymph node (SLN) procedure could 
prevent elective neck dissections that are frequently performed for adequate staging 
and local control. Furthermore, despite the analysis by a trained pathologist, (micro) 
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metastases and occult tumor cells in lymph nodes can be missed by standard 
histopathological examination. Limited examination of one lymph node could 
increase the accuracy of staging in head and neck cancer. Recently van der Vorst et 
al.40 demonstrated the feasibility to detect draining lymph nodes in head and neck 
cancers using the nonspecific fluorescent tracer ICG:HSA. The fluorescent tracer 
however, quickly migrated to lymph nodes beyond the SLN. This present study 
demonstrates the feasibility of specific targeting of cervical lymph node metastases. 
A dose of 75 μg of 7D12-800CW clearly allowed delineation of the primary tumor 
and identification of the cervical lymph node metastases after removal of the skin. 
Histology showed clear co-localization of the NIR fluorescence of 7D12-800CW and 
the cytokeratin staining, that confirmed the presence of tumor cells. Compared 
to the primary tumor however, an increase of nonspecific background signal was 
observed.  Also, the smaller the tumor or metastases, the lower the fluorescent 
signal. Furthermore, the influence of optical properties on the light propagation 
through tissue can result in a blurred delineation of smaller tumors. Altogether, 
these aspects rendered visualization of the metastases slightly difficult, which was 
significantly improved by removal of the skin. Further research is needed to explore 
which is  the minimum size of lymph node metastases  that can be detected 
using 7D12-800CW. Intraoperative detection of lymph node metastases would 
be a better alternative to the non-specific SLN procedure. First, the efficiency of 
an intraoperative histopathological diagnosis on fresh-frozen sections could be 
increased by examination of the fluorescence positive lymph node. Eventually, the 
procedure might even prevent intraoperative pathologic analysis of fresh-frozen 
tissue sections. 
 In conclusion, the present study reports a recently developed fluorescent 
EGFR targeting nanobody, which clearly allowed the identification of orthotopic 
tongue tumors and cervical lymph node metastases in a mouse model. These 
results highlight the potential of this nanobody for clinical translation in the context 
of surgical management of oropharyngeal or OSCC. 
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Irradical tumor resections and iatrogenic ureteral injury remain a significant 
problem during lower abdominal surgery. The aim of the current study was to 
intraoperatively identify both colorectal tumors and ureters in subcutaneous and 
orthotopic animal models using cRGD-ZW800-1 and NIR fluorescence.
Material and Methods
The zwitterionic fluorophore ZW800-1 was conjugated to the tumor specific 
peptide cRGD (targeting integrins) and to the a-specific peptide cRAD. One nmol 
cRGD-ZW800-1, cRAD-ZW800-1, or ZW800-1 alone was injected in mice bearing 
subcutaneous HT-29 human colorectal tumors. Subsequently, cRGD-ZW800-1 was 
injected at dosages of 0.25 and 1 nmol in mice bearing orthotopic HT-29 tumors 
transfected with luciferase2. In vivo biodistribution and ureteral visualization were 
investigated in rats. Fluorescence was measured intraoperatively at several time 
points after probe administration using the FLARE imaging system. 
Results
Both subcutaneous and orthotopic tumors could be clearly identified using cRGD-
ZW800-1. A significantly higher signal-to-background ratio (SBR) was observed in 
mice injected with cRGD-ZW800-1 (2.42 ± 0.77) compared to mice injected with 
cRAD-ZW800-1 or ZW800-1 alone (1.21 ± 0.19 and 1.34 ± 0.19, respectively) when 
measured at 24 h after probe administration. The clearance of cRGD-ZW800-1 
permitted visualization of the ureters and also generated minimal background 
fluorescence in the gastrointestinal tract.
Conclusions
This study appears to be the first to demonstrate both clear tumor demarcation 
and ureteral visualization after a single intravenous injection of a targeted NIR 
fluorophore. As a low dose of cRGD-ZW800-1 provided clear tumor identification, 
clinical translation of these results should be possible.
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INTRODUCTION
In cancer surgery, positive resection margins remain one of the biggest problems, 
resulting in a high number of recurrences and poor prognosis. In contrast to the 
many imaging modalities that can be used preoperatively for diagnosis, staging, 
and surgical planning (CT, MRI, SPECT, PET), real-time, intraoperative imaging 
modalities to assess the extent of disease and to determine adequate resection 
margins are lacking. In most cases, surgeons still have to rely only on palpation and 
visual inspection to discriminate between tumor tissue and normal tissue.1 Since 
this situation has not been changed for many decades, there remains a need for a 
diagnostic tool that can discriminate tumor tissue from normal tissue in real time 
during surgery. 
In addition, iatrogenic ureteral injury is a rare, but serious complication of lower 
abdominal surgery, with a reported incidence rate varying from 0.7% up to 10%.2-4 
Ureteral identification can be challenging, especially in patients with previous surgery 
or inflammation, and during minimally invasive procedures. Early identification of 
ureteral damage permits direct repair and is of paramount importance to reduce 
morbidity and preservation of renal function. 
 Near-infrared (NIR) fluorescence guided surgery is a novel technique that 
enables real-time visualization of tumors and vital structures (i.e. ureters) using 
light in the NIR spectrum.5-7 The use of NIR light has the advantages of being less 
absorbed by tissue and being invisible to the human eye. This results in high tissue 
penetration without altering the look of the surgical field. By conjugating NIR 
fluorescent dyes to tumor specific ligands, intraoperative NIR fluorescent tumor 
detection and demarcation can be achieved. During the last decade, many tumor-
specific ligands, such as antibodies, nanobodies, and peptides have been used for 
this purpose, all with their own advantages and disadvantages.8-11 Furthermore, 
multiple fluorescent dyes have been tested to optimize fluorescent intensity, 
biodistribution, and clearance.12-15 In addition, Metildi et. al. recently showed the 
ability to visualize sub-millimeter tumor deposits along the cecal wall in a patient-
derived orthotopic nude mouse model using a chimeric CEA antibody and visible 
fluorescence.16
 The present study evaluates the use of a low dose fluorescent dye ZW800-
1 conjugated to the cyclic RGD peptide (cRGD) targeting integrin for colorectal 
tumor imaging and ureteral visualization.15 RGD is a small peptide that targets 
integrin α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and αIIbβ3.17-20 Integrins are 
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cell-surface transmembrane heterodimeric glycoproteins that are involved in cell 




 plays a 
key role in the early phase of tumor angiogenesis, tumor cell migration, and is 
overexpressed in various cancer types, including colorectal and breast cancer 22. 
Moreover, an intermediate to high expression of αvβ3 is observed on the (neo)
vasculature of colon carcinoma in about 75% of patients with colon cancer.23,24 
cRGD-ZW800-1 has recently been developed and validated by our group using 
in vitro and in vivo assays with melanoma, breast, liver and lung cancer cell lines 
15. In addition, recent preclinical studies demonstrated successful identification of 










targeting using 18F-galacto-RGD and PET imaging in breast cancer and malignant 
gliomas.28,30-32 
 ZW800-1 is a recently developed zwitterionic fluorescent dye which is 
cleared rapidly by the kidneys, has a high quantum yield, and was engineered 
for high hydrophilicity.33 ZW800-1 has a net charge of 0 after conjugation to a 
targeting ligand with a net charge of -1 prior to conjugation, an absorption peak 
of approximately 772 nm, and an emission peak of 788 nm in fetal bovine serum. 
ZW800-1 is freely filtered by the kidney and is exclusively eliminated from the body by 
the kidneys. As such, non-specific background signal in the intestines is low, making 
it valuable for colorectal tumor imaging, and simultaneously, ureteral visualization 
is enabled. To maximize renal clearance of the conjugate, the hydrophilic variant 
RGDyK was chosen for conjugation to ZW800-1.34 
The aim of the current study was to evaluate the ability to visualize both colorectal 
cancer and ureters using NIR fluorescence and a single injection of cRGD-ZW800-1.
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MATERIAL AND METHODS
Ethical standards and animal care
All animal experiments were approved for animal health, ethics, and research by the 
Animal Welfare Committee of Leiden University Medical Center, the Netherlands. All 
animals received humane care and maintenance in compliance with the ‘‘Code of 
Practice Use of Laboratory Animals in Cancer Research’’ (Inspectie W&V, July 1999). 
All animals were housed in the animal facility of the Leiden University Medical 
Center. Pellet food and fresh tap water were provided ad libitum. The weight of 
the animals was followed throughout the experiment to monitor their general 
health state. Throughout tumor inoculation, imaging, and surgical procedures, the 
animals were anesthetized with 5% isoflurane for induction and 2% isoflurane for 
maintenance in oxygen with a flow of 0.8 L/min and placed on an animal bed with 
an integrated nose mask. 
Tumor models
Subcutaneous colon tumors were induced in 6 week-old CD1-Foxn1nu female 
mice (Charles River Laboratories, Wilmington, MA, USA) weighing 25 - 35 g by 
subcutaneous injection at 4 sites with 5 x 105 HT29-luc2 cells in 40 µL RPMI1640 
medium per site. Tumor growth was monitored longitudinally using a digital caliper 
and with bioluminescence imaging (BLI) after an intraperitoneal injection of 150 
mg/kg of D-luciferin solution (SynChem, Inc., Elk Grove Village, IL) in PBS in a total 
volume of 50 µL 10 minutes prior to imaging using the IVIS Spectrum imaging 
system (Caliper LifeSciences, Hopkinton, MA, USA). In order to induce orthotopic 
tumors, subcutaneously growing HT29-luc2 colon tumors were harvested and 
subsequently transplanted onto the cecum of a healthy mouse, according to the 
model described by Tseng et al.35 (fig. 4a). Briefly, the cecal wall was slightly incised 
to facilitate tumor cell infiltration and small tumor fragments (approximately 2 
mm) were transplanted on the cecal wall using a 6-0 suture. Tumor growth was 
monitored using BLI. 
In Vivo biodistribution and ureteral visualization
The ability to visualize gastrointestinal tumors in close proximity to other organs 
was investigated in nude mice bearing orthotopic HT29 tumors. As cRGD-ZW800-1 
is cleared renally, a single intravenous injection could potentially also permit 
ureteral visualization. However, it showed to be challenging to visualize the ureter 
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in nude mice weighing only 25-35 g. Therefore, to validate in vivo biodistribution 
and ureteral visualization, cRGD-ZW800-1 was also administered to male WAG/Rij 
rats (Harlan, Horst, The Netherlands) weighing approximately 300–350 g. 
NIR fluorescence imaging
When tumors were measured 5 mm in diameter, the fluorescent probe was 
injected. 1 nmol cRGD-ZW800-1 (N = 3), 1 nmol cRAD-ZW800-1 (N = 3), or 1 
nmol ZW800-1 (N = 3) was injected intravenously in mice bearing subcutaneous 
tumors. NIR fluorescent signal was measured at 0.3, 0.5, 1, 2, 4, 8, 24, and 48 h after 
injection using the FLARE imaging system and signal-to-background ratios were 
calculated. Subsequently, cRGD-ZW800-1 was injected at dosages of 1 and 0.25 
nmol in mice with orthotopically transplanted cecal tumors (N = 6). To observe 
in vivo biodistribution and ureteral visualization, 30 nmol cRGD-ZW800-1 was 
injected intravenously in 3 Wag/Rij rats. After injection, NIR fluorescent signal of 
the liver, small bowel, colon, kidney, and bladder was measured over time. NIR 
fluorescence measurements were performed using the FLARE imaging system as 
described before 36.
Histological analysis
Subcutaneous tumors were surgically removed and processed. Snap frozen tissue 
was sectioned at 6 µm and was scanned on the Odyssey Infrared Imaging System 
(LI-COR Biosciences, Lincoln, NE) using the 800 nm channel. Subsequently sections 
were stained using a hematoxylin and eosin to make an overlay. 
Statistical Analysis
For statistical analysis, SPSS statistical software package (Version 17.0, Chicago, IL) 
was used. To generate graphs, GraphPad Prism Software (Version 5.01, La Jolla, 
CA) was used. Signal-to-background ratios (SBR) were calculated by dividing the 
fluorescent signal of the tumor by fluorescent signal of surrounding tissue. SBR was 
reported in mean and standard deviation. To compare SBRs between dose groups 
and time points, and to assess the relation between dose and time, a mixed model 
analysis was used. When a significant difference was detected, a one-way ANOVA 
was used to post-test for differences between separate dose groups and/or time 
points. The one-way ANOVA was corrected using the Bonferroni correction.  P < 
0.05 was considered significant. 
28456 Vorst NW.indd   62 13-03-14   12:29




cRGD and cRAD were conjugated to ZW800-1 as described in the supplementary 
data (Fig. 1). Purity (> 98%) was confirmed by analytical reversed-phase HPLC (770 
nm absorbance) and MALDI-TOF. 
Figure 1 - Structure formulas and optical properties: a: Chemical structures and formulae of cRGDyK and 
cRADyk before and after conjugation to ZW800-1. b: Optical property measurements of cRGD-ZW800-1 and 
cRAD-ZW800-1.
Intraoperative NIR Fluorescence Imaging Mice with Subcutaneous tumors
Three weeks after inoculation, mice were injected intravenously with cRGD-
ZW800-1, cRAD-ZW800-1, or ZW800-1 alone. All subcutaneous tumors of mice could 
be clearly identified after injection of cRGD-ZW800-1 using NIR fluorescence (SBR 
at 24 h after injection was 2.42 ± 0.77; Fig. 2). No adequate tumor-to-background 
ratios were observed in the control mice injected with cRAD-ZW800-1 (SBR was 
1.21 ± 0.19 at 24 h after injection) or ZW800-1 alone (SBR was 1.34 ± 0.19 at 24 
h after injection). Using a mixed-model analysis, differences in SBRs between 3 
study groups and between time points were significant (P = 0.006 and P < 0.0001, 
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respectively; Fig. 2). Post-testing using a one-way ANOVA showed significant 
differences between the cRGD-ZW800-1 and the cRAD-ZW800-1 (P < 0.0001) study 
groups and between the cRGD-ZW800-1 and ZW800-1 alone (P < 0.0001) study 
groups. No significant difference was found between cRAD-ZW800-1 and ZW800-1 
alone (P = 1.0). The highest SBRs were measured at 8 (2.33 ± 0.68) and 24 h (2.42 ± 
0.77) after administration of cRGD-ZW800-1. 
Histological analysis
Using the Odyssey Infrared Imaging System, clear differences were observed 
between 3 study groups. An increased fluorescent signal was observed in tumors 
harvested from mice in which cRGD-ZW800-1 was injected and a weak fluorescent 
signal was measured in tumors harvested from mice in the control groups (cRAD-
ZW800-1 and ZW800-1 alone) (Fig. 3). 
Intraoperative NIR Fluorescence Imaging in Mice with Orthotopic Tumors
In 6 mice with orthotopically transplanted colon tumors, tumor growth was assessed 
using BLI (Fig. 4b). After 30 days, BLI measurements showed approximately 5.0 x 
106 counts and cRGD-ZW800-1 was administered intravenously. cRGD-ZW800-1 
was administered at dosages of 1 (N = 3) and 0.25 nmol (N = 3) (Fig. 4c). In all mice, 
tumors could be adequately differentiated from surrounding healthy bowel tissue 
(Fig. 4c and d). Average SBR in these mice was 2.62 ± 0.17 and 1.75 ± 0.36 for the 1 
and 0.25 nmol dose groups respectively. 
In vivo Biodistribution and Ureteral Visualization in Rats
To assess the potential use of cRGD-ZW800-1 for both intraoperative detection of 
gastrointestinal tumors and ureteral identification, the NIRF intensity of abdominal 
organs was quantified over time in 3 male Wag/Rij rats. After administration of 
cRGD-ZW800-1 intravenously, medial laparotomy was performed and signal in liver, 
small bowel, colon, kidney, and bladder was measured. Time points were 0, 0.1, 0.5, 
1, 2, 3, 4, 8, and 24 h after intravenous administration (fig. 5). Average fluorescence 
intensities (normalized arbitrary units, AU) at t = 2 hour, were: 594 (± 163), 599 (± 
65), 443 (± 169), 6172 (± 3250) and 21714 (± 2102) for the liver, small bowel, colon, 
kidney, and bladder respectively. Figure 5a shows an example in which the ureters 
could clearly be visualized, 30 minutes after injection of cRGD-ZW800-1. 
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Figure 2 – In vivo NIR fluorescence imaging of mice bearing subcutaneous tumors: a: NIR fluorescence 
imaging of mice bearing subcutaneous HT-29-Luc2 tumors 2 h after administration of 1 nmol cRGD-
ZW800-1 (upper row), 1 nmol RAD-ZW800-1 (middle row), and 1 nmol ZW800-1 (lower row). b: NIR 
fluorescence imaging of the same cRGD-ZW800-1 mice 24 and 48 h after dye administration. Scale bars 
represent 1 cm. b: Tumor-to-background ratios over time. Plotted are the tumor-to-background ratios 
(mean, SEM) of cRGD-ZW800-1 (blue line), cRAD-ZW800-1 (yellow), and ZW800-1 alone (green). d: Signal-to-
background ratio (mean, SEM) 24 h after administration of 1 nmol of fluorophore.
DISCUSSION
 The present study reports the use of a ligand (cRGD) conjugated to 
ZW800-1 that targets integrins in low dosage range for NIR fluorescence imaging 
during surgery. cRGD-ZW800-1 was successfully used in both subcutaneous and 
orthotopic mouse models to identify malignant cells. Because contrast agents 
can accumulate in tumors via enhanced permeability and retention (EPR)37-41, 2 
negative control groups (cRAD-ZW800-1 and ZW800-1 alone) were included to 
confirm specificity of the fluorescent signal in tumors. 
With regards to an oncologic resection, in which all tumor cells need to be resected, 
a specific NIR fluorescent signal is vital. We aimed to develop a fluorescent agent 
with a low non-specific tumor accumulation component and high specific 
targeting. Choi et al. recently published the use of the targeted zwitterionic near-
infrared fluorophore cRGD-ZW800-1 and compared it with commercially available 
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fluorophores.15 It was shown that cRGD-ZW800-1 outperformed the commercially 
available dyes in vitro for immunocytometry, histopathology and immunoblotting 
and in vivo for image-guided surgery. However, as this was not the design of the 
study, no negative controls were used in in vivo image-guided surgery models. 
Therefore, the current study aimed to test the specificity of cRGD-ZW800-1. Mice 
injected with cRAD-ZW800-1 or ZW800-1 alone showed no tumor signal both 
during in vivo imaging using the FLARE imaging system and ex vivo imaging 
using the Odyssey imaging system. Since cRGD-ZW800-1 and cRAD-ZW800-1 are 
comparable with regards to size, charge, and solubility, it can be stated that it’s 
highly probable that the cRGD-ZW800-1 signal is specific.  
Figure 3 – Fluorescence microscopy: Shown are hematoxylin and eosin (H&E) staining (left column) with 
a pseudo-colored green NIR fluorescence overlay (Odyssey, right column) of a 5 μm tissue section of a 
subcutaneously growing colon tumor using a 5 X objective. A high fluorescent signal was observed after 
cRGD-ZW800-1 administration using the Odyssey compared to cRAD-ZW800-1 and ZW800-1. Scale bars 
represent 500 μm.
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Figure 4 Intraoperative imaging of orthotopic colon tumors: a: Schematic overview of the induction of 
an orthotopic tumor model. Subcutaneously growing HT29-luc2 colon tumors were resected and 
transplanted onto the cecum of a healthy mouse. b: tumor growth monitoring using noninvasive 
bioluminescence imaging. c: Shown are 2 examples of cRGD-ZW800-1 administered intravenously, which 
allowed clear tumor identification using NIR fluorescence in orthotopic colon tumor bearing mice. cRGD-
ZW800-1 was injected at dosages of 1 nmol and 0.25 nmol. Scale bars represent 1 cm. d: H&E and fluorescence 
overlay of the border between tumor and normal colon tissue.
Imaging in the peritoneal cavity can be challenging, mostly due to high levels 
of background fluorescence when tracers are cleared by the liver. In this study, 
high tumor-to-background ratios were observed in the orthotopic tumor model 
due to the low hepatic clearance and the resulting low fluorescent signal in the 
gastrointestinal tract. 
Since cRGD-ZW800-1 is cleared renally, it permits ureteral visualisation in addition 
to tumor imaging. Noninvasive detection of the ureters using NIR fluorescence 
has several advantages over conventional ureteral stent placing as it can be used 
within minutes after dye administration during both open and laparoscopic 
surgery. Besides, placement of ureteral stents is an invasive procedure that harbors 
an increased risk of complications such as ureteral perforation, urinary tract 
infection, and acute renal failure. Clinical feasibility to identify the ureters using NIR 
imaginghas recently been demonstrated.42 Using cRGD-ZW800-1 for both tumor 
and ureter imaging during lower abdominal procedures, surgical outcome could 
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be greatly improved, while reducing morbidity. Furthermore, this technique will be 
of even greater value in laparoscopic surgery as no tactile information can be used. 
To date, several laparoscopic imaging systems are commercially available, however, 
further technical developments are in progress to facilitate optimal real-time NIR 
fluorescence guidance in relation to surgical anatomy.43,44
Figure 5 – In vivo biodistribution and ureteral visualization in rats: a: Both ureters (arrowheads) could 
clearly be observed after injection of cRGD-ZW800-1 using NIR fluorescence imaging. b: Fluorescence 
intensity of abdominal organs was measured using the Mini-FLARE camera system in 3 rats at several time 
points. c: Signal-to-background ratio of both kidney and ureter is shown over time. Based on these curves 
the ideal window for ureter visualization appears to lie between 10 min and 8 h. Bars represent mean ± SEM.
 Since cRGD has been extensively used for clinical imaging studies45,46, toxicity 
and safety data are more available when compared to newly synthesized ligands. 
In these clinical studies, galacto-cRGD was conjugated to fluorodeoxyglucose (18F). 
However, as cRGD (yK) is more hydrophilic compared to galacto-RGD, the cRGDyK 
variant was used in this study and will be used for clinical translation. 
Another advantage of cRGD-ZW800-1 is that it permits clear tumor and ureteral 
visualization at low dosages compared to current FDA/EMA approved NIR 
fluorophores (ICG and Methylene blue). When the dosages used in mice and rats 
are converted by body surface area, 0.25, 1, and 30 nmol is equivalent to a total 
human dose of 0.096, 0.39, and 1.33 mg respectively. These dosages are much 
lower compared to the commonly used amounts of ICG (10-25 mg) and methylene 
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blue (15-60 mg). In addition, a dose of 0.25 nmol in mice corresponds to a human 
equivalent dose of < 100 µg, which is below the FDA threshold for micro-dosing 
and portends more rapid clinical translation.47,48
 In conclusion, the present study reports the use of a recently developed 
fluorescent probe with minimal background uptake in the gastrointestinal tract. 
cRGD-ZW800-1 showed clear uptake in both a subcutaneous and an orthotopic 
colon cancer mouse model. Moreover, as cRGD-ZW800-1 is cleared renally, ureteral 
visualization is feasible after a single injection. As a low probe dose was used, clinical 
translation of these results is possible.
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Near-infrared (NIR) fluorescence imaging has the potential to improve sentinel 
lymph node (SLN) mapping in vulvar cancer, which was assessed in the current 
study. Furthermore, dose optimization of indocyanine green adsorbed to human 
serum albumin (ICG:HSA) was performed. 
Material and Methods
Nine vulvar cancer patients underwent the standard SLN procedure using 
99mtechnetium-nancolloid and patent blue. In addition, intraoperative imaging was 
performed after peritumoral injection of 1.6 mL of 500, 750 or 1000 mM of ICG:HSA.
Results 
NIR fluorescence SLN mapping was successful in all patients. A total of 14 SLNs 
(average 1.6, range 1-4) were detected: 14 radioactive (100%), 11 blue (79%), and 
14 NIR fluorescent (100%). 
Conclusions
This study demonstrates feasibility and accuracy of SLN mapping using ICG:HSA. 
Considering safety, cost, and pharmacy preferences, an ICG:HSA concentration of 
500 mM appears optimal for SLN mapping in vulvar cancer.
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INTRODUCTION
Vulvar cancer is a relatively rare disease with an annual incidence of approximately 
4000 cases in the United States, resulting in 900 deaths per year.1 Tumor size and 
invasion into adjacent tissues are important factors for staging vulvar cancers, but 
nodal status remains the single most important prognosticator.2 Radical vulvectomy 
with en bloc inguinofemoral lymphadenectomy has been replaced in the surgical 
treatment of vulvar cancer by radical wide local excision or radical vulvectomy 
with inguinofemoral lymphadenectomy using separate groin incisions.3 The latter 
modification has significantly decreased surgery-related morbidity.3 However, 
30% to 70% of patients treated with full inguinofemoral lymphadenectomy still 
suffer from lymphedema.4-6 Only 27% of patients with clinically stage I or II vulvar 
cancer have tumor positive lymph nodes; therefore, approximately 70% of patients 
undergo unnecessary lymphadenectomy.6
 The sentinel lymph node (SLN) biopsy, as introduced in the management 
of cutaneous melanoma by Morton,7 was first described in vulvar cancer by 
Levenback in 1994.8 The SLN procedure in vulvar cancer patients has been validated 
in multicenter trials and its introduction in regular clinical practice has marked a 
significant reduction in lymphedema, wound infection, and wound dehiscence.9, 10 
Currently, the procedure usually involves a combination of a radioactive colloid and 
a blue dye. However, the use of radiotracers requires complex logistics including 
the involvement of a nuclear medicine physician and the transport of radioactivity, 
and is therefore not available in all clinics.. Moreover, blue dyes cannot be visualized 
when the lymph nodes and lymphatic channels are covered by tissue, such as skin 
or fat.
 The use of invisible near-infrared (NIR) light (700-900 nm) has several 
characteristics that can be advantageous in the SLN procedure, which include 
relatively high penetration into living tissue (millimeters to centimeters), when 
compared to blue dyes, and the lack of ionizing radiation.11 Indocyanine green 
(ICG) is one of only 2 clinically available NIR fluorescent agents and is currently 
the most optimal agent for SLN mapping.12 In several studies, intraoperative 
imaging systems in combination with ICG have been used for the SLN procedure 
for various types of cancer.13-18 The lymphatic channels and SLNs in vulvar cancer 
are often located in a relatively superficial location in the groin when compared 
to other tumors; therefore, NIR fluorescence imaging could be particularly useful 
for this indication. Indeed, Crane et al. reported the successful use of ICG alone at 
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a concentration of 645 mM, in conjunction with an intraoperative imaging system 
for the SLN procedure in vulvar cancer.19 In that study involving 10 patients, 26 of 
29 SLNs (90%) were detected in vivo by NIR fluorescence. Furthermore, lymphatic 
channels could be visualized in 5 of 16 groins (31%) containing SLNs.
 Preclinical evidence demonstrated that premixing of ICG with human 
serum albumin (HSA, complex is ICG:HSA) increases the fluorescence intensity and 
hydrodynamic diameter of ICG, resulting in better retention in the SLN.20 The aims of 
the current study were to assess the use of NIR fluorescence imaging using ICG:HSA 
and the Mini-FLARE intraoperative imaging system for the SLN procedure in vulvar 
cancer and to optimize ICG:HSA dose.
MATERIAL AND METHODS
Preparation of Indocyanine Green Adsorbed to Human Serum Albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 mL of sterile water for injection for the 500 µM group, or 
in 5 mL of sterile water for injection for the 750 µM and 1000 µM groups, to yield 
stock solutions of 3.2 mM and 6.4 mM, respectively. Various amounts of this stock 
solution were transferred to a 50 cc vial of Cealb (20% human serum albumin [HSA] 
solution; Sanquin, Amsterdam, The Netherlands) to yield ICG in HSA (ICG:HSA) at a 
final concentration of 500 µM, 750 µM, or 1000 µM.
Intraoperative NIR Fluorescence Imaging
SLN mapping was performed using the Mini-FLARE image-guided surgery system 
as described in detail previously.14 Briefly, the system consists of 2 wavelength 
separated light sources: a “white” LED light source, generating 26,600 lx of 400 to 650 
nm light to illuminate the surgical field and an NIR LED light source, generating 7.7 
mW / cm2 of fluorescence excitation light. White light and NIR fluorescence images 
are acquired simultaneously and displayed in real time, using custom designed 
optics and software. A pseudo-colored (lime green) image of NIR fluorescence 
superimposed over the white light image is also displayed, to provide the NIR 
fluorescence signal in proper anatomical context.
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Clinical Trial
The current dose escalation clinical trial was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and was performed in concordance with 
the ethical standards of the Helsinki Declaration of 1975. Nine consecutive patients 
that planned to undergo a SLN procedure for squamous cell vulvar carcinoma 
were included in this study between June 2010 and January 2011. All patients had 
clinically FIGO stage I vulvar cancer with a unifocal carcinoma measuring less than 
4 cm in diameter, not encroaching the vagina, anus or urethra and with negative 
inguinofemoral nodes as determined by palpation and ultrasonography. Exclusion 
criteria were pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine green. 
 All patients gave informed consent and were anonymized. Patients 
received the standard-of-care SLN procedure.9 For our institution, this implies 
peritumoral injections of 60-100 MBq 99mtechnetium-nanocolloid on the afternoon 
of the day before, or the morning prior to surgery. Before the start of the operation, 
1 mL total of patent blue V (Guerbet, France) was injected at 4 sites peritumorally. 
Immediately after injection of patent blue, 1.6 mL total of ICG:HSA was injected 
as 4 injections at the same location as the patent blue injections. After surgical 
scrub, the Mini-FLARE imaging head was positioned at approximately 30 cm above 
the surgical field. The NIR fluorescence signal was measured percutaneously, prior 
to skin incision, and continuously during the surgical procedure. Throughout the 
procedure, the surgeon was continuously provided with real-time NIR fluorescence 
image guidance. When the SLN could not be found easily by NIR fluorescence, 
the handheld gamma probe could be used for the localization of SLNs. Relative 
brightness of the SLNs was determined by measuring signal-to-background ratios 
(SBR), that is the NIR fluorescence signal of the SLN divided by a directly adjacent 
region. Excised sentinel lymph nodes were analyzed ex vivo for NIR fluorescence 
and radioactivity and were routinely analyzed by histopathological frozen section 
analysis. SLNs were fixed in formalin and embedded in paraffin for hematoxylin, 
eosin, and immunohistopathological staining for AE1/AE3 at multiple levels, with 
an interval of 250 μm, according to the GROningen INternational Study on Sentinel 
nodes in Vulvar cancer (GROINSS-V) study protocol.9
Statistical Analysis
For statistical analysis, SPSS statistical software package (Version 17.0, Chicago, IL) 
was used. Graphs were generated using GraphPad Prism Software (Version 5.01, La 
Jolla, CA). To compare the SBR between concentration groups, a one-way analysis 
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of variance (ANOVA) was performed with pairwise comparison with least square 
difference (LSD) adjustment for multiple comparisons. Assumption of homogeneity 
of variances was assessed using Levene’s test. All statistical tests were two-tailed 
and P < 0.05 was considered significant.
RESULTS
Patient and Tumor Characteristics
Nine consecutive patients with vulvar cancer undergoing SLN mapping were 
included in this study. Patients and tumor characteristics are described in Table 
1. Median body mass index (BMI) was 27 (range 23-45), median age was 50 years 
(range 30-72 years), and median tumor size was 13 mm (range 4-22 mm). In 6 
patients, the tumor was laterally located and in 3 patients the tumor was located 
on, or near, the midline.










1 500 72 33 Right 22
2 500 30 22 Right 10
3 500 67 26 Left 10
4 750 37 29 Midline 17
5 750 42 45 Left 22
6 750 37 23 Right 20
7 1000 72 27 Midline 6
8 1000 50 26 Midline 4
9 1000 74 32 Left 13
Abbreviation: BMI = body mass index
Intraoperative NIR Fluorescence Imaging
Average time between ICG:HSA injection and skin incision was 19 ± 4 minutes. In 
all patients (N = 9), NIR fluorescence imaging using the Mini-FLARE system enabled 
visualization of one or more SLNs (Figure 1). Average time between skin incision 
and resection of the first SLN was 13 ± 5 minutes. A total of 14 SLNs were detected, 
all of which were radioactive and fluorescent (Table 2). Four SLNs from 3 patients 
did not have blue staining from patent blue. After all NIR fluorescent nodes were 
resected, the surgical field was systematically inspected for remaining radioactivity 
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or blue nodes. No additional nodes were found that were not detected by NIR 
fluorescence. No adverse reactions associated with the use of ICG:HSA or the Mini-
FLARE imaging system were observed.
Table 2 – SLN Identification Results
Patient
Number of





1 2 (1 left, 1 right) 2 2 2 0 Unilateral
2 1 (right) 1 1 1 0 Yes
3 1 (left) 1 1 1 1 Yes
4 2 (1 right, 1 left) 2 1 2 0 Unilateral
5 1 (left) 1 1 1 0 No
6 1 (right) 1 1 1 0 Yes
7 1 (left) 1 0 1 0 Yes
8 4 (2 left, 2 right) 4 3 4 0 Yes
9 1 (left) 1 1 1 1 No
Total 14 14 (100%) 11 (79%) 14 (100%) 2 8 of 12 groins
Abbreviations: SLN+ = number of SLNs containing tumor cells
The Effect of Lymphatic Tracer Dose on SLN Brightness
The effect of injected lymphatic tracer dose on fluorescence brightness was 
determined by comparing SBRs between concentration groups. Mean SBRs 
of the SLNs were 12.3 ± 2.9, 16.6 ± 4.3, and 9.5 ± 4.3 for the 500, 750 and 1000 
µM concentration groups, respectively (Figure 2). A one-way ANOVA showed no 
significant effect of concentration on SBR (P = 0.16), and pairwise comparison 
with LSD adjustment for multiple comparison showed no difference between the 
individual concentration and SBR, although a trend was found for a decreased SBR 
of the 1000 µM group when compared to the 750 µM group (P = 0.07). However, 
due to the small sample size, the current pilot study may not have sufficient power 
to detect significant differences in dose groups. 
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Figure 1 – Sentinel lymph node mapping using NIR fluorescence imaging in vulvar cancer: Peritumoral 
injection of 1.6 mL of 500 µM ICG:HSA (injection site covered by hand) identifies lymphatic channels, which 
converge in a SLN (arrow) that can be seen percutaneously (top row). Identification of the SLN (arrow) and 2 
afferent lymphatic channels (arrowheads) is demonstrated using NIR fluorescence imaging 17 min after 
injection of ICG:HSA (bottom row). Camera exposure times were 100 msec (top row) and 45 msec (bottom 
row). Scale bars represent 1 cm.
Figure 2 – Optimization of ICG:HSA dose: Signal-to-background ratio (mean ± S.D.) of vulvar SLNs 
(ordinate) is plotted as a function of injected dose of ICG:HSA (abscissa). The SBRs of the 500, 750, and 100 
µM concentration groups were not significantly different, although a trend was found favoring 750 µM over 
1000 µM (P = 0.07).
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Percutaneous Visualization of Lymphatic Channels
The mean BMI of patients in which lymphatic channels were visualized percutaneously 
to all SLN containing groins (N = 5 patients) was 24.8 ± 2.2. In patients with bilateral 
SLNs in which percutaneous visualization was possible for the groin (N = 2 patients), 
the mean BMI was 31.0 ± 2.8, and in patients where percutaneous visualization of 
lymphatic channels was not possible (N = 2 patients), the mean BMI was 38.5 ± 9.2. A 
one-way ANOVA showed a significant difference in the BMIs between these 3 groups 
(P = 0.024). A pairwise comparison with LSD adjustment for multiple comparison 
showed a significantly higher BMI for the group in which percutaneous visualization 
of lymphatic channels was not possible, when compared to the group in which 
percutaneous visualization of lymphatic channels was possible (P = 0.009). 
DISCUSSION
The current study showed feasibility and accuracy of SLN mapping in vulvar cancer using 
ICG:HSA and the Mini-FLARE imaging system. In all 9 cases, the Mini-FLARE permitted 
the gynecologist to perform SLN mapping under direct image-guidance after skin 
incision. The flexible gooseneck of the Mini-FLARE could be used to position the system 
at any required location over the surgical field, which ensured no interference with the 
procedure. Indeed, no additional time was needed to complete the procedure, with 
an average time between skin incision and resection of the first SLN of 13 ± 5 minutes.
 All radioactive SLNs could also be detected by NIR fluorescence. This higher 
detectability compared to the study by Crane et al. that utilized ICG alone19 may be 
due to improved brightness of ICG:HSA over ICG, better retention in the SLN, better 
imaging system performance, an optimized tradeoff between injection concentration 
and tracer dilution within lymphatic channels, or a combination thereof.14 In contrast, 4 
out of 14 SLNs could not be detected by patent blue, which is comparable to previous 
findings.10, 19, 21 Lymphatic channels could be visualized in the majority of patients prior to 
skin incision. This aided the gynecologist in determining the location of the incision and 
facilitated a more efficient identification of SLNs. In the patients where percutaneous 
visualization of lymphatic channels was not possible, a higher BMI was observed when 
compared to patients where the lymphatic channels could be visualized percutaneously. 
Crane et al. observed similar findings.19 Future studies will have to determine whether 
NIR fluorescence imaging can replace radiocolloids in the SLN procedure in vulvar 
cancer, which could potentially be feasible only in non-obese patients. This could be 
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particularly beneficial in clinics where radiotracers are not available. Furthermore, as 
the patient population in Western societies tends to suffer from increasingly higher 
BMIs, the penetration depth has to be increased for NIR fluorescence imaging to be a 
generally usable imaging modality. To accomplish this, current research is focusing on 
improved fluorophores (some of which are currently in the process of clinical approval22) 
and  improved camera systems using optimized detection techniques to maximize the 
depth at which a fluorophore can be detected.23, 24
In the current study, no significant differences in NIR fluorescence signal 
were observed between the different concentrations that were administered. 
However, a trend was observed showing a decline of signal in the 1000 mM group, 
which is in line with previously reported results in breast cancer.14 A decrease of 
fluorescence signal with an increase in concentration can be explained by an effect in 
fluorescence quenching.12 Fluorescence quenching occurs when the concentration 
of a fluorophore is too high, causing molecules to absorb the emitted light of 
other nearby molecules, thereby effectively attenuating the fluorescence signal. 
In the current study, ICG was adsorbed to HSA prior to injection. Preclinical work 
has shown premixing to increase the fluorescence brightness of ICG and improve 
retention in the SLN.20 Flow to higher tier nodes seemed to have been avoided, as 
no additional NIR fluorescent nodes were identified that were not radioactive.  An 
ongoing study is investigating whether the albumin is actually needed for optimal 
SLN mapping in vulvar cancer. When the optimal imaging parameters have been 
determined, larger trials can be performed to assess patient benefit.
In conclusion, the current study demonstrates the feasibility of SLN mapping 
in vulvar cancer patients using ICG:HSA and the Mini-FLARE image-guided surgery 
system. The preferred dose can be determined by local preparation preferences 
because no differences between tested doses were observed. In general, a dose 
of 500 mM seemed to be optimal, as it requires minimal manipulation of ICG and 
albumin volumes.
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In early cervical cancer, a total pelvic lymphadenectomy is the standard of care even 
though most patients have negative nodes and thus undergo lymphadenectomy 
unnecessarily. Although the value of sentinel lymph node mapping in early stage 
cervical cancer has not yet been established, near-infrared (NIR) fluorescence 
imaging is a promising technique to perform this procedure. NIR fluorescence 
imaging is based on invisible NIR light and can provide high sensitivity, high-
resolution, and real-time image-guidance during surgery.
Material and Methods
Clinical trial subjects were 9 consecutive cervical cancer patients undergoing total 
pelvic lymphadenectomy. Prior to surgery, 1.6 mL of indocyanine green adsorbed 
to human serum albumin (ICG:HSA) was injected transvaginally and submucosally 
in 4 quadrants around the tumor. Patients were allocated to 500, 750, or 1,000 µM 
ICG:HSA concentration groups. The Mini-FLARE™ imaging system was used for NIR 
fluorescence detection and quantitation.
Results
Sentinel lymph nodes were identified in all 9 patients. An average of 3.4 ± 1.2 sentinel 
lymph nodes was identified per patient. No differences in signal to background 
of the sentinel lymph nodes between the 500, 750, and 1,000 µM dose groups 
were found (P = 0.73). In 2 patients, tumor-positive lymph nodes were found. In 
both patients, tumor-positive lymph nodes confirmed by pathology were also NIR 
fluorescent.
Conclusion
This study demonstrated preliminary feasibility to successfully detect sentinel lymph 
nodes in cervical cancer patients using ICG:HSA and the Mini-FLARE™ imaging 
system. When considering safety, cost-effectiveness, and pharmacy preferences, 
an ICG:HSA concentration of 500 µM was optimal for sentinel lymph node mapping 
in cervical cancer patients. 
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INTRODUCTION
 Approximately 11,000 women are diagnosed with cervical cancer 
annually in the United States, resulting in over 4,000 deaths per year.1 Cervical 
cancer is also the most common cause of cancer-related death in women in 
developing countries.2 The prognosis of cervical cancer patients depends on 
tumor stage and tumor size, but nodal status remains the single most important 
prognostic factor.  The surgical treatment of invasive cervical cancer depends 
upon the FIGO stage of the patient at time of diagnosis.3 In early stage cervical 
cancer, a radical hysterectomy is performed in combination with a bilateral 
pelvic lymphadenectomy to detect lymphatic spread. Nodal tumor involvement 
occurs in up to 27% of early stage cervical cancer patients 4 and in these patients, 
radiotherapy or chemoradiation is the primary treatment of choice.5 Therefore, a 
total lymphadenectomy is performed unnecessarily in a substantial fraction of 
patients, exposing them to the risk of lymphedema and surgical injuries. 
 SLN mapping and biopsy is an accepted procedure for vulvar cancer, 
cutaneous melanomas, and breast cancer; however, its reliability for clinical use 
in the treatment of early stage cervical cancer has not yet been established.6,7 
Research on the use of the SLN procedure in early stage cervical cancer patients has 
been extensively described using a blue dye, a radiocolloid such as 99mTechnetium 
(99mTc), or a combination of both with various results.8,9 Van de Lande et al. published 
a literature review involving over 800 patients with cervical cancer in which they 
described detection rates of 84%, 88%, and 97% when using blue dye alone, 99mTc 
alone, or a combination of both, respectively.10 Regarding the sensitivity to detect 
the SLNs, 99mTc, alone or in combination with blue dye, yielded the highest pooled 
sensitivity (92%, range 79%-98%); however, this was not significantly higher than 
the pooled sensitivity of blue dye alone (82%, range 67%-92%). 
 Due to the midline position of the cervix, it often has a bilateral multifarious 
drainage pattern, which makes the SLN procedure in cervical cancer patients 
more challenging than in breast cancer patients, for example. The main lymphatic 
drainage patterns have been described previously11, and several studies have 
shown that satisfactory SLN detection in cervical cancer is established when SLNs 
are detected on both sides of the pelvis. Of note, status of a SLN on one side of the 
pelvis does not predict the nodal status of the other side.12 
 
28456 Vorst NW.indd   89 13-03-14   12:30
Chapter 6
90
 NIR fluorescence imaging is a technique that can be used in real time 
during surgery. This technique uses invisible near-infrared light that can be 
visualized using specialized camera systems.13 NIR fluorescence imaging has several 
advantages, such as relatively high tissue penetration (up to 5 millimeters without 
special techniques), low autofluorescence, and the lack of ionizing radiation.14 
Recent preclinical and clinical studies have demonstrated that near-infrared (NIR) 
fluorescence imaging using the NIR fluorescence agent indocyanine green (ICG) 
enables real-time intraoperative visualization of lymphatic channels and detection 
of the SLNs in various forms of cancer without the need for radioactivity.15 
Furthermore, previous preclinical work has demonstrated that adsorption of ICG 
to human serum albumin (HSA, complex is ICG:HSA) increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection 
and better retention in the SLN.16
 Crane et al. recently described that the use of NIR fluorescence imaging in 
cervical cancer patients is technically feasible.17 ICG was injected after laparotomy. In 
this pilot study, a detection rate of 60% was reached, bilateral SLNs were detected in 
30% of patients and 1 of 2 patients who had nodal involvement was false-negative. 
 The aim of the current study was to assess the intraoperative use of NIR 
fluorescence imaging using ICG:HSA and the Mini-FLARE™ imaging system in SLN 
biopsy in cervical cancer patients. A secondary goal was to optimize the dose of 
the ICG:HSA NIR fluorescent lymphatic tracer.
MATERIAL AND METHODS
Preparation of Indocyanine Green Adsorbed to Human Serum Albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml 
(3.2 mM) stock solution for the 500-µM concentration group. Of this solution, 7.8 
cc was transferred to a 50- cc vial of Cealb (20% human serum albumin (HSA) 
solution; Sanquin, Amsterdam, The Netherlands) to yield ICG in HSA (ICG:HSA) at a 
final concentration of 500 µM. ICG (25 mg vials) was resuspended in 5 cc of sterile 
water for injection to yield a 5.0 mg/ml (6.4 mM) for the 750-µM and 1,000-µM 
concentration groups. Of this solution, 5.8 cc or 7.8 cc was transferred to a 50-cc vial 
of Cealb (20% human serum albumin (HSA) solution to yield ICG in HSA (ICG:HSA) 
at a final concentration of 750 µM or 1,000 µM, respectively.
28456 Vorst NW.indd   90 13-03-14   12:30
Sentinel lymph node mapping in cervical cancer using NIR fluorescence
91
Intraoperative NIR Imaging System (Mini-FLARE™)
SLN mapping was performed using the Mini-FLARE™ image-guided surgery system 
as described by Mieog et al.15  Briefly, the system consists of 2 wavelength-isolated 
light sources: a “white” light source, generating 26,600 lx of 400-650 nm light and 
a “near-infrared” light source, generating 7.7 mW/cm2 of 760 nm light. Color video 
and NIR fluorescence images are simultaneously acquired and displayed in real 
time using custom optics and software that separate the color video and NIR 
fluorescence images. A pseudo-colored (lime green) merged image of the color 
video and NIR fluorescence images is also displayed. The imaging head is attached 
to a flexible gooseneck arm, which permits positioning of the imaging head virtually 
anywhere over the surgical field, and at extreme angles. For intraoperative use, the 
imaging head and imaging system pole stand are wrapped in a sterile shield and 
drape (Medical Technique Inc., Tucson, AZ).
Clinical Trial
The single-institution clinical trial was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and was performed in accordance with 
the ethical standards of the Helsinki Declaration of 1975. A total of 9 consecutive 
patients with cervical cancer that planned to undergo a radical abdominal 
trachelectomy or a radical hysterectomy and a total pelvic lymphadenectomy 
were included. All patients provided informed consent and were anonymized. 
Exclusion criteria were pregnancy, lactation or an allergy to iodine, shellfish, or 
indocyanine green. All procedures were performed by 2 gynecologists who were 
assisted by experienced researchers.  Before the start of surgery, 1.6 mL ICG:HSA 
(concentration: 500, 750 or 1,000 µM) was transvaginally injected submucosally 
in 4 quadrants around the cervical tumor using a 21G, 1½ inch needle. Directly 
after the ICG:HSA injection, surgical scrub and sterile covering of the operation 
field commenced, and a laparotomy was performed. Before the systematic pelvic 
lymphadenectomy was performed, all standard locations (along the external iliac 
vessels and the hypogastric artery, along the common iliac artery, the obturator 
fossa and the lateral parametrium) were examined for NIR fluorescence using 
the Mini-FLARE™ imaging system. Fluorescent hotspots exhibiting a signal-to-
background ratio (SBR) ≥ 1.1 in vivo were considered positive by NIR fluorescence. All 
fluorescent hotspots were denominated as SLNs and were subsequently resected 
and measured for fluorescence ex vivo. Then, the systemic pelvic lymphadenectomy 
was performed and all resected LNs were also measured for fluorescence ex vivo. 
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Lymphadenectomy consisted of removal of all lymph node-bearing fatty tissue 
along the external iliac vessels, the common iliac artery, the hypogastric artery, and 
from the obturator fossa 18. Also, the area lateral to and underneath the superior 
vesical arteries (lateral parametrium) was cleared from the lymphatic tissue. The 
radical hysterectomy and abdominal trachelectomy were performed according 
to the standard procedure. In case of a radical trachelectomy, histopathological 
frozen analysis was performed and when nodes were found to contain metastases, 
a hysterectomy was performed in addition. Afterwards, all resected lymph nodes 
were examined by routine histopathological analysis, and lymph nodes were fixed 
in formalin and embedded in paraffin for routine hematoxylin and eosin staining. 
SLNs and non-SLNs were examined separately. 
Statistical Analysis
For statistical analysis and to generate graphs, GraphPad Prism Software (Version 
5.01, La Jolla, CA) was used. Differences in SBR between concentration groups were 
tested with a one-way analysis of variance (ANOVA) with subsequent pairwise 
comparisons corrected according to the Bonferroni correction. Assumption of 
equal variances was confirmed using Levene’s test. All statistical tests were two-
tailed and P < 0.05 was considered significant. 
RESULTS
Patient and Tumor Characteristics
Patient and tumor characteristics are described in Table 1. Nine patients with 
stage Ib cervical cancer undergoing primary surgery were included in the study. 
Of these patients, median BMI was 21 (range 18-35), median age was 40 years 
(range 29-77 years), and median tumor size was 3.05 cm (range 0.7-11 cm). One 
patient presented with an exophytic cervical tumor measuring 11 cm in length 
and 4 cm in width protruding into the vagina. Five patients underwent a radical 
hysterectomy and 3 patients underwent a radical trachelectomy. In one patient, 
extensive endometriosis precluded radical hysterectomy. In this patient, the uterus 
was left in situ, but a pelvic lymphadenectomy was performed.
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Type of Surgery Tumor Type Tumor Size 
(cm)
1 500 35 35 IB1 Radical Trachelectomy Adenosquamous 2.5
2 500 43 26 IB2 Radical Hysterectomy Squamous 4.5
3 500 77 21 IB2 Radical Hysterectomy Squamous 11.0
4 750 46 30 IB1 No resection Squamous n/a
5 750 59 21 IB1 Radical Hysterectomy Squamous 4.2
6 750 29 22 IB1 Radical Trachelectomy Squamous 2.5
7 1000 30 18 IB1 Radical Trachelectomy Squamous 1.0
8 1000 40 20 IB1 Radical Hysterectomy Squamous 0.7
9 1000 34 21 IB1 Radical Hysterectomy Squamous 3.6
Intraoperative NIR Fluorescence Imaging
In all patients (N = 9), NIR fluorescence imaging enabled identification of 1 or more 
fluorescent hotspots. An example of the NIR fluorescence images of the procedure 
in cervical cancer is shown in Figure 1. Average time between injection of ICG:HSA 
and NIR fluorescence imaging was 51 ± 18 min. A total of 31 fluorescent hotspots 
were detected. On average, 3.4 ± 1.2 (range 1-5) fluorescent hotspots per patient 
were identified by NIR fluorescence (Table 2). Within these hotspots, a total of 41 
lymph nodes were found after histopathological examination, yielding an average 
of 4.6 ± 2.1 true lymph nodes per patient . In 3 fluorescent hotspots, adipose tissue 
only, with no lymph tissue present, was found after histopathological examination. 
An average of 25.1 lymph nodes (range 10-39) per patient were harvested. 
Histological analysis showed that 2 of 9 patients had metastases in a total of 3 
SLNs. No other lymph node metastases were observed. 
Localization of Sentinel Lymph Nodes
A total of 31 fluorescent hotspots were confirmed to be SLNs. All SLNs were pelvic 
nodes and were identified along the left (n = 8) and right (n = 6) external iliac 
vessels, the right common iliac vessels (n = 4), the left (n = 5) and right (n = 4) 
obturator fossa, and the left (n = 2) and right (n = 2) lateral parametrium. Table 2 
provides exact locations for all SLNs. In 8 of 9 patients, bilateral SLNs were found. 
After histological confirmation, 3 positive SLNs were found in 2 patients. In the first 
patient, the positive SLNs were located in the left lateral parametrium and along 
the right external iliac vessels. In the second patient, the positive SLN was located 
along the left external iliac vessels. 
28456 Vorst NW.indd   93 13-03-14   12:30
Chapter 6
94
Figure 1 – NIR Fluorescence-Based SLN mapping using ICG:HSA and Mini-FLARE™: Identification of 2 
SLNs (arrows), located along the left iliac vessels, with NIR fluorescence imaging is demonstrated in a cervical 
cancer patient, 45 min after administration of 750 µM ICG:HSA. Camera exposure time was 100 msec. Scale 
bar represents 1 cm.
Ex vivo imaging of lymph nodes
All lymph nodes were examined for fluorescence ex vivo using the Mini-FLARE™ 
imaging system. In 4 of 9 patients additional fluorescent hotspots (N=10) were 
identified, which were not identified during in vivo NIR fluorescence imaging 
(Table 2). Within 8 of these 10 hotspots, a total of 10 lymph nodes were found 
after histopathological examination and within 2 of 10 these hotspots, adipose 
tissue only, with no lymph node tissue present, was found after histopathological 
examination. The hotspots that contained lymph nodes were harvested along the 
left (n = 1) and the right (n = 1) external iliac vessels, and the left (n = 1) and 
the right (n = 5) obturator fossa. The hotspots that contained only adipose tissue 
were harvested along the left (n = 1) and the right (n = 1) external iliac vessels. No 
additional metastases were found during ex vivo analysis. 
Optimization of ICG:HSA Dose
In all dose groups (500, 750, and 1,000 µM), fluorescence intensity of the SLN was 
significantly higher than the fluorescence intensity of surrounding tissue (P<0.001). 
Mean SBRs of the SLNs were 10.1 ± 1.2, 10.3 ± 1.2 and 12.0 ± 5.7 for the 500 µM, 
750 µM, and 1,000 µM dose groups, respectively (Figure 2). A one-way ANOVA 
test showed no significant differences in SBRs of SLNs between the different dose 
groups (P = 0.76). 
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Figure 2 – Brightness of SLNs as a Function of ICG:HSA Dose: Signal-to-background ratio (mean ± S.D) 
of the SLNs (ordinate) as a function of injected dose of ICG:HSA (abscissa). Statistical comparisons are as 
follows: The SBRs of the 500, 750, and 1,000 µM concentration groups were not significantly different. 
DISCUSSION
 The current study showed the feasibility of the SLN procedure in early 
stage cervical cancer patients using ICG:HSA and the Mini-FLARE™ imaging system. 
The Mini-FLARE™ imaging system that was used in the current study displays NIR 
fluorescence signal, color signal, and a merge of both and illuminates the surgical 
field with white light. This enabled the gynecologist to perform the SLN detection 
and resection under direct image guidance. The imaging head of the Mini-FLARE™ 
system is attached to a flexible gooseneck arm, which permitted flexible positioning 
of the imaging head at extreme angles over the surgical field. This is of particular 
importance in large abdominal surgery. During all procedures, intraoperative 
imaging using this imaging system was successful and uneventful.
 No differences in SBR of the SLNs between the 500, 750, and 1,000 µM dose 
groups were found. The location of the NIR fluorescent SLNs was in concordance 
with formerly published drainage patterns.11 Furthermore, bilateral SLNs were found 
in 8 of 9 patients. The 3 tumor-positive SLNs (in 2 patients) were located along the 
left external iliac vessels (n = 1), the right external iliac vessels (n = 1), and in the left 
lateral parametrium (n = 1). Identification of a parametrial SLN is rather remarkable 
because there is presently no consensus on removal of parametrial lymph nodes 
during total pelvic lymphadenectomy.19-22 Although larger clinical trials will be 
required to answer this question, from this study we can at least conclude that 
parametrial lymph nodes are identifiable using ICG:HSA and Mini-FLARE™. 
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 The detection rate of SLNs in our pilot-study was 100% and this detection 
rate is in concordance with a prospective, multicenter cohort study of 590 patients 
that examined SLN mapping in cervical cancer patients and observed a detection 
rate of 93.5% when a combination of patent blue and radiocolloids was used.23 
In the current study, on average, a total of 3.4 SLNs were identified per patient 
intraoperatively, which is also consistent with previously published data.8,9 In the 
recently published study by Crane et al.17 on NIR fluorescence SLN mapping in 
cervical cancer patients, ICG was injected after laparotomy and NIR fluorescence 
measurements were made directly after injection. Furthermore, ICG was diluted in 
patent blue prior to injection. These differences in study design along with the use 
of a different imaging system hinder a direct comparison of the results.
  The optimal time interval between injection of ICG:HSA and NIR 
fluorescence imaging is still unknown.  Nevertheless, timing of imaging could be of 
great importance in terms of detection rate, sensitivity, and SBRs of SLNs. The mean 
interval between administration of ICG:HSA and NIR fluorescence measurements 
in the current study was 51 min. This time interval was relatively long because the 
ICG:HSA injection was performed prior to surgery, followed by surgical scrub and 
operation time to expose the iliac vessels. During surgery, no more than several 
minutes were needed for SLN detection and resection.
 Ex vivo NIR fluorescence imaging of total lymphadenectomy specimens 
detected 10 additional fluorescent hotspots in 4 of 9 patients. Detection of these 
additional fluorescent hotspots during ex vivo imaging could possibly be explained 
by the relatively long time interval between ICG:HSA administration and performance 
of the total lymphadenectomy. Although ICG:HSA has an improved hydrodynamic 
diameter compared to ICG alone, passage through the SLN to second tier nodes 
can still possibly occur if the time interval is long enough. An alternative explanation 
for the additional ex vivo detected fluorescent hotspots is that these hotspots were 
missed in vivo due to technical limitations, as for example, the limited penetration depth 
(millimeters) for NIR fluorescent light. Future larger studies are needed to optimize 
timing and to evaluate the importance of additional fluorescent hotspots that are 
missed in vivo and are detected in the resection specimen. Nevertheless, to bypass this 
pitfall, the development of new lymphatic tracers that are retained in the SLN without 
flowing through to higher tier nodes is imperative to optimize NIR fluorescence SLN 
mapping in cervical cancer.
 In the current study, fluorescent hotspots were found in vivo (n = 3) and ex vivo 
(n = 2) that did not contain lymphatic tissue but consisted of adipose tissue, which is 
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not an uncommon observation in the SLN procedure. A plausible explanation for these 
fluorescent hotspots is that fluorescent lymph fluid can exit the lymphatic channel, 
due to extensive manipulation during surgery or anatomical aberrations, for example. 
If detection of a relatively small number of these hotspots does not obfuscate the 
identification of the true SLNs, this phenomenon does not negatively influence the 
SLN procedure.
 In a recently published dose-finding clinical study performed by our group 
using NIR fluorescence SLN mapping in breast cancer patients, an optimal ICG:HSA 
dose range between 400 and 800 µM was found.15 In the 1,000 µM ICG:HSA dose group, 
the fluorescent intensity and the SBR of the SLNs decreased, most probably caused by 
an effect known as fluorescence quenching.24 In the current study, no differences were 
found in SBRs between the 500, 750, and 1,000 µM dose groups. This lack of difference 
combined with pharmacy preferences, safety, previous results, and costs make a dose 
of 500 µM most convenient to perform the SLN procedure in cervical cancer patients.
 As in other areas of surgery, the use of laparoscopy is expanding in cancer 
surgery. Lymphadenectomies are being performed laparoscopically as standard of care 
in several centers. NIR fluorescence may also be of great value in laparoscopic surgery 
because palpation is not possible and the surgeon can only rely on visual inspection 
and preoperative imaging. To implement NIR fluorescence in laparoscopic surgery, 
laparoscopic NIR fluorescence camera systems are currently being developed and 
tested.25 
 In conclusion, we assessed the potential value of NIR fluorescence imaging in 
SLN mapping in early stage cervical cancer patients. Although sample size was small, 
this study showed a high SLN detection rate (100%) and no false-negative lymph nodes. 
However, to prove actual patient benefit and to assess sensitivity more precisely, larger 
clinical trials will be necessary.
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Near-infrared fluorescence imaging using indocyanine green (ICG) has recently been 
introduced as a novel technique for sentinel lymph node (SLN) mapping in early-
stage cervical cancer. Although preclinical research has shown that ICG adsorbed 
to human serum albumin (ICG:HSA) improves its performance, the need for HSA 
has not yet been confirmed in cervical cancer patients. The current randomized 
study aims to determine whether ICG:HSA offers advantages over using ICG alone. 
Material and Methods
Eighteen consecutive early-stage cervical cancer patients scheduled to undergo 
pelvic lymphadenectomy were included. Prior to surgery, 1.6 mL of 500 µM ICG:HSA 
or 500 µM ICG alone was injected transvaginally in 4 quadrants around the tumor. 
The Mini-FLARE imaging system was used for intraoperative NIR fluorescence 
detection and quantitation. 
Results
SLNs were identified intraoperatively in 78% of the patients. Patient and tumor 
characteristics were equally distributed over both treatment groups. No significant 
difference in signal-to-background ratio (9.3 vs. 10.1, P = .72) or average number of 
detected SLNs (2.9 vs 2.7, P = .84) was found between the ICG:HSA group and the 
ICG alone group, respectively.  
Conclusion
In conclusion, this double-blind, randomized trial showed no advantage of ICG:HSA 
over ICG alone for the SLN procedure in early-stage cervical cancer. Further 
optimization is required to improve the intraoperative detection rate. 
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INTRODUCTION
As part of surgical management in early-stage cervical cancer, bilateral 
pelvic lymphadenectomy is considered standard of care. However, pelvic 
lymphadenectomy is associated with complications, such as lymphedema, the 
risk of nerve injury, and lymphocyst formation.1 Because lymph node involvement 
occurs in approximately 12% to 22% of early-stage cervical cancer patients, the 
majority of patients do not benefit from a pelvic lymphadenectomy, but may 
suffer from its complications.2,3 Over the last decades, the sentinel lymph node 
(SLN) concept has proven to be feasible and safe in vulvar cancer, melanoma, and 
breast cancer for selecting patients who would benefit from lymphadenectomy. 
In addition, the SLN can be used for ultra staging to aid in the identification of 
micrometastases.4 However, due to the bilateral multifarious drainage pattern 
of the cervix, the SLN procedure is more challenging in cervical cancer patients 
than in breast cancer patients, for example. SLN biopsy in early-stage cervical 
cancer patients has been extensively described using blue dye, a radiocolloid, or a 
combination of both, with various results.5 
 Intraoperative near-infrared (NIR) fluorescence imaging using indocyanine 
green (ICG) has emerged as a novel technique for SLN detection in cervical 
cancer patients.6-10 NIR fluorescence imaging has several advantages, such as a 
relatively high tissue penetration and low autofluorescence. ICG is currently the 
only clinically available NIR lymphatic tracer. However, due to its relatively low 
fluorescence brightness (quantum yield) and its small hydrodynamic diameter, it is 
not an optimal lymphatic tracer. Preclinical work has demonstrated that adsorption 
of ICG to human serum albumin (HSA, complex is ICG:HSA), by simply mixing it, 
increases the fluorescence intensity (a threefold) and hydrodynamic diameter.11 
These advantages could provide improved detection and retention of the tracer 
in the SLN. On the other hand, the use of albumin adds cost and complexity to 
the procedure. Moreover, the use of human blood products, such as HSA, poses 
regulatory hurdles in certain countries, such as the United States. 
The aim of this double-blind randomized trial was to confirm feasibility of NIR 
fluorescence imaging for SLN mapping in cervical cancer and to assess whether 
ICG alone could render the same fluorescence intensity in the SLNs as ICG:HSA. 




Preparation of Indocyanine Green adsorbed to Human Serum Albumin
Indocyanine green (25-mg vials) was purchased from Pulsion Medical Systems 
(Munich, Germany) and was resuspended in 10 cc of sterile water. To obtain a 
500 µM final concentration, 7.8 mL of the 3.2-mM ICG solution was diluted in 42.8 
mL of sterile water for injection or 42.8 ml of Cealb (20% human serum albumin, 
Sanquin, Amsterdam, The Netherlands) for the preparation of ICG alone or ICG:HSA, 
respectively. A dose of 500 µM was chosen based on previous studies that showed 
that the optimal dose of ICG:HSA lies between 400 and 800 µM and has the benefit 
of minimal manipulation of ICG and albumin volumes.6,12
Intraoperative Near-Infrared Imaging System (Mini-FLARE)
SLN mapping was performed using the Mini-Fluorescence-Assisted Resection and 
Exploration (Mini-FLARE) image-guided surgery system as described previously 12. 
Briefly, the system consists of 2 wavelength isolated light sources: a “white” light 
source, generating 26,600 lx of 400-650 nm light, and a “near-infrared” light source, 
generating 7.7 mW/cm2 of 760 nm light. Color video and NIR fluorescence images 
are simultaneously acquired and displayed in real time using custom optics and 
software that separate the color video and NIR fluorescence images. A pseudo-
colored (lime green) merged image of the color video and NIR fluorescence images 
is also displayed. The imaging head is attached to a flexible gooseneck arm, which 
permits positioning of the imaging head at extreme angles virtually anywhere over 
the surgical field. For intraoperative use, the imaging head and imaging system pole 
stand are wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
Clinical Trial
The double-blind, randomized, noninferiority trial comparing ICG:HSA with ICG 
alone was approved by the Medical Ethics Committee of the Leiden University 
Medical Center and was performed in accordance with the ethical standards of 
the Helsinki Declaration of 1975. All patients planning to undergo a total pelvic 
lymphadenectomy for early stage cervical cancer were eligible for participation 
in the study. Exclusion criteria were pregnancy, lactation, or an allergy to iodine, 
shellfish, or indocyanine green. All patients gave informed consent and were 
anonymized. Patients were randomized by the Department of Clinical Pharmacy. 
Treatment allocation was performed by block randomization. Before the start of 
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surgery, 1.6 mL of 500 µM ICG:HSA or ICG alone was transvaginally injected by 
the surgeon submucosally in 4 quadrants of the cervix. Directly after injection, 
following surgical scrub and sterile covering of the operation field, a laparotomy 
was performed.  
 Prior to the systematic pelvic lymphadenectomy, all standard locations 
(along the external iliac vessels and the hypogastric artery, the common iliac 
artery, the obturator fossa and the lateral parametrium) were examined for NIR 
fluorescence using the Mini-FLARE imaging system. Both the surgeon and the Mini-
FLARE operator, who was responsible for analyzing the data, were blinded to the 
treatment allocation. All fluorescent hotspots, containing one or more lymph nodes, 
were denominated as SLNs and were subsequently resected and measured for 
fluorescence ex vivo. Subsequently, the standard systemic pelvic lymphadenectomy 
was performed and all resected lymph nodes were also measured for fluorescence 
ex vivo. Lymphadenectomy consisted of removal of all lymph node-bearing fatty 
tissue along the external iliac vessels, the common iliac artery, the hypogastric 
artery, and from the obturator fossa 13. Also, the area lateral to and underneath the 
superior vesical arteries (lateral parametrium) was cleared from the lymphatic tissue. 
The radical hysterectomy or abdominal trachelectomy were performed according 
to the standard procedure. Afterwards, all resected lymph nodes were examined 
by routine histopathological analysis; lymph nodes were fixed in formalin and 
embedded in paraffin for routine hematoxylin and eosin staining. SLNs and non-SLNs 
were examined separately. Additionally, a substantial part of the SLNs and clinical 
suspected nodes were subsequently examined using a cytokeratin staining. 
Power Calculation and Statistical Analysis
The power calculation is based on data from previous studies, in which in vitro 
a threefold difference in fluorescent brightness (quantum yield) was reported 
between ICG alone and ICG:HSA and in vivo signal-to-background ratio of 10.1 ± 
1.2 was observed during SLN detection by ICG:HSA 6,11. These data revealed that 
18 patients are needed to achieve 91% power to detect non-inferiority using a 
one-sided, 2-sample t test (α = 0.025) with a margin of equivalence of 5.0 while 
assuming no difference between the signal-to-background ratio (SBR) of ICG:HSA 
and ICG alone. For statistical analysis, SPSS statistical software package (Version 
16.0, Chicago, IL) was used. To compare the SBR and the number of SLNs identified 
between ICG:HSA and ICG alone, a 1-sided, 2-sample t test was performed. P < 0.05 
was considered significant.





Eighteen consecutive early-stage cervical cancer patients scheduled to undergo 
a pelvic lymphadenectomy were randomized to ICG:HSA or ICG alone for NIR 
fluorescence SLN imaging. All patients were clinically staged as FIGO stage IB1 
cervical cancer. Of these 18 patients, the median age was 40 years (range, 28-67), 
median body mass index was 25 (21-38), and median tumor size was 1.6 cm (range, 
0.3-5.0 cm). In one patient in whom preoperative pathology was not conclusive 
(either cervical cancer or endometrial cancer), postoperative pathological 
evaluation showed endometrial cancer. In all patients a complete bilateral pelvic 
lymphadenectomy was performed, except for one case. In this case the surgeon 
did not complete the lymphadenectomy, due to pathologically proven metastatic 
lymphatic disease by intraoperative frozen section and excessive blood loss during 
surgery. Patient and tumor characteristics and previous treatment were equally 
distributed over the treatment groups (Table 1).
NIR Fluorescence Imaging
The results of the NIR fluorescence detection of SLNs are presented in Table 2. During 
surgery, NIR fluorescence imaging enabled identification of 1 or more fluorescent 
hotspots in 14 out of 18 (78%) patients (Figure 1). In 11 patients (61%) fluorescent 
hotspots were identified bilaterally, whereas in 3 patients (17%) hotspots were 
identified unilaterally. In 4 patients (22%) no fluorescent hotspots were detected 
intraoperatively. Average time between injection of ICG:HSA or ICG alone and 
imaging was 43 ± 14 min and did not lengthen the standard of care surgery. On 
average, 2.8 ± 2.2 hotspots were detected intraoperatively by NIR fluorescence, 
yielding an average of 4.2 ± 3.7 SLNs per patient at pathological examination. An 
average of 24.5 (range, 9-46) lymph nodes per patient were harvested when a 
complete bilateral lymphadenectomy was performed.
In addition, all lymph nodes were examined for fluorescence ex vivo directly after 
surgical resection in the operating room. In 11 of 18 patients, a total of 29 additional 
fluorescent hotspots could be identified, which were not identified during in vivo 
NIR fluorescence imaging. When the ex vivo detected fluorescent hotspots and the 
in vivo detected fluorescent hotspots were combined, NIR fluorescence imaging 
enabled identification of 1 or more fluorescent hotspots in 16 out of 18 (89%) 
patients, thus in 2 more patients compared to in vivo identification alone. In 13
28456 Vorst NW.indd   106 13-03-14   12:30
Comparing lymphatic tracers in cervical cancer patients
107
patients (72%) these were identified bilaterally, in 3 patients (17%) unilaterally, and 
in 2 patients (11%) there were no fluorescent hotspots detected in vivo or ex vivo.
 Histological analysis showed lymph node metastases in 6 out of 18 
patients of whom 4 patients had macrometastases (> 2 mm) and 2 patients had 
micrometastases (≤ 2 mm) 14. In 5 of 6 patients with lymph node metastases, one 
or more tumor positive nodes were fluorescent. Though, in 2 of these 6 patients, 
the fluorescent nodes were only detected ex vivo. Furthermore, in 1 patient, the 
resection specimen contained a nonfluorescent fibrotic nodule with mature fat 
cells, some lymphoid infiltration, and a micrometastatic lesion. No metastases were 
found in this patient’s fluorescent nodes.




 (N = 9)
P
N % N %
Age (median, range) 40 (28 - 67) 40 (30 - 50) .86

































































Tumor size (median, range) 1.4 (0.6 - 5.0) 1.8 (0.3 - 3.6) .88
 ICG:HSA, indocyanine green adsorbed to human serum albumin
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Figure 1 – NIR Fluorescence-Based SLN Mapping using ICG:HSA and Mini-FLARE: Identification of a 
SLN (arrow), located along the right iliac vessels, with NIR fluorescence imaging is demonstrated in a cervical 
cancer patient after administration of 500 µM ICG:HSA. 
Comparison between treatment groups
The primary endpoint of this study was the average brightness of the SLN, expressed 
in SBR. The average SBR of ICG:HSA (9.3 ± 3.6) and ICG alone (10.1 ± 4.5) were 
not significantly different (P = .72). No significant difference was observed in the 
average number of in vivo identified fluorescent hotspots between ICG:HSA and 
ICG alone (2.9 ± 1.7 vs 2.7 ± 2.6, P = .84). Similarly, there was no significant difference 
in intraoperative detection rate (P = .13) or presence of fluorescent nodes after ex 
vivo inspection (P = .82).  
DISCUSSION
The current 18-patient clinical study confirmed the feasibility of the SLN procedure 
in early-stage cervical cancer using NIR fluorescence imaging with ICG. The overall 
intraoperative detection rate was 78%, and in 61% of all patients fluorescent nodes 
could be identified bilaterally. This double-blind randomized trial did not show any 
advantages of ICG:HSA over ICG alone in SBR, average number of intraoperatively 
detected fluorescent hotspots, or percentage of patients in whom fluorescent 
nodes could be detected. 
The recent introduction of NIR fluorescence imaging has provided new opportunities 
in the field of SLN mapping. Preclinical studies indicated that adsorption of ICG to 
HSA increases the fluorescence intensity and the hydrodynamic diameter, thereby 
providing improved detection and better retention in the SLN.11 In the current study, 
ICG:HSA performed equally well as ICG alone. This is in concordance with a previous 
study performed by our group in which no differences were found between the 
use of ICG:HSA and ICG alone in SLN mapping in breast cancer patients 15. In lymph 
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fluids a high protein constitution is found.16 A potential explanation for the lack of 
difference between ICG:HSA and ICG alone is that ICG rapidly binds to endogenous 
proteins when drained in the lymphatic system, eliminating the need for premixing 
ICG and HSA. 

































Average number of intraoperative 
NIR hotspots ± SD
2.8 ± 2.2 2.9 ± 1.7 2.7 ± 2.6 .84
Signal-to-background ratio 9.7 ± 3.9 9.3 ± 3.6 10.1 ± 4.5 .72
Average lymph nodes in 
lymphadenectomy ± SD
24.5 ± 8.8 23.4 ± 4.3 25.6 ± 11.6 .62
Average number of additional 
hotspots ex vivo ± SD
1.6 ± 2.0 1.0 ± 1.3 2.2 ± 2.4 .21























































ICG:HSA, indocyanine green adsorbed to human serum albumin; ITC, isolated tumor cells
 The detection rate in this study is in concordance with previously reported 
detection rates in studies using NIR fluorescence for SLN mapping in early-stage 
cervical cancer, which vary from 60% to 100%.6-9 Large studies in early-stage cervical 
cancer patients using radiocolloid tracers reported higher detection rates varying 
from 88% to 99%.17-23 Possible explanations for the lower detection rate observed 
in this study could be the inclusions of patients with larger tumors (>2 cm) and, 
especially, the learning curve associated with cervical injection of the tracer and 
the intraoperatively exposure of tissue to maximize NIR fluorescence detection.17,24 
Unlike the present study, our initial 9-patient study of NIR fluorescence SLN mapping 
in cervical cancer utilized two clinicians for all NIR lympathic tracer injections. 
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Although the learning curve could be of significant effect on the intraoperative 
identification rate and time needed to identify the SLN, it is unlikely that the learning 
curve interferes with the SBR, which was used to power the present trial and to test 
difference between ICG alone and ICG:HSA. Assessment of the learning curve will 
be essential before NIR fluorescence can be compared to conventional techniques 
using radiocolloid tracers in a sufficient powered study.
 After resection, additional fluorescent lymph nodes, which were missed 
during intraoperative inspection with the Mini-FLARE, were identified in the 
resection specimens of 11 out of the 18 patients. Intraoperative detection of these 
additional fluorescent nodes would have considerably improved the detection rate 
and the false negative rate. Difficulty in the intraoperative detection of these nodes 
could be based on the relatively limited tissue penetration of NIR light (several 
millimeters) compared to radiocolloid tracers, or the learning curve associated 
with positioning tissue intraoperatively to maximize NIR fluorescence detection. 
Moreover, radiocolloid tracers permit preoperative localization of the SLN, which 
assists surgical planning. Still, radiocolloids have the disadvantage that there is 
no real-time visualization during the operation, and detection is hampered if the 
SLNs are located near the point of the tracer injection. NIR fluorescence imaging is 
suitable for real-time identification and detection of SLNs located in the vicinity of the 
injection site. In addition, NIR fluorescence has as a much better tissue penetration 
when compared to blue dyes. Therefore, a combination of a radiocolloid and a 
NIR fluorescence tracer might be preferable. In a recent study, van der Poel et al. 
reported the successful use of such a multimodal tracer combining radioactivity 
and NIR fluorescence in sentinel lymph node mapping in prostate cancer patients 
using a NIR fluorescence laparoscope.25
 In conclusion, this double-blind, randomized trial showed no advantage 
of ICG:HSA in comparison to ICG alone for the SLN procedure in early-stage cervical 
cancer. Further optimization of NIR fluorescence imaging is required to improve the 
intraoperative detection rate to permit this technique to compete with radiocolloid 
tracers.
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Regional lymph node involvement is the most important prognostic factor in 
cutaneous melanoma. Since only 20% of melanoma patients have occult nodal 
disease and would benefit from a regional lymphadenectomy, the sentinel lymph 
node (SLN) biopsy was introduced. NIR fluorescence has been hypothesized to 
improve SLN mapping. The objective was to assess the potential of intraoperative 
near-infrared (NIR) fluorescence imaging to improve SLN mapping in melanoma 
patients and to examine the optimal dose of indocyanine green adsorbed to 
human serum albumin (ICG:HSA). 
Material and Methods
Fifteen consecutive cutaneous melanoma patients underwent the standard 
SLN procedure using 99mtechnetium-nancolloid and patent blue. In addition, 
intraoperative NIR fluorescence imaging was performed after injection of 1.6 mL 
of 600, 800, 1000 or 1200 mM of ICG:HSA in four quadrants around the primary 
excision scar.
Results
NIR fluorescence SLN mapping was successful in 93% of patients. In one patient, no 
SLN could be identified using either conventional methods or NIR fluorescence. A 
total of 30 SLNs (average 2.0, range 1-7) were detected, 30 radioactive (100%), 27 
blue (73%), and 30 NIR fluorescent (100%). With regard to the effect of concentration 
on SBR a trend (P = 0.066) was found favouring the 600, 800 and 1000 mM groups 
over the 1200 mM group. 
Conclusion
This study demonstrates feasibility and accuracy of SLN mapping using ICG:HSA. 
Considering safety, cost, and pharmacological characteristics, an ICG:HSA 
concentration of 600 mM appears optimal for SLN mapping in cutaneous melanoma, 
though lower doses need to be assessed. 
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INTRODUCTION
 Regional lymph node involvement is the most important prognostic 
factor in cutaneous melanoma patients and complete lymph node dissection is 
the current standard treatment for patients with nodal metastasis.1 Only 20% of 
melanoma patients have occult nodal disease and therefore will benefit from a 
regional lymphadenectomy.2 However, the remaining 80% of patients without 
nodal involvement will be exposed to the risk of morbidity without offering a 
therapeutic advantage when performing a lymphadenectomy. The sentinel lymph 
node (SLN) biopsy was introduced by Morton et al.3 to obtain a minimal invasive 
assessment of regional nodal involvement and is now regarded as standard-of-care 
in staging cutaneous melanoma patients with primary lesions of at least 1 mm 
thick. 
 The SLN biopsy in melanoma patients is generally performed using 
a combination of radioactive colloid and blue dye. The use of this combination 
facilitates detection rates of over 90% and false-negative rates of approximately 
5%.3-5 However, the use of radioactive colloid comes with certain disadvantages, 
such as the involvement of a nuclear physician, high costs, and the lack of visual 
information. In addition, blue dye staining can result in hampered visibility of the 
surgical field and results in tattooing of the injection site lasting for several months. 
Consequently, blue dye staining is omitted in some institutions when the primary 
tumour is located in the facial region. The blue dye cannot be seen through skin 
and fatty tissue.
 The use of invisible near-infrared (NIR) light (700-900 nm) has several 
characteristics that can be advantageous in the SLN procedure, which include 
relatively high penetration into living tissue (several millimetres) and the lack of 
ionizing radiation.6 Indocyanine green (ICG) is one of only two clinically available 
NIR fluorescent agents and is currently the most optimal agent for SLN mapping.7 In 
several studies, intraoperative imaging systems in combination with ICG have been 
used for the SLN procedure for various types of cancer.8-13 The lymphatic channels 
and SLNs in cutaneous melanoma patients are often relatively superficially located. 
Therefore, NIR fluorescence imaging could be particularly useful for this indication. 
Indeed, several groups reported on the successful use of NIR fluorescence and ICG 
for SLN mapping in melanoma patients. 14-18  
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Preclinical evidence demonstrated that premixing of ICG with human serum 
albumin (HSA, complex is ICG:HSA) increases the fluorescence intensity and 
hydrodynamic diameter of ICG, resulting in better retention in the SLN.19 The aims 
of the current study were to assess the use of NIR fluorescence imaging using 
ICG:HSA and the Mini-FLARE intraoperative imaging system for the SLN procedure 
in melanoma patients. Furthermore, the optimal dose of ICG:HSA to perform a NIR 
fluorescence SLN procedure was assessed. 
MATERIAL AND METHODS
Preparation of Indocyanine Green Adsorbed to Human Serum Albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 mL of sterile water for injection for the 600 µM group, or in 
5 mL of sterile water for injection for the 800 µM, 1000 µM and 1200 µM groups, to 
yield stock solutions of 3.2 mM and 6.4 mM, respectively. Various amounts of this 
stock solution were transferred to a 50 cc vial of Cealb (20% human serum albumin 
[HSA] solution; Sanquin, Amsterdam, The Netherlands) to yield ICG in HSA (ICG:HSA) 
at a final concentration of 600 µM, 800 µM, 1000 µM or 1200 µM.
 
Intraoperative NIR Fluorescence Imaging
SLN mapping was performed using the Mini-FLARE image-guided surgery system 
as described in detail previously.9 Briefly, the system consists of 2 wavelength 
separated light sources: a “white” LED light source, generating 26,600 lx of 400 
to 650 nm light to illuminate the surgical field and an NIR LED light source, 
generating 7.7 mW / cm2 of 760 nm fluorescence excitation light. White light 
and NIR fluorescence images are acquired simultaneously and displayed in real 
time, using custom designed optics and software. A pseudo-coloured (lime 
green) image of NIR fluorescence superimposed over the white light image is also 
displayed, to provide the NIR fluorescence signal in proper anatomical context. 
Clinical Trial
The current dose escalation clinical trial was approved by the Medical Ethics 
Committee of the Leiden University Medical Center and was performed in 
concordance with the ethical standards of the Helsinki Declaration of 1975. 
Fifteen consecutive patients that were planned to undergo a therapeutic 
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re-excision and a SLN procedure for cutaneous melanoma were included 
in this study between April 2010 and June 2011. Exclusion criteria were 
pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine green. 
 All patients gave informed consent and were anonymized. Patients 
received the standard-of-care SLN procedure. For our institution, this implies 
injections at four quadrants around the primary excision scar of 60-100 MBq 
99mtechnetium-nanocolloid on the afternoon of the day before, or the morning 
prior to surgery. Before the start of the operation, approximately 1 mL total of patent 
blue V (Guerbet, France) was injected at four quadrants around the primary excision 
scar. Immediately after injection of patent blue, a total of 1.6 mL of ICG:HSA was 
injected at the same four sites as the patent blue injections. ICG:HSA was injected 
at a concentration of 600, 800, 1000 and 1200 µM. In each concentration group, 3 
patients were included (N = 12 patients). Subsequently, 3 patients were included 
at the optimal ICG:HSA concentration.  
 After surgical scrub, the Mini-FLARE imaging head was positioned at 
approximately 30 cm above the surgical field. The NIR fluorescence signal was 
measured percutaneously, prior to skin incision, and continuously during the surgical 
procedure. Throughout the procedure, the surgeon was continuously provided with 
real-time NIR fluorescence image guidance. When the SLN could not be found easily 
by NIR fluorescence, the handheld gamma probe could be used for the localization 
of SLNs. Relative brightness of the SLNs was determined by measuring signal-to-
background ratios (SBRs); that is the NIR fluorescence signal of the SLN divided by 
the (auto)fluorescent signal of a directly adjacent region. Excised sentinel lymph 
nodes were analyzed ex vivo for NIR fluorescence and radioactivity and were routinely 
analyzed by histopathology. SLNs were fixed in formalin and embedded in paraffin 
for haematoxylin, eosin, and immunohistopathological staining using the S-100 and 
MART-1 markers at six levels, with an interval of 50-150 μm.
Statistical Analysis: For statistical analysis, SPSS statistical software package 
(Version 17.0, Chicago, IL) was used. Graphs were generated using GraphPad Prism 
Software (Version 5.01, La Jolla, CA). Signal-to-background ratios were reported as 
median and range. To test differences between groups, the Kruskal-Wallis one-way 
analysis of variance test and the Dunn’s Multiple Comparison Test were used to test 
for differences between time and dose groups. Statistical tests were two-tailed and 
P < 0.05 was considered significant.




Patient and Tumour Characteristics
Fifteen consecutive patients with cutaneous melanoma undergoing SLN mapping 
were included in this study. Patients and tumour characteristics are described in 
Table 1. Median body mass index (BMI) was 24 (range 18 - 32), median age was 55 
years (range 21 - 70 years), and median Breslow’s depth was 1.9 mm (range 0.7 - 7 
mm). In 1 patient, the melanoma was located in the head and neck region, in 4 
patients at the higher extremities, in 9 patients at the trunk and in 1 patient at the 
lower extremities. 
Intraoperative NIR Fluorescence Imaging
Average time between ICG:HSA injection and skin incision was 12.6 ± 3.6 minutes. 
In 14 patients, one or more SLNs were identified. A total of 30 SLNs were detected, 
all of which were radioactive and fluorescent (Table 2). Twenty-two out of 30 SLNs 
(73%) were stained blue. A typical example of  NIR fluorescence imaging using the 
Mini-FLARE imaging system is shown in figure 1. In one patient, no SLN could be 
identified using either conventional methods or NIR fluorescence. Average time 
between skin incision and resection of the first SLN was 10.2 ± 3.9 minutes. The 
location of the SLNs is summarized in Table 2. In each patient, following resection 
of all NIR fluorescent nodes, the surgical field was systematically inspected for 
remaining radioactivity or blue nodes. No additional nodes were found that were 
not detected by NIR fluorescence. No adverse reactions associated with the use of 
ICG:HSA or the Mini-FLARE imaging system were observed.
The Effect of Lymphatic Tracer Dose on SLN Brightness
The effect of injected lymphatic tracer dose on fluorescence brightness was 
determined by comparing median SBRs between concentration groups (Fig. 2). 
Median SBRs of the SLNs were 12.33 (range: 10.90 – 20.92), 16.59 (range: 12.94 – 
23.73), 15.47 (range: 14.87 – 18.42) and 6.76 (range: 6.14 – 10.14) for the 600, 800, 
1000 and 1200 µM concentration groups, respectively. The independent samples 
Kruskal-Wallis Test to test for difference in signal-to-background ratios showed a 
trend favouring the 600,800 and 1000 µM dose groups over the 1200 µM dose 
group (P = 0.066).  
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Table 1 – Patient and Tumour Characteristics
Characteristic N %
Age (median, range) 55 (21 - 70)
Gender (% male) 53
Body Mass Index (median, range) 24 (18 - 32)
Skin type
- II 8 53
- III 7 47
Breslow (median, range) 1,9 (0,7 - 7)
Clark classification
- 3 4 27
- 4 10 67
- N/A 1 6
Tumour localization
- Head and neck 1 6
- Upper extremities 4 27
- Ventral trunk 4 27
- Dorsal trunk 5 34
- Lower extremities 1 6
Type of Surgery
- Primary excision 1 6
- Re-excision 14 94
Percutaneous Visualization of Lymphatic Channels and Sentinel Lymph Nodes
Prior to the incision, the ability to identify lymphatic vessels and SLNs using NIR 
fluorescence was assessed. In 13 of 15 patients (87%), lymphatic vessels running 
away from the site of injection could be identified percutaneously (Fig. 1). In 3 of 15 
patients (20%), the location of a total of 8 SLNs could be identified prior to incising 
the skin. These SLNs were all located in the neck and on the ventral trunk. 
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Figure 1 – Sentinel lymph node mapping using NIR fluorescence imaging in cutaneous melanoma: 
Lymphatic channel (arrowhead) and SLNs (arrows) can be clearly identified percutaneously (top row). 
Identification of the first SLN (middle row)  and second SLN (bottom row) is demonstrated using NIR 
fluorescence imaging at 15 min after injection of 1.6 mL of 1000 µM ICG:HSA around the excision scar.
Figure 2 – Optimization of ICG:HSA dose: Signal-to-background ratio (mean ± S.D.) of melanoma SLNs 
(ordinate) is plotted as a function of injected dose of ICG:HSA (abscissa). A trend was found favouring the 
600, 800 and 1000 µM over 1200 µM (P = 0.066).
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Table 2 – SLN Identification Results
Characteristic N %
SLN Detection
- Number of SLNs Identified 30
- Average Number of SLNs Identified (S.D.) 2.0 ± 1.6
Method of Detection
- Radioactive 30 100
- Blue 22 73
- Near-Infrared Fluorescence 30 100
Average Time between Injection of ICG:HSA and Skin Incision (S.D.) 12.6 ± 3.6
Average Time between Skin Incision and SLN Resection (S.D.) 10.2 ± 3.9
Pecutaneous identification
- Lymphatic vessels (no. of patients) 13 87
- Sentinel lymph nodes (no. of nodes) 8 27
Sentinel lymph node localization
- Axilla 18 60
- Neck 2 7
- Groin 4 13
- Ventral trunk 5 17
- Dorsal trunk 1 3
Histology*
- Negative 11 72
- Macrometastases 1 7
- Micrometastases 1 7
- Isolated Tumour Cells and Micrometastases 1 7
Adjuvant treatment
- None 12 80
- Axillary Lymph Node Dissection 2 13
- Follow up 1 7
Complications
- No 15 100
- Yes 0 0
*No SLNs detected in 1 patient using both conventional techniques and NIR fluorescence




The current study demonstrates feasibility of NIR fluorescence SLN mapping using 
ICG:HSA and the Mini-FLARE imaging system in melanoma patients. The accuracy 
of the SLN procedure using NIR fluorescence was similar to that of radiocolloids 
and superior to that of blue dye staining. The use of both NIR fluorescence and 
radiocolloids lead to a 100% SLN detection rate. Whereas only 73% of all SLNs were 
stained blue. These results are in concordance with previous studies performed 
by our group on NIR fluorescence SLN mapping in breast and vulvar cancer 
patients.9,20,21 
 An advantage of using NIR fluorescent light is that it is capable of 
penetrating several millimetres into living tissue. In cutaneous melanoma, there is a 
high variability in localization of the SLN mostly depending on the site of the primary 
tumour. Not infrequently, different SLNs can be found at completely different sites 
in the human body, which can lead to a prolonged search and even the need of 
displacing the patient on the operating table. In these cases, real-time percutaneous 
assessment of lymphatic drainage, from the primary tumour to the SLN will have 
a substantial added value. Percutaneous assessment of lymphatic vessels was 
possible in 87% of patients in the current study. Moreover, in 20% of patients, the 
SLNs could be identified through the skin. SLNs in cutaneous melanoma patients 
are often superficially located, making NIR fluorescence imaging highly suitable 
for this indication. Percutaneous visualization can be influenced by the skin type of 
patients, as melanin and hemoglobin determine skin color and have high scattering 
and absorption properties in the NIR spectral range. In this study, no differences 
were observed as all patients had skin type II/III. Moreover, when located deeper, 
for example in the axilla, no SLNs could be identified percutaneously using NIR 
fluorescence. The advantages of NIR fluorescence using ICG:HSA could allow more 
efficient detection of the SLN, which can result in less damage of healthy tissue, 
and possibly increase sensitivity.22 Though, in the current study, in one patient, no 
SLN could be identified using NIR fluorescence or the conventional technique, for 
which no explanation could be appointed.       
 For future clinical use of this new technique it is important to determine the 
dose of ICG:HSA that provides optimal imaging results. We observed a trend in SBR 
differences between the ascending concentrations of ICG:HSA leading to a decline 
of signal in the 1200 µM group. This is in line with previously reported results in 
breast cancer.9 A decrease of fluorescence signal with an increase in concentration 
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can likely be explained by fluorescence quenching.7 To assess the possibility of 
using lower concentrations for fluorescence SLN mapping in melanoma patients, 
a dose-finding study with concentrations ranging from 50 mM – 500 mM of ICG:HSA 
will be reported separately (Clinicaltrials.gov identifier: NCT01121718).
In the process of optimization of the SLN procedure using NIR fluorescence in 
breast cancer patients, we have previously demonstrated in a randomized trial that 
there is no advantage of using ICG premixed with HSA over ICG alone20 and that 
patent blue can be omitted when NIR fluorescence is used.23 For optimization of 
this technique in melanoma patients, future studies investigating the additional 
value of premixing ICG with HSA and the necessity to use patent blue have to be 
performed. Moreover, in the current study SLN localization was performed directly 
after tracer administration. In a previous study by our group in SLN biopsy in oral 
cavity and oropharyngeal cancers, rapid migration of ICG:HSA beyond the SLN was 
observed.24 The migration beyond the SLN requires localization of SLN directly after 
injection of the tracer, to prevent detection of many second-tier lymph nodes.
 In conclusion, our current study demonstrates the feasibility of SLN 
mapping in cutaneous melanoma patients using ICG:HSA and the mini-FLARE 
image-guided surgery system. With respect to logistical and safety issues, a dose 
of 600µM of ICG:HSA seems to be optimal. NIR fluorescence has a 100% accuracy 
in SLN detection and adds the value of percutaneous lymphatic drainage and in 
some cases SLN assessment.  
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Elective neck dissection is frequently performed during surgery in head and 
neck cancer patients. The sentinel lymph node (SLN) procedure can prevent the 
morbidity of a neck dissection and improve lymph node staging by fine pathology. 
Near-infrared (NIR) fluorescence imaging is a promising technique to identify the 
sentinel lymph node (SLN) intraoperatively. This feasibility study explored the use of 
indocyanine green adsorbed to human serum albumin (ICG:HSA) for SLN mapping 
in head and neck cancer patients.
Material and Methods
A total of 10 consecutive patients with oral cavity or oropharyngeal cancer and a 
clinical N0 neck were included. After exposure of the neck, 1.6 mL of ICG:HSA (500 
µM) was injected at 4 quadrants around the tumor. During the neck dissection, levels 
I, II, III and IV were measured for fluorescence using the Mini-FLARE imaging system. 
Results
In all 10 patients, NIR fluorescence imaging enabled visualization of one or 
more SLNs. A total of 17 SLNs were identified. The mean contrast between the 
fluorescent signal of the lymph nodes and of the surrounding tissue was 8.7 ± 6.4. 
In 3 patients, of which 1 was false-negative, lymph node metastases were found. 
After administration of ICG:HSA, the average number of fluorescent lymph nodes 
significantly increased over time (P < 0,001). 
Conclusion
This study demonstrated feasibility to detect draining lymph nodes in head and 
neck cancer patients using NIR fluorescence imaging. However, the fluorescent 
tracer quickly migrated beyond the SLN to higher tier nodes.
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INTRODUCTION
In head and neck cancer patients, cervical lymph node involvement is the 
single most important prognostic factor.1,2 To obtain adequate staging and local 
control of the cervical region, elective neck dissections are frequently performed, 
even in patients with clinical and radiological N0 stage. In approximately 25% of 
these patients, lymph node metastases are found.3 Furthermore, micrometastases 
and isolated tumor cells are often missed during standard pathological workup. 
To decrease the morbidity of neck dissection and to improve lymph node 
staging by fine pathology, the sentinel lymph node (SLN) procedure has been 
advocated. The SLN procedure is based on the theory that flow from a tumor 
travels sequentially to the first tier node (i.e. the sentinel node) and subsequently 
to the remaining lymph node basin. The SLN procedure is currently standard of 
care in breast cancer and melanoma in most centers. Although much work has 
been performed in head and neck cancer, the SLN procedure has not yet been 
established as standard of care.4-7 As in breast cancer, the use of radiocolloids 
and a blue dye can be considered the gold standard to locate the SLN. However, 
the disadvantages of radiocolloids are the lack of real-time intraoperative visual 
information and the need for a nuclear physician; and disadvantages of blue dyes 
include limited depth penetration and blue staining of the surgical field. 
 Recently, the use of near-infrared (NIR) fluorescent light has been introduced to 
intraoperatively to identify lymph nodes, tumors and vital structures.8 NIR fluorescence 
using the fluorescent dye indocyanine green (ICG) has been successfully used for sentinel 
lymph node mapping in breast cancer, melanoma, cervical cancer, and vulvar cancer.9-12 
The concept of NIR fluorescence guided SLN mapping in oropharyngeal cancer has 
also been reported in humans.13 However, in the study by Bredell et al.13, the interval 
between injection of ICG and imaging varied between 5 and 30 min, which can result 
in identification of higher tier nodes.. Preclinical work suggests that premixing ICG with 
human serum albumin (complex: ICG:HSA) could improve the fluorescent properties 
and improves retention in the SLN due to its increased hydrodynamic diameter.14 
Furthermore, the injected dose of ICG (without HSA) used by Bredell et al. was 10 mg 
per patient. Several clinical dose-finding studies have shown that a significant lower 
dose (0.5-1.0 mg ICG:HSA) can successfully be used for sentinel lymph node mapping 
in other indications.10-12 The aim of the current study was to assess the feasibility of NIR 
fluorescence and ICG:HSA for SLN mapping in head and beck cancer using 1.6 ml of 
500 µM ICG:HSA and the Mini-FLARE imaging system. 




Preparation of Indocyanine Green Adsorbed to Human Serum Albumin
ICG (25 mg vials) was from Pulsion Medical Systems (Munich, Germany) and was 
resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2-mM) 
stock solution. Of this solution, 7.8 cc was transferred to a 50-cc vial of Cealb (20% 
human serum albumin (HSA) solution; Sanquin, Amsterdam, The Netherlands) to 
yield ICG in HSA (ICG:HSA) at a final concentration of 500 µM. 
Intraoperative NIR Fluorescence Imaging
SLN mapping was performed using the Mini-FLARE image-guided surgery system 
as described before.11 Briefly, the system consists of 2 wavelength-isolated light 
sources: a “white” light source, generating 26,600 lx of 400 to 650- nm light and a 
“near-infrared” light source, generating 7.7-mW/cm2 of 760-nm light. Color video 
and NIR fluorescence images are simultaneously acquired and displayed in real 
time using custom optics and software that separate the color video and NIR 
fluorescence images. A pseudo-colored (lime green) merged image of the color 
video and NIR fluorescence images is also displayed. The imaging head is attached 
to a flexible gooseneck arm, which permits positioning of the imaging head virtually 
anywhere over the surgical field, and at extreme angles. For intraoperative use, the 
imaging head and imaging system pole stand are wrapped in a sterile shield and 
drape (Medical Technique Inc., Tucson, AZ).
Clinical Trial
The single-institution clinical trial was approved by the Medical Ethics Committee 
of the Leiden University Medical Center and was performed in accordance with 
the ethical standards of the Helsinki Declaration of 1975. A total of 10 consecutive 
patients with oral cavity or oropharyngeal cancer, and a clinical and radiological N0 
neck were included. All patients underwent ultrasound guided cytology of lymph 
nodes in the neck region to assess nodal status. All patients provided informed 
consent and were anonymized. Exclusion criteria were pregnancy, lactation or an 
allergy to iodine, shellfish, or indocyanine green. 
After exposure of the neck following subplatysmal flap elevation, 1.6-mL 
ICG:HSA (500 µM) was injected at 4 quadrants around the tumor using a 21G, 1½ 
inch needle. During the neck dissection, levels I, II, III and IV were measured for 
fluorescence using the Mini-FLARE imaging system after injection of ICG:HSA. To 
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assess the occurrence of drainage to higher tier nodes and the optimal time of 
imaging after injection, measurements were performed at 5, 10, 15, 20, 25, 30, 45 and 
60 min after injection. All first draining NIR fluorescent hotspots were considered 
SLNs and were marked using sutures. The neck dissections consisted of resection of 
level I, IIa, IIb and III and in some cases level IV. The resection of the primary tumor 
afterwards was performed following standard procedure. Afterwards, all resected 
lymph nodes were examined by routine histopathological analysis; lymph nodes 
were fixed in formalin and embedded in paraffin for routine hematoxylin and eosin 
staining. SLNs and non-SLNs were examined separately. 
Statistical Analysis
For statistical analysis and to generate graphs, GraphPad Prism Software (Version 
5.01, La Jolla, CA) was used. Age, body mass index (BMI) and tumor size were 
reported as median and range. Signal-to-background ratio (SBR) was reported as 
mean and standard deviation. Difference in number of lymph nodes identified 
between time points was tested using a repeated measures ANOVA.
RESULTS
Patient and Tumor Characteristics
Patient and tumor characteristics are detailed in Table 1. Ten patients with oral cavity 
or oropharyngeal tumors and a clinical and radiological stage N0 were included. 
Median patient age was 59.5 years (range 33-73 years), median BMI was 24 (range 
19-35 kg/m2), and median primary tumor size was 2.2 cm (range 0.3-5.2 cm). 
Location of primary tumor was the tongue in 7 patients, tonsil region in 2 patients, 
and retromolar trigone in 1 patient. Four patients underwent a hemiglossectomy, 
4 patients underwent a commando resection, and 2 patients underwent a pull-
through resection. Nine patients underwent a unilateral neck dissection and 1 
patient a bilateral neck dissection. One patient was previously treated for a laryngeal 
cancer and developed a second primary tumor after a disease-free period of 10 y, 
for which the patient was treated and included in the current study. This patient 
was initially treated with surgical removal of the tumor and bilateral radiotherapy 
of the neck region. After histological examination, 9 patients were diagnosed with 
a squamous cell carcinoma and 1 patient with a basal cell adenocarcinoma.
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Type of Surgery Tumor Type
Tumor Size 
(cm)
1 33 22 Tongue Hemiglossectomy Squamous 1.7
2 73 25 Tongue Hemiglossectomy Squamous 5.2
3 64 24 Oropharynx Commando resection Basal cell 
adenocarcinoma
1.3
4 62 22 Tongue Hemiglossectomy Squamous 3.3
5 58 23 Trigonum 
Retromolare
Commando resection Squamous 0.3
6 55 27 Tongue Hemiglossectomy Squamous 1.6
7 52 32 Tongue Hemiglossectomy Squamous 3
8 63 35 Oropharynx Commando resection Squamous 4
9 53 24 Tongue Pull through resection Squamous 2.4
10 61 19 Tongue Pull through resection Squamous 2
BMI: Body Mass  Index
Intraoperative NIR Fluorescence Imaging
In all patients (N = 10), NIR fluorescence imaging enabled identification of 1 or 
more SLNs. An example of the intraoperative identification of a SLN using NIR 
fluorescence is shown in Figure 1. A total of 17 SLNs were detected. On average, 
1.7 ± 0.8 SLNs per patient were detected and a total of 22.9 ± 9.7 lymph nodes were 
resected per patient (Table 2). The average contrast between fluorescent signal of 
the SLN and the surrounding tissue was 8.7 ± 6.4. In 3 patients, the identified SLNs 
were located in level I, in 5 patients in level IIA and in 2 patients in level III. No adverse 
reactions or complications occurred during the current study. Histological analysis 
showed that 3 out of 10 patients had metastatic disease, all in a single lymph node. 
In 2 cases, the tumor-positive lymph node was the NIR fluorescent SLN, and in 1 
patient the tumor-positive lymph node was a non-SLN located in level 2A, which 
was also not NIR fluorescent. No adverse reactions occurred. 
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Table 2 – Results from In Vivo SLN Imaging
Patient no. NIR 
Hotspots 
Total LNs
Harvested LN+ Mean SBR
Location of NIR 
Hotspots
1 3 14 No 16.3 2A
2 1 26 No 21.0 1
3 1 30 No 12.0 1
4 3 35 Yes (SLN +) 3.2 1
5 2 9 No 2.6 2A
6 1 20 Yes (SLN +) 4.2 2A
7 2 24 No 5.2 3
8 1 15 No 4.2 3
9 2 17 Yes (SLN -) 5.7 2A
10 1 39 No 12.3 2A
NIR: Near Infrared, LN: Lymph Node, SBR: Signal-to-background
Intraoperative lymphatic mapping
To assess the occurrence of drainage to higher tier nodes and the optimal time of 
imaging after injection, NIR fluorescence was measured at several time points after 
injection (Fig. 2). All first draining NIR fluorescent hotspots were considered SLNs 
and were marked using sutures. Additional lymph nodes that became fluorescent 
during later imaging time-points were allocated as higher tier non-SLNs. In 7 of 10 
patients SLNs could be identified within 5 min after injection. In 3 patients, SLNs 
were detected after 10, 15 and 30 min, respectively. Using a repeated measures 
ANOVA test, the average number of fluorescent lymph nodes significantly increased 
over time (P < 0.001; Fig. 3).
DISCUSSION 
 The current study examined the feasibility of using the Mini-FLARE 
imaging system and ICG:HSA for intraoperative fluorescence guided SLN mapping 
in head and neck cancer patients. In all patients, 1 or more SLNs could be identified 
during surgery, and in the majority of patients the SLN could be identified within 
5 min after injection. The average contrast between fluorescence of the SLNs and 
background fluorescence was 8.7, which is consistent with SBRs that were reported 
for fluorescence SLN mapping studies using ICG:HSA in other cancer types.9-11 
Another important finding of the current study was that after several min, ICG:HSA 
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drains to second tier nodes, which can possibly result in the identification of false-
positive sentinel nodes. 
 Bredell et al. was the first to describe the successful use of NIR fluorescence 
in SLN mapping in oropharyngeal cancer patients. In this study, the time between 
injection of ICG (without HSA) and imaging varied between 5 and 30 min. Based 
on the present study, this could result in identification of higher tier lymph nodes. 
Furthermore, the injected dose of ICG used in the previous study was 10 mg, which 
is considerably higher than the dose used in the present study (0.62 mg). In breast 
cancer patients, our group has shown that when ICG is injected in a high dose, a 
phenomenon known as quenching can occur, which can result in a decrease of 
the NIR fluorescence signal.11
 Based on previous preclinical results, ICG was premixed with HSA in the 
current study to obtain better retention in the SLN and to increase quantum 
yield.14 However, it still remains unclear if premixing ICG with HSA is necessary or 
significantly improves performance. A randomized clinical trial in breast cancer 
patients reported no differences between using ICG:HSA and ICG alone.9 However, 
the effect of premixing ICG with HSA is potentially indication-specific, therefore this 
should be examined for head and neck cancer patients. 
Another approach recently presented by van der Poel et al. is combining 
fluorescence and radioactivity in 1 lymphatic tracer by simply premixing 99mTc-
NanoColl and ICG.15 Using this multimodal tracer injected by the nuclear physician 
before surgery, time of surgery will probably be shortened because the dye does 
not have to be injected during surgery. Furthermore, preoperative SLN localization 
and subsequent surgical planning can be performed using a lymphoscintigraphy 
or a SPECT/CT exam. Heuveling et al. demonstrated SLN mapping in rabbits using 
Nanocolloidal albumin which was covalently conjugated to IRDye-800CW, which 
showed excellent retention in the SLN after 24 hr.16 However, translation of this 
compound to a clinical setting remains challenging due to regulatory issues. 
 The current study showed a relatively wide range in time between 
injection of ICG:HSA and identification of the SLN, which was 30 min in 1 patient. 
This particular patient was treated for a primary laryngeal tumor by resection 
and cervical radiotherapy 10 y prior to the current study, and only 1 fluorescent 
lymph node could be detected. After pathological workup, 15 lymph nodes were 
detected.  Radiation can influence microvasculature and damage the capillary 
network, which manifests itself as telangiectatic vessels that increase over time.17 
Other studies showed that repair of damaged endothelium by angiogenesis
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Figure 1 – Sentinel lymph node mapping using NIR fluorescence imaging in oropharyngeal cancer 
patients: Peritumoral injection of 1.6 mL of 500-µM ICG:HSA identifies a SLN (arrow) in an oropharyngeal 
cancer patient. M = sternocleidomastoid muscle and S = submandibular gland.  
Figure 2 – Sentinel lymph node mapping in head and neck cancer over time: One SLN (arrows) can be 
clearly identified 5 min (top row) postinjection of 1.6 mL of 500-µM ICG:HSA around the primary tumor. 
Identification of higher tier nodes was observed after 25 min (middle row), and the number of fluorescent 
lymph nodes increased further at 45 min postinjection (bottom row). M = sternocleidomastoid muscle and 
S = submandibular gland.
is inhibited by radiotherapy.18 Similar damage and aberrant repair may occur in 
lymphatic microvessels after radiation. Therefore, a possible explanation for the 
relatively long time to identify the SLN in this patient was that damage to the 
lymphatic microvessels perturbed drainage in the irradiated neck. Furthermore, 
it is known from rectal cancer studies that an average of approximately 5 times 
fewer nodes can be identified in resection specimens when patients are treated 
with neoadjuvant radiation compared to patients only treated with surgery.19 When 
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translating these results to head and neck cancer patients, prudence should be 
applied in patients pretreated with radiation since SLN mapping can be more 
challenging in these patients.
Figure 3 – Lymph node identification as a function of postinjection time: Number of fluorescent lymph 
nodes (mean ± S.D.) is plotted as a function of time after injection of 500- µM ICG:HSA. The number of 
fluorescent lymph nodes significantly increased over time (P < 0.001)
 Based on standard pathology, in 1 of 3 patients with positive nodes, 
tumor cells were detected in a non-SLN, while the SLNs did not contain tumor. The 
reason for this patient being false-negatively staged remains unclear. A potential 
explanation could be that in case of multiple drainage patterns, a subset of SLNs 
can become fluorescent later, and will be incorrectly identified as higher tier lymph 
nodes. Future research should therefore be focused on fluorescent tracers that are 
retained in the first draining node(s), which makes it possible to perform imaging 
later after injection of the dye. Furthermore, the relatively low depth sensitivity 
of the current generation imaging systems (on the order of millimeters), could 
be an explanation for false-negative results. Another potential explanation could 
be the occurrence of a skip metastasis in this particular patient, which has been 
reported previously in head and neck cancer patients.20 Since only 10 patients were 
included in the current study, a final potential explanation for this patient being 
false-negative is the learning curve associated with tracer injection and imaging. 
Therefore, the false-negative rate has to be assessed in larger patient series. 
  In conclusion, the current study successfully showed the use of NIR 
fluorescence and ICG:HSA for intraoperative identification of the SLN in oropharynx 
and oral cavity cancer patients. Optimal dosage, true false-negative rate, and 
optimization of lymphatic tracers and possibly multimodal hybrid tracers, are topics 
for future studies.
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Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) has the 
potential to improve sentinel lymph node (SLN) mapping of breast cancer. In the 
current randomized clinical trial, the value of blue dyes when used in combination 
with NIR fluorescence was assessed. Furthermore, the possibility to perform SLN 
mapping without radiotracers was preliminarily examined. 
Material and Methods
Clinical trial subjects were 24 consecutive breast cancer patients scheduled to 
undergo SLN biopsy. All patients received standard of care using 99mTechnetium-
nanocolloid and received 1.6 mL of 500 µM ICG injected periareolarly. Patients 
were randomly assigned to undergo SLN biopsy with or without patent blue. To 
assess the need for radiocolloids to localize the SLN(s), the surgeon did not use 
the handheld gamma probe during the first 15 min after the axillary skin incision.
Results
SLN mapping was successful in 23 of the 24 patients. No significant difference was 
found in signal-to-background ratio between the patent blue group and no patent 
blue group (8.3 ± 3.8 vs. 10.3 ± 5.7, respectively, P = 0.32). In both groups, 100% 
of SLNs were radioactive and fluorescent and in the patent blue group, only 84% 
of SLNs were stained blue. In 25% of patients, the use of the gamma probe was 
necessary to localize the SLN within the first 15 minutes. 
Conclusion
This study shows that there is no benefit of using patent blue for SLN mapping 
in breast cancer patients when using NIR fluorescence and 99mTechnetium-
nanocolloid. NIR fluorescence imaging outperformed patent blue in all patients.
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INTRODUCTION
Sentinel lymph node (SLN) mapping is regarded as standard of care in staging of 
the axilla in breast cancer patients with clinically negative axillary lymph nodes.1 
To locate the SLN, different techniques can be used. Combining a radiotracer 
and blue dye staining achieves the highest identification rates (95%-97%) and 
is therefore preferred2-5; however, both methods have several disadvantages. 
Radioactive colloids require involvement of a nuclear physician, do not provide 
visual information intraoperatively, and the time window in which they can be 
used is limited due to the half-life of 99mTechnetium. Moreover, a substantial part of 
patients undergoes SLN mapping using only a blue dye, since radioactive isotopes 
are not widely available in every medical center. The percentage of patients in whom 
only blue dye staining is used for SLN mapping varies from 4 – 50% in developed 
countries.6-9 Blue dyes cannot be seen through skin and fatty tissue, permit only 
limited visualization of afferent lymphatic vessels, and in case a lumpectomy is 
performed, tattooing of the breast can be seen up until several months after blue 
dye injection. 
Due to these disadvantages, optical imaging using the near-infrared (NIR) 
fluorescence lymphatic tracer indocyanine green (ICG) has been put forward as 
an alternative for, or an addition to conventional SLN mapping. Feasibility of this 
technique has been extensively reported in breast cancer patients10-16 and other 
cancer types.17 A previous dose-finding study performed by our group recently 
demonstrated that NIR fluorescence using a dose of 500 µM ICG adsorbed to human 
serum albumin was most convenient.18 A follow-up double-blind randomized 
clinical trial demonstrated no advantages of premixing ICG with human serum 
albumin in comparison to ICG alone at a dose of 500 µM for NIR fluorescence SLN 
mapping.19 
 In the clinical trials discussed above, the NIR fluorescence signal of ICG 
was consistently visualized earlier than the blue dye staining. In the total of 60 
SLNs that were detected in the 2 studies (N = 42 patients), only 48 (80%) were 
stained blue, while 60 (100%) SLNs could be detected with NIR fluorescence.18,19 
Therefore, NIR fluorescence imaging has the potential to replace blue dyes in SLN 
mapping in breast cancer patients. If the use of blue dye staining could be omitted, 
disadvantages like tattooing of the breast and blue staining of the surgical field 
in case of a lumpectomy could be prevented. Furthermore, the use of blue dyes 
may interfere with NIR fluorescence imaging by absorbing the fluorescent light 
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and thereby decreasing the NIR fluorescent signal. Finally, anaphylactic reactions 
to blue dyes, although rare, can be life threatening. Because NIR fluorescent light 
penetrates relatively deep into tissue (up to 0.5-1 cm), it also has the potential to 
replace the use of radiotracers. However, omitting the use of radiotracers may only 
be reserved for selected patients, for example those with a sufficiently low body 
mass index (BMI). 
In the current randomized clinical trial, the added value of using blue dye staining 
when used in combination with NIR fluorescence and radiotracer was assessed. 
Furthermore, the possibility to perform SLN mapping without radiotracers was 
preliminarily explored. 
METHODS
Preparation of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2 
mM) stock solution. To obtain a 500-µM dilution of ICG, 7.8 mL of the 3.2-mM ICG 
solution was diluted in 42.8 mL of sterile water. In a previous study, we determined 
that the optimal dose of ICG lies between 400 µM and 800 µM18, therefore a dose 
of 500 µM was chosen.
Intraoperative Near-Infrared Imaging System (Mini-FLARE™)
SLN mapping was performed using the Mini-Fluorescence-Assisted Resection and 
Exploration (Mini-FLARE™) image-guided surgery system, as described earlier.18 
Briefly, the system consists of 2 wavelength isolated light sources: a “white” light 
source, generating 26,600 lx of 400 to 650 nm light, and a “near-infrared” light 
source, generating 7.7 mW/cm2 of 760 nm light. Color video and NIR fluorescence 
images are simultaneously acquired and displayed in real time using custom optics 
and software that separate the color video and NIR fluorescence images. A pseudo-
colored (lime green) merged image of the color video and NIR fluorescence images 
is also displayed. The imaging head is attached to a flexible gooseneck arm, which 
permits positioning of the imaging head at extreme angles virtually anywhere over 
the surgical field. For intraoperative use, the imaging head and imaging system pole 
stand are wrapped in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
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Clinical Trial
This randomized, single-institution trial comparing NIR fluorescence SLN mapping 
with or without patent blue was approved by the Medical Ethics Committee of the 
Leiden University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. All patients planning to undergo a SLN 
procedure for invasive breast cancer or high-risk carcinoma in situ were eligible for 
participation in the trial. Patients had clinically negative axillary nodes as assessed 
by palpation and ultrasonography. Exclusion criteria were pregnancy, lactation or 
an allergy to iodine, shellfish, or indocyanine green. All patients gave informed 
consent and were anonymized. 
 As part of the SLN procedure, patients were injected periareolarly with 
approximately 100 MBq 99mTechnetium-nanocolloid the day before surgery. Before 
the start of the operation, patients were randomly assigned to receive or not receive 
an injection with patent blue. Patients were randomized by the Department of 
Surgery and treatment allocation was performed by block randomization. For 
patients  randomized to be injected with patent blue, 1 mL total of patent blue (Bleu 
Patenté V, Guerbet, Brussels, Belgium) was injected intradermally and periareolarly 
at 4 sites before the start of the operation. All patients were intradermally and 
periareolarly injected with 1.6 mL total of 500 µM ICG at 4 sites before the start 
of the operation. Patent blue and ICG injections were performed by the surgeon. 
Subsequently, gentle pumping pressure was applied to the injection site for 1 min. 
After surgical scrub and sterile covering of the operation field, NIR fluorescence 
imaging was performed with the imaging head of the Mini-FLARE™ at approximately 
30 cm distance to the surgical field. The lights in the operating room were turned 
off and the complete procedure could be performed using the white light source 
of the Mini-FLARETM.  Camera exposure times were between 5 to 250 ms. A SLN 
exhibiting a signal-to-background ratio (SBR) ≥ 1.1 in situ was considered positive 
by NIR fluorescence. 
 To assess the need for radiocolloids to localize the SLN(s), the surgeon 
did not use the handheld gamma probe during the first 15 min of the operation 
starting from the axillary skin incision. In case the SLN(s) were not localized using 
only ICG or ICG in combination with patent blue within the first 15 min, the surgeon 
was allowed to use the handheld gamma probe for SLN localization.  
 Routine histopathological frozen analysis of SLNs was performed during 
surgery. After frozen section, SLNs were fixed in formalin and embedded in paraffin 
for routine hematoxylin and eosin staining and immunohistopathological staining 
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for AE1/AE3 at 3 levels, with an interval of 150 to 250 µm, according to the Dutch 
guidelines for SLN analysis. Patients underwent an axillary lymph node dissection if 
the SLN was found to contain metastases. If micrometastases (< 0.2 mm) or isolated 
tumor cells were found, no axillary lymph node dissection was performed.
Power Calculation and Statistical Analysis
To show non-inferiority, a power calculation based on data from our previous 
studies 18,19 revealed that 24 patients are needed to achieve 91% power to detect 
a difference of 5.0 in SBR between the 2 groups with the null hypothesis that the 
mean SBR of each group is 10.0 ± the standard deviation of 3.5 and the alternative 
hypothesis that the mean of the no blue dye group is 15.0 with a significance level 
of 0.05 using a two-sided two-sample t test. For statistical analysis, SPSS statistical 
software package (Version 16.0, Chicago, IL) was used. To compare patient 
characteristics, SBR and the number of SLNs identified between the patent blue 
group and no patent blue group, the independent-sample t test and chi-square 
test were used. P < 0.05 was considered significant. 
RESULTS
Patient and Tumor Characteristics: Twenty-four consecutive breast cancer 
patients undergoing SLN mapping using 99mTechnetium-nanocolloid and ICG were 
randomized to be injected with or without patent blue. The median age of the 
included patients was 59 years (range: 39-75) and the median BMI was 24 kg/m2 
(range: 19- 47).  BMI was significantly higher in the no patent blue group (P = 0.042). 
Other patient, tumor, and treatment characteristics were equally distributed over 
the treatment groups (Table 1). The average time between injection of ICG and the 
skin incision was not significantly different between treatment groups and was 15.2 
± 3.0 min and 13.2 ± 3.0 min for the patent blue and no patent blue patient groups, 
respectively. No adverse reactions associated with the use of ICG or the Mini-FLARE 
imaging system occurred. No postoperative complications of the sentinel lymph 
node procedure were observed.
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Table 1 – Patient and Tumor Characteristics
Patent Blue 
(N = 12)
No Patent Blue 
(N = 12)
Characteristic N % N % P
Age in years (Median, 
Range) 54 (39-75) 67 (48-71) 0.15
Body Mass Index 




- II* 2 17 2 17
- III+ 10 83 10 83
Previous Procedure of Breast 0.54
- Excision fibroadenoma 1 8 0 0
- Neoadjuvant Chemotherapy 2 17 1 8
- Neoadjuvant 
Hormonal Therapy 0 0 1 8
Multifocality 0 0 1 8 0.31
Tumor side 0.41
- Left 6 50 7 59
- Right 6 50 5 42
Tumor localization 0.69
- Upper Outer 7 59 7 59
- Lower Outer 0 0 0 0
- Lower Medial 0 0 0 0
- Upper Medial 3 25 3 25
- Central 2 17 2 17
Type of Operation 0.36
- Mastectomy 2 17 3 25
- Wide Local Excision 9 75 9 75
- SNB Only 1 8 0 0
Pathological Tumor 
Size in mm (Median, Range) 15 (5-35) 16 (5-50) 0.12
Histological Type 1
- Infiltrating Ductal 
type Adenocarcinoma 10 83 10 83
- Infiltrating Lobular 
type Adenocarcinoma 1 8 1 8
- Ductal Carcinoma In Situ 1 8 1 8
Histological Grade 0.56
- I 4 33 3 25
- II 4 34 3 25
- III 3 2 5 42
- No grading possible (DCIS) 1 8 1 8
*Skin type II: White: usually burns easily; tans minimally (Northern European), +Skin type III: III. White (average): some-
times burns; tans gradually to light brown (Central European)
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Intraoperative NIR Fluorescence Imaging: In 23 of 24 patients, at least one SLN 
(Figure 1) was identified (Table 2). In one patient included in the no patent blue 
group, no SLN could be detected, even when using the gamma probe A total 
of 19 and 18 SLNs were resected in the patent blue and no patent blue groups, 
respectively. In the patent blue group, 19 of 19 (100%) of SLNs were NIR fluorescent, 
17 of 19 (89%) SLNs were radioactive and 16 of 19 (84%) SLNs were blue. In the no 
patent blue group, 18 of 18 (100%) SLNs were NIR fluorescent and 18 of 18 (100%) 
of SLNs were radioactive. The afferent lymphatics were visualized percutaneously 
in 83% and 75% of patients in the patent blue and no patent blue patient groups, 
respectively. No significant difference was observed. In all patients that were 
administered with patent blue, the NIR fluorescence signal in the SLN was detected 
before patent blue was visualized.
Average brightness of the SLN, expressed in signal-to-background ratio 
(SBR), was 8.3 ± 3.8 and 10.3 ± 5.7 for the patent blue and the no patent blue 
group, respectively (Figure 2; Table 2). No significant difference in SBR was observed 
between the treatment groups (P = 0.32). Average time between skin incision and 
SLN identification was 12.4 ± 7.7 min and 18.1 ± 18.9 min for the blue dye and no 
blue dye patient groups, respectively. No significant difference was observed (P = 
0.35). In one patient in the no patent blue group, time between skin incision and 
SLN detection was 66.91 min. This patient received neoadjuvant chemotherapy, 
and the SLN was located in the area next to the latissimus dorsi muscle. Excluding 
this outlier, average time between skin incision and SLN identification was 12.4 ± 
7.7 min and 13.2 ± 10.3 for the patent blue and no patent blue treatment groups, 
respectively (P = 0.83).  
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Figure 1 - NIR fluorescence imaging during sentinel lymph node mapping in a breast cancer patient: 
In the upper row, the periareolar injection site (open arrowhead) and an afferent lymphatic channel (arrow) 
are clearly visualized. In the lower row, identification of the SLN (arrowhead) with NIR fluorescence imaging 
is demonstrated 10 min after incision. Camera exposure times were 30 ms (top row) and 100 ms (bottom 
row). Scale bars represent 1 cm. Patent blue was omitted in this patient.
Figure 2 – Difference in brightness of SLNs between treatment groups: Signal-to-background ratios 
(mean ± S.D.) of breast SLNs are plotted. The SBRs of blue and no blue patient groups were not significantly 
different.
To assess the need for radiotracers to localize the SLN(s), the surgeon did 
not use the handheld gamma probe during the first 15 min starting from skin 
incision. After the first 15 min, the use of the handheld gamma probe was necessary 
to locate the SLN(s) in 2 patients in the patent blue group and 4 patients in the 
no patent blue group. In all other patients, the handheld gamma probe was only 
used to verify the SLN for radioactivity ex vivo and to verify if any SLNs were missed. 
The average BMI of patients in whom the gamma probe was needed for SLN 
identification (33.1 ± 9.9) was significantly higher than in patients in whom the 
gamma probe could be omitted (24.4 ± 5.4; P < 0.01; Figure 3). 
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Figure 3 - Influence of body-mass index on the necessity to use the gammaprobe:  The BMI of patients 
was plotted. The average BMI of patients in whom the gamma probe was needed for SLN identification (33.1 
± 9.9) was significantly higher than in patients in whom the gamma probe could be omitted (24.4 ± 5.4) (P 
< 0.01).  
DISCUSSION
NIR fluorescence imaging has been extensively described as a tool for the SLN 
procedure in various types of cancer. In previous work, we demonstrated that 
a dose of 500 µM of ICG, without premixing with human serum albumin, was 
optimal to perform NIR fluorescence SLN mapping in breast cancer 18,19. In the 
current randomized clinical trial, the added value of patent blue staining, when 
used in combination with NIR fluorescence, was assessed in breast cancer patients 
undergoing the SLN procedure. Regarding time to identify the SLN, no significant 
difference between the 2 treatment groups was observed. In one patient in the 
no patent blue group, the SLN mapping lasted 67 min. A possible explanation for 
this relatively long time to locate the SLN could be that this patient was treated 
with neoadjuvant chemotherapy (NAC). It has been proposed that NAC alters the 
lymphatic drainage network, thereby possibly hampering the accuracy of the SLN 
procedure.20 This could possibly be an explanation for the difficult identification 
of the SLN in one of our patients. However, in the current study, 2 more patients 
were treated with NAC and in those patients time between skin incision and SLN 
identification was in concordance with the average time between skin incision and 
SLN identification that was observed in all other patients (approximately 13 min). 
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N % N % N %  
Number of SLNs Identified 37 19 18
Number of SLNs 
Identified per Patient 0.54
- No SLN 1 4 0 0 1 8
- One SLN 12 50 7 58 5 42
- Two SLNs 9 38 4 33 5 42
- Three SLNs 1 4 1 8 0 0
- Four SLNs 1 4 0 0 1 8
Average Number of SLNs 
Identified (SD) 1.5 ± 0.8 1.6 ± 0.7 1.5 ± 1.0 0.81
Method of Detection
- Radioactive  35 95 17 89 18 100
- Blue 16 84 16 84 0 0
- Fluorescent 37 100 19 100 18 100
Signal-to-Background 
Ratio 9.2 ± 4.8 8.3 ± 3.8 10.3 ± 5.7 0.32
Percutaneous Lymph 
Drainage Visualization 0.84
- Yes 12 50 6 50 6 50
- Partially 7 29 4 33 3 25
- No 5 21 2 17 3 25
Average Time between 
Injection and Skin Incision 
(min, SD)
14.8 ± 3.3 15.2 ± 3.0 13.8 ± 3.9 0.17
Average Time between 
Skin Incision and SLN 
Resection (min, SD)
12.2 ± 7.9   12.4 ± 7.7   18.1 ± 18.9
0.35
Histology sentinel lymph 
node 0.10
- Negative 16 67 6 50 10 83
- Isolated Tumor Cells 4 17 4 33 0 0
- Micrometastases 2 8 0 0 2 17
- Macrometastases 2 8 2 17 0 0
Axillary Lymph Node 
Dissection 0.14
- No 22 92 10 83 12 100
- Yes 2 8 2 17 0 0
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A meta-analysis of studies that examined the SLN procedure in patients treated 
with NAC included 1273 patients and reported an identification rate of 90% and a 
false-negative rate of 12% 21; additionally, a more recent meta-analysis reported 
similar results.22 These results are not significantly different from meta-analyses 
of SLN biopsy in patients who are naïve to chemotherapy.23 Nonetheless, results 
of SLN biopsy after NAC remain conflicting. The prospective multicenter German 
SENTINA trial is currently accruing patients to evaluate the accuracy of the SLN 
procedure after NAC.
Comparing the patent blue and no patent blue patient groups, brightness 
of the SLNs was higher in the no patent blue group (difference in SBR is 2.0); however, 
this difference was not significant. Furthermore, in the patent blue group, only 84% 
of NIR fluorescent SLNs were stained blue, which is in concordance with previous 
studies.18,19 These results indicate that NIR fluorescence using ICG can replace blue 
dye staining, which would have several advantages. First, the use of blue dyes 
stains the surgical field in an unnatural color that persists over the course of several 
months after surgery. Second, blue dyes cannot be visualized when covered by 
overlying tissue, while ICG can be detected through millimeters to a centimeter of 
overlying tissue. Third, in many cases, ICG can be seen percutaneously, which allows 
lymphatic mapping before surgery, which possibly decreases time to identify the 
SLN.
An obvious next step in the optimization of the SLN procedure would be 
to evaluate the need for radiotracers. Although radiotracers have superior tissue 
penetration, they expose caregivers and patients to ionizing radiation and they can 
only be detected using a gamma probe, which does not provide the surgeon with 
visual information. Furthermore, the time window for SLN identification is limited 
due to the short half-life (6 hours) of 99mTechnetium. To explore the necessity of 
intraoperative radiotracers in addition to NIR fluorescence, the surgeon was not 
allowed to use the gamma probe during the first 15 min of the surgery. In 6 of 
24 patients (25%), the surgeon could not identify the SLN within the first 15 min 
and in one patient, no SLN could be detected at all. In the current study, average 
BMI of patients in whom the gamma probe was used for SLN identification was 
significantly higher than in patients in whom the gamma probe was not necessary. 
These results are in concordance with previous studies that showed a significant 
correlation between time to identify the SLN and BMI 24,25. Furthermore, when only 
patent blue is used for SLN mapping, the SLN detection rate is significantly higher 
in patients with a BMI < 30 compared to patients with a BMI > 30 26. This suggests 
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that BMI plays an important role in selecting those patients whom are eligible 
for NIR fluorescence SLN mapping without the use of radiotracers. However, the 
current study was not powered to compare NIR fluorescence and radiocolloids and 
this has to be addressed in a future sufficiently powered clinical trial. Furthermore, 
since larger series will be required to determine the safety and SLN identification 
rate when radiotracers are omitted,  the use of NIR fluorescence imaging using ICG 
as a lymphatic tracer is at present particularly attractive to hospitals unable to work 
with radioactive isotopes,.
Another approach within the field of SLN mapping is combining 
fluorescence and radioactivity in one lymphatic tracer by simply premixing ICG 
and 99mTc-NanoColl (complex: ICG-99mTc-NanoColl) which has been performed in 
prostate cancer patients.17 Using this multimodal tracer injected by the nuclear 
physician before surgery, time of surgery will probably be shortened because no 
dye injection and massage is needed in the surgical theatre. A clinical trial in breast 
cancer patients using this hybrid multimodal radiocolloid is currently ongoing in 
our center. 
In conclusion, this randomized trial showed no advantage of using patent 
blue for the SLN procedure in breast cancer when NIR fluorescence and radiotracers 
are used. Combining these results with previous work, a dose of 500 µM ICG injected 
in a total of 1.6 ml is recommended for NIR fluorescence SLN mapping in breast 
cancer patients and patent blue can be omitted. 
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The fundamental principle of oncologic surgery is the complete resection of 
malignant cells. However, small tumors are often difficult to find during surgery 
using conventional techniques. Our objectives were to determine if optical imaging, 
using a contrast agent already approved for other indications, could improve 
hepatic metastasectomy with curative intent, to optimize dose and timing, and to 
determine the mechanism of contrast agent accumulation. 
Material and Methods
We exploited the high tissue penetration of near-infrared (NIR) light using the 
FLARE™ image-guided surgery system and the NIR fluorophore indocyanine green 
(ICG) in a clinical trial of 40 patients undergoing hepatic resection for colorectal 
cancer metastases. 
Results
A total of 71 superficially located (< 6.2 mm beneath the liver capsule) colorectal 
liver metastases were identified and resected using NIR fluorescence imaging. 
Median tumor-to-liver ratio (TLR) was 7.0 (range 1.9-18.7) and no significant 
differences between time-points or doses were found. ICG fluorescence was seen 
as a rim around the tumor, which we show to be entrapment around CK7-positive 
hepatocytes compressed by the tumor. Importantly, in 5 of 40 patients (12.5%, 95% 
CI: 5.0-26.6), additional small and superficially located lesions were detected using 
NIR fluorescence, and were otherwise undetectable by preoperative computed 
tomography (CT), intraoperative ultrasound (IOUS), visual inspection, and palpation.
Conclusion
We conclude that NIR fluorescence imaging, even when utilizing a non-targeted, 
clinically available NIR fluorophore, is complementary to conventional imaging and 
able to identify missed lesions by other modalities.  
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INTRODUCTION
Prognosis and survival of colorectal cancer patients depends primarily 
on the occurrence of distant metastases, which occur most frequently in the 
liver.1 A resection with curative intent can offer patients with colorectal liver 
metastases a 5-year survival rate of 36% to 60%.2-5 Despite improvements in 
preoperative imaging modalities, surgical techniques, and chemotherapy 
regimens, intrahepatic recurrence rates vary from 11% to 37.5% after hepatic 
metastasectomy, and 65% to 85% of these recurrences appear within 2 years after 
resection.2,6-9 A possible explanation for this high intrahepatic recurrence rate is 
that some hepatic metastases are already present at the time of liver resection, but 
were undetected by the technology typically available in the community setting, 
namely, preoperative imaging, intraoperative ultrasound (IOUS), and inspection/
palpation by the surgeon. For example, it is known that small and superficially 
located liver metastases are difficult to identify using available imaging modalities 
such as preoperative computed tomography (CT), MRI, and IOUS.10-12 
Near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) 
is a promising technique to intraoperatively visualize the contrast between liver 
metastases and normal liver tissue in real time.13-15 This type of optical imaging is 
relatively inexpensive and is quickly becoming widely available. Unlike visible light, 
which is used to excite fluorophores such as fluorescein, NIR light can penetrate 
several millimeters into tissue and through blood. ICG is excreted exclusively 
into the bile after intravenous injection; it has been hypothesized that colorectal 
liver metastases can be visualized due to passive accumulation of ICG caused by 
hampered biliary excretion, which results in a fluorescent rim around the metastases. 
However, the mechanism of ICG accumulation has not yet been explored.
Recently, Ishizawa et al.13 described the intraoperative detection of 
colorectal liver metastasis using NIR fluorescence imaging after intravenous 
injection of 0.5 mg/kg ICG, 1 to 14 days prior to surgery, as part of an ICG-retention 
liver function test. The dose and interval between ICG injection and surgery are key 
determinants of the remaining background fluorescence signal in the liver and the 
fluorescent rim surrounding the tumor. In a preclinical study in rats performed by 
our group, the influence of injection time prior to surgery and dose of ICG pertaining 
to the contrast between the fluorescent rim around the hepatic metastases and 
normal liver tissue (tumor-to-liver ratio) was examined.16 In this preclinical study, 
the highest tumor-to-liver ratio (TLR) was reached when ICG was injected 72 h prior 
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to surgery. Furthermore, this study demonstrated that even small liver metastases 
(≈ 1 mm) could be identified using NIR fluorescence. In the current study, these 
preclinical results were translated to a clinical trial in patients with colorectal liver 
metastases in order to optimize intraoperative identification of liver metastases 
using ICG. Furthermore, the mechanism of ICG accumulation in the transition area 
between tumor and normal liver tissue was investigated, and the value added by 
NIR fluorescence imaging was determined.
MATERIAL AND METHODS
Preparation and Administration of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2 mM) 
stock solution. Of this stock solution 4 or 8 mL, corresponding to doses of 10 or 20 
mg, were administered intravenously. 
Clinical Trial
The study was approved by the Local Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. All patients were evaluated for 
hepatic treatment by a multidisciplinary specialized liver unit (Surgeon, Oncologist, 
Interventional radiologist and an experienced abdominal radiologist). From 2010 to 
2012, a total of 40 patients with suspected colorectal liver metastases, based on a 
preoperative 4-phase CT-scan (Toshiba Aquilion 64, Tokyo, Japan) of the thorax and 
abdomen with a slice thickness of 5 mm, who were planned to undergo curative 
intended liver resection were included. All patients provided informed consent. 
Exclusion criteria were pregnancy, lactation or an allergy to iodine, shellfish or 
indocyanine green. 
Patients received 10 mg or 20 mg of ICG diluted in a total volume of 4 
mL and 8 mL, respectively, as an intravenous bolus at 24 or 48 h prior to surgery 
on an inpatient base. This resulted in 4 groups of 4 patients per group (N = 16 
patients). Subsequently, 24 patients were included at the optimal combination of 
ICG dose and injection time. After mobilization of the liver, first visual inspection, 
palpation, and IOUS were performed to determine the number and location of the 
liver metastases. To evaluate the additional benefit of NIR fluorescence imaging, all 
28456 Vorst NW.indd   162 13-03-14   12:30
NIR fluorescence-guided resection of colorectal liver metastases
163
liver segments were imaged using the Mini-FLARE™ imaging system, which has 
been described previously.17 Directly following liver resection, resection specimens 
were delivered to the Department of Pathology, where the specimens were sliced 
into 5 to 7 mm thick slices and examined by an experienced pathologist for NIR 
fluorescence using the Mini-FLARE™ imaging system.
Fluorescence Microscopy
Based on macroscopic evaluation and ex vivo fluorescence imaging, tissue was 
acquired from the transition zone between the tumor and the normal liver from 
multiple patients. Excised tissue was snap-frozen and sectioned at 5 μm for 
fluorescence and regular microscopy. Sections were measured for fluorescence 
using the Nuance multispectral imager (CRi, Woburn, MA) mounted on a Leica 
DM IRE2 inverted microscope (Leica, Wetzlar, Germany). Subsequently, these slides 
were stained with hematoxylin and eosin. Consecutive slides were stained for the 
presence of CD31 (Dako, M0823), CK7 (Dako, M7018) and CD68 (Dako, M0814) to 
correlate fluorescence to blood vessels, bile ducts and macrophages, respectively. 
White light images were subsequently merged with fluorescence images.
Statistical Analysis
For statistical analysis, SPSS statistical software package (Version 17.0, Chicago, 
IL) was used. Tumor-to-liver (TLR) signal, rim fluorescence, and background 
fluorescence were reported as median and range. Tumor size was reported as 
mean with standard deviation. To test differences between groups, the Kruskal-
Wallis one-way analysis of variance test was used to test for differences between 
time and dose groups. Statistical tests were 2-tailed and P < 0.05 was considered 
significant. 95% binomial confidence intervals of the percentage of patients in 
whom additional metastases were identified were calculated using the Adjusted 
Wald Method by GraphPad QuickCalcs (GraphPad Software, La Jolla, CA). 





Patient and tumor characteristics of the 40 patients are listed in Table 1. None 
of the patients suffered from hepatitis or liver cirrhosis, and 22 patients received 
neoadjuvant chemotherapy. In 7 patients, no liver resection was performed 
due to invasion of tumor into the portal vein (N = 3), the presence of additional 
irresectable liver metastases (N = 2), or the appearance of lymph node metastases 
(N = 2). Nevertheless, these patients were included for TLR, rim fluorescence, and 
background fluorescence analysis. 
Table 1 – Study subject characteristics (N = 40).
Characteristic Median [Range] or (%)
Age 63 [45 - 77]
BMI 25 [19 - 38]
Sex Male: 21 (52.5%)  Female: 19 (47.5%)
Primary tumor location
 - Colon 21 (52.5%)
 - Sigmoid 5 (12.5%)
 - Rectum 13 (32.5%)
 - Anus 1 (2.5%)
Neo-adjuvant chemotherapy 22 (55.0%)
Type of resection
 - Hemihepatectomy 6 (15.0%)
 - Metastasectomy / segmentectomy 19 (47.5%)
 - Metastasectomy / segmentectomy + RFA 7 (17.5%)
 - RFA only 1 (2.5%)
            - No resection 7 (17.5%)
Abbreviations: BMI: body mass index; RFA: radiofrequency ablation.
Optimization of ICG Dose and Injection Timing (N=16 patients)
To determine the effect of ICG dosage and post injection imaging time, patients were 
allocated to 2 dose groups and imaged at 2 time-points after ICG administration, 
resulting in 4 groups containing 4 patients per group. Fluorescence intensity of the 
rim around the liver metastases was significantly higher than the fluorescent signal 
in the liver (P < 0.001). Median tumor-to-liver ratio (TLR) in all 16 patients was 7.3 
(range: 1.9-18.7). Median TLRs were 5.0 (range: 2.2-15.4), 6.7 (range: 2.7-9.2), 10.5 
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(range: 1.9- 18.7), 8.0 (range: 7.0-9.3) for the 10 mg at 24 hr, 20 mg at 24 hr, 10 mg 
at 48 hr and 20 mg at 48 hr patient group, respectively. Median rim fluorescence 
(normalized pixel value) was 530.1 (range: 257.89-823.0), 938.4 (range: 902.3-1239.1), 
648.6 (range: 137.1-1929.36), 608.5 (range: 507.6-688.1) for the 10 mg at 24 hr, 20 
mg at 24 hr, 10 mg at 48 hr and 20 mg at 48 hr patient group, respectively. Median 
background fluorescence (normalized pixel value) was 98.3 (range: 53.6-127.6), 
209.1 (range: 96.1-356.5), 64.6 (range: 53.4-112.4), and 77.4 (range: 67.5-96.2) for 
the 10 mg at 24 hr, 20 mg at 24 hr, 10 mg at 48 hr, and 20 mg at 48 hr patient group, 
respectively. Using the independent samples Kruskal-Wallis Test, no significant 
differences in signal-to-background ratios (P = 0.70), rim fluorescence (P = 0.67) 
and background fluorescence were observed (P = 0.08). Since no differences in TLRs 
were observed between the various groups, the optimal dose was determined by 
clinical and logistical preferences (the minimal dose of 10 mg of ICG administered 
24 h prior to surgery). 
Intraoperative Detection of Colorectal Liver Metastases (N=40):
Subsequently, 24 more patients were included to assess the added value of NIR 
fluorescence imaging during resection of colorectal liver metastases. Results of 
liver metastases detection are summarized in Table 2. Using a combination of 
preoperative CT scanning, IOUS, visual inspection, and/or palpation, a total of 100 
lesions were identified as suspected colorectal liver metastases. After resection, 3 
of these lesions were histologically proven to be benign, for a net detection of 97 
metastatic lesions by conventional imaging. NIR fluorescence imaging (Figure 1) 
detected a total of 71 lesions proven histologically to be metastases, all of which 
were ≤ 6.2 mm from the surface of the liver capsule. However, only 66 of the 71 
lesions identified using NIR fluorescence overlapped with conventional imaging 
(Table 2 and Figure 2). Most important, in 5 patients (12.5 %, 95% CI 5.0 – 26.6), 
superficially located, otherwise occult liver metastases were detected using NIR 
fluorescence only, but not by conventional imaging (i.e., preoperative CT, IOUS, 
intraoperative visualization, and intraoperative palpation) (Figure 1). Sensitivity 
of the preoperative CT scanning, intraoperative visual inspection/palpation in 
combination with IOUS, and NIR fluorescence imaging were 75%, 95% and 73%, 
respectively. In 3 patients, an additional wedge resection was performed to resect 
these metastases, and in 2 patients the preoperatively planned metastasectomy 
was extended to resect the additional metastases. In these 5 patients, the total 
number of metastases (including the occult metastases detected only by NIR
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Figure 1 – NIR fluorescence imaging of colorectal liver metastases: A colorectal liver metastasis (arrow) 
is clearly identified by a rim around the tumor in vivo (top row), 24 h after injection of 10-mg ICG. Normal liver 
tissue (arrowhead) shows minimal background uptake of ICG. In 5 patients, small, superficial, otherwise 
occult metastases (middle row, arrow) were identified by NIR fluorescence imaging. Benign lesions (bottom 
row, dashed arrow) could be differentiated from malignant lesions by a lack of a fluorescent rim around the 
lesion.
Figure 2 – Methods of detection of colorectal liver metastases: Venn diagram showing how the 97 
hepatic metastases were detected as a function of each modality alone or in combination.
fluorescence) were 4, 3, 3, 2 and 2.  After resection, these lesions were found to be 
2, 3, 4, 6, and 9 mm in diameter. Histopathological examination confirmed these 
lesions to be colorectal liver metastases. One of these 5 occult lesions, which was 9 
28456 Vorst NW.indd   166 13-03-14   12:30
NIR fluorescence-guided resection of colorectal liver metastases
167
Table 2 – Methods of detection.
Modality




patients Size of metastases (mm)
Preoperative CT-scan 73 (75) 39 29.9 ± 19.1
IOUS, palpation and inspection 92 (95) 40 26.3 ± 19.5
NIR fluorescence 71 (73) 37 29.0 ± 29.8
Preoperative CT-scan, IOUS, 
inspection palpation and/or NIR 
fluorescence
97 (100) 40 24.5 ± 19.7
*  Liver metastases were confirmed by histology or in the case of nonresected lesions by clinical appearance, IOUS, and CT.
mm in diameter, was labeled as a complicated cyst based on IOUS and CT, whereas 
the clear NIR fluorescent ring around the lesion suggested that it was a liver 
metastasis. Twenty-six liver metastases (27%) identified by conventional imaging 
could not be detected using NIR fluorescence and all were deeper than 8 mm from 
the liver surface. All fluorescent liver metastases presented a fluorescent rim around 
the tumor. The overall (N=40) median TLR was 7.0 (range, 1.9 – 18.7). The use of 
neoadjuvant chemotherapy did not significantly influence the TLR (7.5 ± 5.1 vs. 7.1 
± 2.9, P = 0.77). In addition to liver metastases, a total of 8 hemangiomas, 13 cysts, 
and 4 bile duct hamartomas were identified in 13 patients. These hemangiomas, 
cysts, and bile duct hamartomas did not show a NIR fluorescent signal or rim (Figure 
1). Thus, NIR fluorescence imaging might help differentiate malignant liver lesions 
from some benign lesions. As might be expected based on the mechanism of ICG 
contrast (described below), extrahepatic tumor-positive lymph nodes were not 
fluorescent (data not shown).  
Ex Vivo Detection of Colorectal Liver Metastases
Liver resection specimens were sliced in 5 to 7-mm slices and subsequently the 
slices were imaged with the Mini-FLARE imaging system. In all patients for whom 
a liver resection was performed (N = 33), ex vivo NIR fluorescence imaging was 
performed. All known metastases were identified ex vivo by a clear fluorescent ring 
around the lesion. 
Immunohistochemistry and Fluorescence Microscopy
Fluorescence signal was located in liver tissue directly surrounding the tumor 
and was located both intracellularly and extracellularly (Figure 3B). In liver tissue, 
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in the area near the tumor, compressed hepatocytes and increased ductular 
transformation, periportal fibrosis, and presence of Kupffer cells were observed. 
Immunohistochemical analysis showed a close relation between fluorescence and 
CK7 staining (Figure 3C). CK7 is expressed by immature hepatocytes in the areas 
of ductular transformation. No relation was found between fluorescence and the 
presence of Kupffer cells (CD68) and blood vessels (CD31).
DISCUSSION
The main objective of this study was to evaluate the potential of intra-
operative NIR fluorescence imaging to improve oncologic resection of colorectal 
metastases to liver. As confirmed by pathological analysis, all superficially located (< 
6.2 mm beneath the liver surface) metastases were identified using NIR fluorescence. 
Additionally, in 5 patients, occult metastases were detected using NIR fluorescence 
only and were missed by conventional detection methods (Figure 2). Moreover, 
this study provides increased understanding of the mechanism responsible for 
the rim fluorescence and increases the understanding of the effect of different 
administration time-points and doses of ICG on tumor detection. This is crucial for 
the implementation of this technique and interpretation of results in future studies. 
An important recent study using visible wavelength optical imaging 
showed real-time identification of ovarian cancer metastases.18 Because of the 
relatively low tissue penetration of visible light, this technology is limited to tumors 
already on the surface of anatomical structures. Even when using NIR fluorescence 
imaging, however, penetration depth is still a major issue. The penetration depth of 
NIR fluorescence light is highly dependent on the optical properties, i.e., absorption 
and scatter, of the tissue being imaged. Liver is highly absorbing compared to 
other tissues, such as breast and subcutaneous tissue of axilla, resulting in higher 
attenuation (i.e., lower signal).19 In the current study, 26 metastases that were 
located 8 mm or more beneath the liver capsule could not be identified using 
NIR fluorescence. Preoperative CT scanning and IOUS are more appropriate for 
deeper lesions and did successfully identify these 26 lesions. However, superficially 
located, small occult metastases are known to be difficult to detect using IOUS, 
inspection, and palpation.10,11 Although IOUS is still required to identify deep (≥ 6 
mm) metastases in the liver, our results suggest that NIR fluorescence imaging is 
complementary and helps to find small, superficially located liver metastases. 
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The use of NIR fluorescence imaging to detect liver metastases is dependent 
on the clearance of ICG by the liver. To optimize the use of this technique, it is 
necessary to examine the influence of ICG dose and timing of ICG administration 
prior to surgery. In the current study, differences in dose and timing did not 
significantly influence the TLR. A previously performed study in rats by our group 
showed an optimal TLR in the group where ICG was administered at 72 h prior 
to surgery.16 In the current clinical study, liver signal at 24 to 48 h postinjection of 
10-mg ICG was comparable to preinjection baseline level which we measured in a 
previous study in patients undergoing a pancreatoduodenectomy, eliminating the 
need to test other time-points.20 Therefore, NIR fluorescence imaging at 72 h after 
ICG administration was not performed. Other clinical work performed by Ishizawa 
et al. suggested an interval between administration of ICG and liver surgery of at 
least 2 days to lower background fluorescence and to obtain adequate TLRs.13 
Figure 3 – Pathologic examination of the tumor border: 
A. After resection and slicing of the same specimen, the rim around the tumor can be visualized ex vivo. 
B. Shown are hematoxylin and eosin (HE) staining with a pseudo-colored green NIR fluorescence overlay  
 of a 20 μm tissue section of a colorectal liver metastasis using a 5 X objective. The fluorescent rim in  
 stromal tissue appears in the transition zone between tumor (T) and normal liver tissue (L). 
C.  Shown is liver tissue located in the fluorescent rim of a colorectal liver metastasis. Consecutive frozen  
 sections (5 μm) are stained with hematoxylin  and eosin (HE) and for CD68, CD31, and CK7.   
 Microscopic color images (left column), NIR fluorescence images (middle column), and a pseudo- 
 colored green merge (right column) were obtained (100X zoom). The NIR fluorescence signal is mainly  
 located intracellularly and shows a high correlation with CK7 staining.
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However, in latter study a substantially higher dose of ICG (0.5 mg/kg; ≈ 35 mg per 
subject) was administered. In the current study, a relatively low dose of ICG (0.13-
0.26 mg/kg) was used and it was therefore possible to reach acceptable TLRs and 
sufficiently low background liver fluorescence at 24 h after administration of 10 mg 
ICG, which is safe and desirable from a logistical point of view. 
Because no clinical data on lesion detection rates and standard deviation 
of the measurements were available prior to the study, a formal sample size 
calculation was not possible. However, we have provided 95% coincidence intervals 
for the 12.5% of patients in which additional lesions were detected only by NIR 
fluorescence (95% CI: 5.0-26.6). Well-powered future studies can now be designed 
based on these data.
The detection rate of additional occult liver metastases during surgery is 
strongly dependent on the preoperative and intraoperative imaging modalities 
used. In the current study preoperative CT and IOUS were acquired to assess 
the extent of the disease. However, multiple novel imaging instruments are 
available for improved preoperative and intraoperative assessment of occult liver 
metastases. MRI benefits from increased soft tissue contrast and the availability of 
hepatocyte-specific contrast agents, which yields a higher sensitivity compared to 
CT for the detection of subcentimeter liver metastases and in case of neoadjuvant 
chemotherapy 21,22. Moreover, FDG-PET or PET-CT has been shown to be of 
additional value to detect extrahepatic disease 21. However, the sensitivity of 
detection of occult liver metastases using PET is not higher than CT 21. Despite the 
possible higher detection rate using MRI, it can be expected that lesions missed 
during preoperative imaging, can be detected during IOUS or palpation, which will 
therefore not significantly alter the finding of the current study. Next to preoperative 
imaging modalities, novel modalities for intraoperative assessment of occult liver 
metastases, such as contrast enhanced IOUS, have been introduced to improve 
sensitivity 23,24. However, NIR fluorescence has been shown to add value when used 
in combination with contrast enhanced IOUS as well 23. 
An important aspect of our study is that it can be readily translated to 
the community setting. First, it utilizes a contrast agent already FDA-approved 
for other indications. Second, multiple optical imaging systems are now available 
commercially and are comparable in size, cost, and upkeep to an IOUS instrument. 
And, finally, unlike PET, MRI, and other emerging imaging technologies that require 
significant infrastructure investment and high operational costs, cart-based optical 
imaging is potentially viable in any clinical setting.
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Although the false-positive rate in the current study was zero, previous 
studies have reported that non-malignant lesions (large regenerative nodules and 
atypical hyperplastic nodules) display ICG uptake.13,14 The pattern of uptake appears 
to be important. In large regenerative nodules and atypical hyperplastic nodules, 
NIR fluorescence is seen throughout the tumor (not rim only). In the benign lesions 
(hemangiomas, cysts, and bile duct hamartomas) of our study, no fluorescence rim 
was seen. Clearly, larger clinical trials will be needed to determine the true false-
positive rate and pattern of uptake of ICG as a function of benign lesion histology.
Using fluorescence microscopy, we observed intracellular accumulation 
of ICG in and around CK7-positive cells directly surrounding the tumor, and being 
compressed by it. The architecture of the liver parenchyma is often changed by the 
presence of hepatic metastases leading to compression of hepatic parenchyma, 
inflammatory infiltrate, ductular transformation, and increased presence of 
immature hepatocytes.25-27 It is known that immature hepatocytes often have 
impaired expression of their organic anion transporters, which are essential for the 
transport of many organic anions, including ICG.28-32 For example, in the absence of 
multidrug resistance P-glycoprotein 2, the biliary excretion of ICG can be reduced 
by 90%.33 Therefore, the pattern of rim fluorescence could be explained by the 
presence of immature hepatocytes in the liver tissue surrounding the tumor that 
have taken up ICG, but exhibit impaired biliary clearance.
As in other areas of surgery, the use of laparoscopy is expanding to liver 
surgery. Minor liver resections such as left lateral hepatectomies are being performed 
laparoscopically as standard-of-care in several centers.34 NIR fluorescence may 
also be of great value in laparoscopic surgery because palpation of the liver is not 
possible and the surgeon can only rely on visual inspection, IOUS, and preoperative 
imaging. To implement NIR fluorescence in laparoscopic liver surgery, laparoscopic 
NIR fluorescence camera systems are currently being developed and tested.35-37
In conclusion, this study demonstrated identification of otherwise 
undetectable cancer metastases in 12.5% of patients and suggests that intraoperative 
NIR fluorescence imaging is complementary to conventional techniques for the 
detection of liver metastases from colorectal cancer and has great potential for 
laparoscopic procedures.
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Intraoperative visualization of pancreatic tumors has the potential to improve 
radical resection rates. Intraoperative visualization of the common bile duct and 
bile duct anastomoses could be of added value. In this study, we explored the 
use of indocyanine green (ICG) for these applications, and attempted to optimize 
injection timing and dose.
Material and Methods
Eight patients undergoing a pancreaticoduodenectomy were injected intravenously 
with 5 or 10 mg ICG. During and after injection, the pancreas, tumor, common bile 
duct, and surrounding organs were imaged in real-time using the Mini-FLARE™ 
near-infrared (NIR) imaging system.
Results
No clear tumor-to-pancreas contrast was observed, except for incidental contrast 
in one patient. The common bile duct was clearly visualized using NIR fluorescence, 
within 10 minutes after injection, with a maximal contrast between 30 to 90 min 
after injection. Patency of biliary anastomoses could be visualized due to biliary 
excretion of ICG. 
Conclusion
No useful tumor demarcation could be visualized in pancreatic cancer patients 
after intravenous injection of ICG. However, the common bile duct and biliary 
anastomoses were clearly visualized during the observation period. Therefore, 
these imaging strategies could be beneficial during biliary surgery in cases where 
the surgical anatomy is aberrant or difficult to identify. 
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INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer-related mortality in 
the United States, with an incidence of approximately 38,000 cases and an estimated 
34,000 deaths. The overall 5-year survival rate is very low (< 5%).1 Approximately 
10% to 15% of patients are eligible for surgical resection, which is presently the only 
potentially curative treatment option. Even after curative resection, the reported 
5-year survival rates are disappointing and vary from 10% to 17 %.2-5 Several factors, 
such as tumor size, lymph node status, tumor grade, and blood vessel invasion are 
correlated with prognosis. Involvement of tumor margins is an important prognostic 
factor, as reported survival for R0 (radical) resections (20.3 months) is twice that 
of R1 resections (10.3 months).6 For preoperative staging and determination of 
resectability, the imaging procedure of choice is a multiphase, multidetector helical 
computed tomography (CT) with intravenous administration of a contrast agent 
combined with an endoscopic ultrasonography.7 
During pancreatic surgery, assessment of the extent of the pancreatic 
tumor is made based on visual inspection and palpation, sometimes in conjunction 
with intraoperative ultrasonography.8,9 Intraoperative tumor identification remains 
challenging, partly because the surrounding pancreatic tissue is frequently 
inflamed. Local recurrence rates of 72% to 86% are reported10-12, which in part could 
be caused by inadequate intraoperative evaluation of the location and extent of 
the tumor.   
 Near-infrared (NIR) fluorescence imaging is a promising technique to 
facilitate intraoperative, real-time, visual information.13-15 In order to detect tumors 
using NIR fluorescence, contrast agents that target tumor-specific characteristics 
can be used to selectively label tumor cells.16-19 Novel NIR fluorescent agents have 
been developed that target tumor-specific cell surface marker16-20, enzymatic 
activity17,19,21, or increased glucose metabolism.22 However, these tumor-specific 
agents are not yet available for clinical use. The only NIR fluorescent contrast 
agents currently available, methylene blue and indocyanine green (ICG), are not 
tumor-specific. However, the enhanced permeability and retention (EPR) effect 
can potentially be used to obtain accumulation of non-targeted contrast agents 
in tumors.23,24 Due to newly formed, more porous blood vessels, molecules can 
passively accumulate into the surrounding tissue. Furthermore, poorly developed 
lymphatics in the tumor result in an increased retention. Previous studies showed 
breast carcinomas and liver tumors could be identified noninvasively with NIR 
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fluorescence using ICG based on the EPR effect.25-28 The aim of our study was to 
assess the applicability of NIR fluorescence imaging using ICG to provide a clear 
tumor-to-background contrast in oncologic pancreatic surgery. 
Because ICG is almost exclusively excreted into the bile, it can also be used for
intraoperative NIR fluorescence exploration of the biliary anatomy.29-31 This can 
be useful in patients with a difficult laparoscopic cholecystectomy, due to an 
aberrant biliary anatomy or an acute cholecystitis, for example. Furthermore, ICG 
can potentially be used to assess anastomosis patency in patients undergoing bile 
duct reconstruction. This is a well-suited setting to study both biliary anatomy and 
anastomosis patency intraoperatively, as the common bile duct can be visualized 
for a long time during pancreaticoduodenectomy.
MATERIAL AND METHODS
Intraoperative Near-Infrared Imaging System (Mini-FLARE™)
Intraoperative imaging was performed using the hand-held Fluorescence-
Assisted Resection and Exploration (Mini-FLARE™) image-guided surgery system 
as described by Mieog et al (manuscript accepted for publication). This system 
consists of two wavelength isolated light sources: a “white” light source, generating 
26,600 lx of 400-650 nm light and a NIR light source, generating 7.7 mW/cm2 of 760 
nm light. Color video and NIR fluorescence images are simultaneously acquired and 
displayed in real-time using custom optics and software that separate the color 
video and NIR fluorescence images. A pseudo-colored (lime green) merged image 
of the color video and NIR fluorescence images is also displayed. The imaging 
head is attached to a flexible gooseneck arm, which permits positioning of the 
imaging head virtually anywhere over the surgical field, even at extreme angles. For 
intraoperative use, the imaging head and imaging system pole stand are wrapped 
in a sterile shield and drape (Medical Technique Inc., Tucson, AZ).
Preparation and Administration of Indocyanine Green
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 mM) 
stock solution. Of this stock solution 2 or 4 mL, corresponding with doses of 5 or 
10 mg, was administered. 
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Clinical Trial
The study was approved by the Local Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. A total of 8 consecutive patients 
with suspected ampullary or pancreatic head carcinoma planned to undergo 
curative resection were included. All patients provided informed consent. 
Exclusion criteria included pregnancy, lactation or an allergy to iodine, shellfish, 
or indocyanine green. The surgical technique used in our center implies a 
standard pancreaticoduodenectomy with resection of peripancreatic tissues 
and lymph nodes. Following resection, reconstruction is performed with 
pancreaticojejunostomy, choledochojejunostomy, and pylorojejunostomy for 
pylorus preserving pancreaticoduodenectomy or a gastrojejunostomy as part of 
Whipple’s procedure. After opening the omental bursa, performing the Kocher 
maneuver, and exploration of the hepatoduodenal ligament, the pancreatic tumor 
was fully exposed. The Mini-FLARE imaging system was positioned 30 centimeters 
above the surgical field. Next, 4 patients were intravenously administrated 5 mg 
ICG diluted in 2 mL sterile water as a bolus and 4 patients were intravenously 
administrated 10 mg ICG diluted in 4 mL sterile water as a bolus. All operating 
room lights, with the exception of the white light and NIR light of the Mini-FLARE 
imaging system, were dimmed. The NIR fluorescence measurements of the 
pancreatic tumor, pancreas, duodenum, stomach, liver, gall bladder, and common 
bile duct were recorded at the time of injection (T=0),  45 seconds and 3-, 10-, 30-, 
60-, 90-, 120-, 180- min post-injection. At each measurement, camera exposure 
times were set appropriately to prevent the NIR fluorescence signal from reaching 
saturation. Bile duct imaging ended at 90 min because the bile duct was resected 
at this time as part of the pancreaticoduodenectomy. Furthermore, imaging of the 
choledochojejunostomy was performed to assess leakage and patency. Fluorescent 
intensity of these structures was quantified using the custom Mini-FLARE software. 
To calculate tumor-to-pancreas ratios, tumor and healthy pancreas regions of 
interest were manually drawn, guided by palpation. Signal-to-background ratios 
(SBR) for the common bile duct were manually drawn, and a background region of 
interest was drawn on direct surrounding tissue.




For statistical analysis and graph design, GraphPad Prism Software (Version 5.01, 
La Jolla, CA) and SPSS (Version 17.0, Chicago, IL) were used. All data were reported 
as mean ± standard deviation or median and range. To compare the signal-to-
background ratios between the two concentration groups, T-tests were used. 
Repeated-measures ANOVAs were used to test differences between time points. 
All statistical tests were two-tailed and P < 0.05 was considered significant. 
RESULTS
Patient and tumor characteristics
Patient and tumor characteristics are listed in Table 1. Eight patients undergoing 
surgery for a suspected ampullary or pancreatic head carcinoma were included in 
the study. In one patient, the common bile duct was cut several minutes after ICG 
administration and therefore measurements beyond 3 min were excluded from the 
analysis. Four patients underwent a complete Whipple procedure, three patients 
underwent a pylorus preserving pancreaticoduodenectomy, and one patient had 
an irresectable tumor, resulting in a biopsy without further resection.
Tumor Imaging
Directly after injection, superficial arterial flow of ICG was identified by NIR 
fluorescence on the surface of the pancreas followed by venous drainage. In the 
5- mg patient group (N = 4), a mean tumor-to-pancreas ratio of 0.89 ± 0.25 was 
observed. In the 10-mg patient group (N = 4), a mean tumor-to-pancreas ratio 
of 1.22 ± 0.39 was observed (Figure 1a). Time had no significant effect on tumor-
to-pancreas ratio (P = 0.899). Tumor-to-pancreas ratios were significantly higher 
in the 10-mg group, when compared to 5-mg group (P = 0.002). In one patient 
(patient 5, 10-mg dose group), a clear NIR fluorescent hotspot was observed on the 
pancreas (Figure 1b). Histological analyses confirmed that the signal corresponded 
to tumor tissue surrounding the pancreatic duct. Other than this incidental finding, 
no contrast was observed.
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Figure 1 - Tumor-to-Pancreas Contrast using NIR Fluorescence and ICG:
A. Tumor-to-pancreas ratios (mean ± SD) of the pancreatic tumors over time, per dose group.
B. Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right panel) of   
 intraoperative imaging of the pancreas. In this example, clear contrast (arrow) is shown between   
 pancreatic tumor and normal pancreatic tissue (P), 20 min after administration of 10 mg of ICG. 
 However, this was an incidental finding in one patient. The duodenum is marked with the letter D.
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A.  Signal-to-background ratios (mean ± SD) of the common bile duct over time, per dose group. Signal-
to-background ratios (SBR) for the common bile duct were calculated. A background region-of- 
interest was drawn on direct surrounding tissue.
B.  Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right panel) of 
intraoperative imaging of the common bile duct in a patient who underwent a cholecystectomy during 
previous surgery, 30 min after administration of 5 mg ICG. A clear contrast is shown between common 
bile duct (arrow) and surrounding tissue. 
C.  Color video (left panel), NIR fluorescence (middle panel) and a color-NIR overlay (right panel) of a 
choledochojejunostomy (arrow), 30 min after completion of the anastomosis. NIR fluorescence signal of 
excreted ICG is visualized intraluminally in the jejunum, indicating anastomotic patency and absence of 
leakage.
Imaging of the Common Bile Duct using NIR Fluorescence
Within 10 min after administration of ICG, the common bile duct, cystic duct, and 
common hepatic duct could clearly be identified by NIR fluorescence (Figure 2a and 
b) in all patients. The NIR fluorescence signal of the liver outshined the left and right 
hepatic ducts and therefore prevented a clear visualization. The fluorescent signal 
of the bile ducts lasted until 90 min postinjection, at which point the bile duct was 
resected, along with the head of the pancreas and the duodenum, as part of the 
pancreaticoduodenectomy. No difference was observed between the 5-mg and 10-mg 
groups (P = 0.849). Time significantly influenced signal-to-background ratio (P = 0.002). 
An optimum was found between 30 and 90 min postinjection, with a maximum mean 
signal-to-background ratio of 6.24 ± 1.32 at 60 min postinjection. After completion of 
the choledochojejunostomy, anastomotic patency could be confirmed by visualizing 
the NIR fluorescence signal passing the anastomosis into the jejunum (Figure 2c). 
DISCUSSION
 The first objective of this study was to exploit the EPR effect23,24 to induce 
retention of the non-targeted probe ICG in pancreatic tumors. However, in all but 
one patient, no useful intraoperative tumor-to-pancreas ratios in pancreatic cancer 
patients were observed using NIR fluorescence and ICG. In one patient, a clear 
hotspot was observed on the pancreas, which corresponded with the resected 
adenocarcinoma. No pathological characteristics were observed that could 
account for this phenomenon. Several factors might explain the observed lack 
of contrast in all other patients. Healthy pancreas tissue showed a relatively high 
uptake of ICG, whereas tumor tissue showed similar uptake. As washout of NIR 
fluorescence signal was comparable in both healthy pancreas tissue and tumor
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The NIR fluorescence signal of the pancreas, stomach, liver, duodenum and 
common bile duct was measured at fixed time intervals (Figure 3). As reported in 
preclinical studies30, within the first 2 min vascular signal (an arterial phase followed 
by a venous phase) could be visualized. The pancreas, stomach and duodenum 
showed comparable washout patterns. As ICG is cleared by the liver, the liver and 
common bile duct exhibited high levels of NIR fluorescence, indicating hepatic 
uptake and clearance in bile. 
Figure 3 - Biodistribution of ICG in Organs Exposed During Pancreaticoduodenectomy: Shown are 
NIR fluorescence intensities of organs exposed during pancreaticoduodenectomy. Measurements of the 
duodenum were taken over an area not containing bile. Intensities are shown over time for both 5 mg (left 
panel) and 10 mg (right panel) groups. 
tissue, no EPR effect could be visualized. This is possibly the result of different tumor 
biology of pancreatic cancer when compared to breast cancer, in which the EPR 
effect has been observed in previous studies. Several earlier studies reported a 
lower perfusion of tumor tissue in comparison with healthy pancreas tissue32,33, 
which might decrease availability of ICG for a potential EPR effect of the tumor. 
Furthermore, previous studies that reported an EPR effect of ICG in breast tumors 
used detection methods (laser scanning or optical tomography), that may detect 
lower concentrations of ICG but require post-processing, and are therefore not 
applicable for real-time intraoperative imaging.26,27 
 Novel NIR fluorescent probes are being developed to increase signal 
penetration depth and decrease background uptake. For multiple applications 
within cancer surgery, it is imperative to design improved tumor targeting probes. 
Tumor targeting can be accomplished by conjugating a fluorophore to a targeting 
ligand such as antibodies or peptides, for example.16,19,21,22 It is expected that several 
of those tumor targeted probes will be available for first-in-human trials within the 
coming years.
 The second objective of this study was to evaluate the biodistribution 
of ICG and its clearance by the liver into the bile. Patients undergoing a 
pancreaticoduodenectomy are well suited for this study, as the bile ducts and 
abdominal organs can be studied for a relatively long time. As stated before, 
iatrogenic common bile duct injury occurs in patients undergoing cholecystectomy. 
A non-invasive imaging modality that can visualize the common bile duct 
intraoperatively could potentially reduce the incidence of common bile duct injury 
28456 Vorst NW.indd   184 13-03-14   12:30
NIR fluorescence imaging of pancreatic tumors
185
in these patients. For example, this technique can help the surgeon identify vital 
structures during difficult laparoscopic cholecystectomies in patients with acute 
cholecystitis or aberrant biliary anatomy. This technique could potentially prevent 
the need to convert to an open procedure. 
 In this study, the common bile duct was identified using NIR fluorescence 
imaging after ICG administration in all patients. This is in concordance with 
preclinical data, described by Matsui et al.30 and in clinical studies of patients 
undergoing cholecystectomy.29,31 A useful contrast between the common bile duct 
and surrounding tissue was observed starting at 10 min postinjection. The optimal 
timing of ICG administration prior to imaging lies between 30 and 90 min. In this 
interval, mean SBRs of 5 to 6 were observed. Ideally, background fluorescence levels 
of all surrounding organs should be minimal. In this study, the liver signal remained 
high throughout the imaging interval. Although this did not prevent a contrast 
being observed between common bile duct and surrounding tissues, future 
studies should focus on optimal timing to minimize background fluorescence, 
especially when studying the liver. Indeed, in a separate study, in which patients 
with colorectal liver metastases were injected intravenously with 10 mg ICG at 24 
hours prior to liver surgery, liver fluorescence decreased to background levels, while 
bile duct imaging was still possible. However, compared to the fluorescent intensity 
observed in the present study, the bile duct signal was significantly decreased by 88 
%.34 Therefore, novel NIR fluorescent agents should be developed that are excreted 
into bile, with minimal liver uptake, thereby reducing background fluorescence 
and increasing the ability to visualize bile ducts. In contrast to most other imaging 
systems, the Mini-FLARE imaging system used in this study can display the NIR 
fluorescence signal in relation to the surgical anatomy, by simultaneously displaying 
color video and NIR fluorescence. This feature is of added benefit in performing 
true image-guided surgery. The Mini-FLARE can only be used during open surgery. 
However, most cholecystectomies are performed by laparoscopy. In order to enable 
intraoperative NIR fluorescence imaging during laparoscopic surgery, laparoscopic 
camera systems are currently being developed and tested.31,35,36 Furthermore, as 
with all novel techniques, large clinical studies are necessary to prove the added 
value of NIR fluorescence imaging in patients undergoing a cholecystectomy. 
These trials can use the data presented in this study to select the optimal time of 
imaging after ICG administration.
 This study showed that no useful tumor demarcation could be visualized in 
pancreatic cancer patients using intraoperative NIR fluorescence imaging after ICG 
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administration. Furthermore, our study showed the ability to visualize the common 
bile duct after ICG administration and demonstrated the influence of time on signal-
to-background ratio. Moreover, patency of the jejunal-biliary anastomosis could be 
visualized. For a translation to clinical practice, larger trials should be executed.  This 
is dependent on broad availability of commercial intraoperative NIR fluorescence 
imaging systems. When these imaging systems become available for use in the 
clinic in the coming years, the true value of this technique can be assessed.
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Intraoperative identification of parathyroid adenomas can be challenging. We 
hypothesized that low-doses methylene blue (MB) and near-infrared fluorescence 
(NIRF) imaging could be used to identify parathyroid adenomas intraoperatively.
Material and Methods
MB was injected intravenously after exploration at a dose of 0.5 mg/kg into 12 
patients who underwent parathyroid surgery. NIRF imaging was performed using 
the Mini-FLARE™ imaging system. 
Results
In 10 of 12 patients, histology confirmed a parathyroid adenoma. In 9 of these 
patients, NIRF could clearly identify the parathyroid adenoma during surgery. 
Seven of these 9 patients had a positive preoperative 99mTc-sestamibi SPECT scan. 
Importantly, in two patients, parathyroid adenomas could be identified only using 
NIRF. 
Conclusion
This is the first study to show that low-dose MB can be used as NIRF tracer for 
identification of parathyroid adenomas, and suggests a correlation with preoperative 
99mTc-sestamibi SPECT scanning.
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INTRODUCTION
Primary hyperparathyroidism is a common endocrine disorder caused by 
overproduction of parathyroid hormone (PTH) by adenomatous or hyperplastic 
parathyroid glands. In hyperparathyroidism patients, resection of these glands is the 
only curative treatment. The wide variability of the anatomical location, shape, and 
number of parathyroid glands makes successful parathyroid surgery challenging. 
Various preoperative imaging modalities contribute to detailed surgical planning, 
which is particularly important when using a minimally invasive surgical approach.1-3 
Currently, a combination of a cervical ultrasonography (US) and a 99mTc-sestamibi 
planar scan, whether or not combined with a single-photon emission computed 
tomography (SPECT) 3D scan, is most often used for preoperative localization. 
However, only few intraoperative imaging modalities are available. Despite that the 
current success rate of parathyroidectomy exceeds 95% without any intraoperative 
imaging adjuncts in the hands of experienced surgeons,1,4 intraoperative imaging 
tools could aid in the localization of difficult localized parathyroid adenoma and in 
addition possibly reduce time of surgery.5 
For intraoperative localization, radioguided parathyroidectomy using 
99mTc-sestamibi has been reported.6,7 This technique, however, lacks real-time visual 
information. High-dose methylene blue (MB), used as a blue dye, was introduced by 
Dudley and colleagues in 19718 for the intraoperative identification of parathyroid 
adenomas  by a simple peripheral infusion.6,9,10 reporting sensitivity and specificity 
of  79% and 93% respectively.10,11 However, a major disadvantage of using MB is that 
the high dose (7.5 mg/kg) required for visualization of blue color by the human 
eye brings a substantial risk of serious adverse events, such as toxic metabolic 
encephalopathy.12 A different, recently introduced, technique is the use of visible 
fluorescence and aminolevulinic acid (ALA) to identify parathyroid glands, which 
was successfully tested in clinical studies.13-15 However, ALA can cause phototoxic 
reactions for which patients have to be shielded from direct light exposure for 
48 hours. Furthermore, sub-surface detectability using ALA is minimal due to 
high absorption and scatter of visible light in living tissue. Therefore, novel and 
improved intraoperative imaging modalities to aid the surgeon in localization of 
the parathyroid glands are needed during parathyroid surgery. 
 Near-infrared (NIR) fluorescence imaging is a promising technique that also 
facilitates intraoperative, real-time, visual information.16-18 This technique is based 
on the use of exogenous NIR fluorescent contrast agents that can be detected 
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by intraoperative imaging systems to visualize specific tissues. Advantage of this 
technique are its high sensitivity and high tissue penetration of approximately 
5 millimeters. As such, it has wide applications, including sentinel lymph node 
mapping in several tumor types.19-22 MB, which was used for parathyroid adenoma 
identification as stated above, has the advantageous property that it becomes 
a moderate-strength fluorophore emitting at ≈ 700 nm when diluted to levels 
that are almost undetectable to the human eye. When lower doses of MB can still 
provide clear identification of parathyroid adenomas using NIR fluorescence, this 
could significantly reduce the risk for adverse events.23 The aim of this study was to 
assess feasibility of using low-dose MB for intraoperative NIR fluorescence-guided 
detection of parathyroid adenomas. Furthermore, the concordance between 




This study was approved by the Medical Ethics Committee of the Leiden University 
Medical Center and was performed in accordance with the ethical standards of 
the Helsinki Declaration of 1975. All patients planning to undergo a resection of a 
parathyroid adenoma for primary hyperparathyroidism or parathyromatosis were 
eligible for participation in the study. Exclusion criteria were pregnancy or lactation, 
the use of serotonin reuptake inhibitors, serotonin, and noradrenalin reuptake 
inhibitors and/or tricyclic antidepressants, severe renal failure, G6PD-deficiency, 
or an allergy to MB. All patients gave informed consent and were anonymized. 
Patients received standard of care diagnostic work-up, which for our center implied 
a preoperative 99mTc-sestamibi-SPECT, which was sometimes combined with a 
low-dose computed tomography (CT) scan for preoperative surgical planning. If 
indicated a preoperative cervical US was performed. After subplatysmal dissection, 
retraction, draping and initial surgical exploration of the suspected parathyroid 
adenoma in the neck region, 0.5 mg/kg of MB (concentration 10 mg/ml) was 
infused intravenously over 5 min. Subsequently, NIR fluorescence imaging of 
the neck region was performed using the Mini-FLARE NIR fluorescence imaging 
system, which has been described previously.20 In one patient a thoracotomy was 
performed after SPECT-CT localization of the parathyroid adenoma in pericardium. 
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After resection of the putative parathyroid adenoma, an intraoperative PTH assay 
was performed. Post-operative histopathological examination was obtained, which 
served as gold standard for parathyroid adenoma identification. Parathyroid tissue 
was snap frozen and sectioned at 10 µm for fluorescence microscopy.
Fluorescence Microscopy
Snap frozen tissue was sectioned at 10 µm for fluorescence microscopy, which was 
performed on a Zeiss LSM 700 Confocal Laser Scanning Microscope and a Zeiss 
HBO 100 Microscope Illuminating System (Jena, Germany) using a 633 nm laser 
for excitation and a 650 nm high pass emission filter. Subsequently, tissue sections 
were stained with hematoxylin and eosin (H&E).
Statistical Analysis
For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, IL) 
was used. Signal-to-background ratios were calculated by dividing the fluorescent 
signal in the parathyroid adenoma by fluorescent signal of surrounding healthy 
tissue. Patient age and body mass index (BMI) were reported in median and range 
and signal-to-background was reported in mean and standard deviation. To 
compare fluorescent signal in the parathyroid adenoma with fluorescent signal in 




Patient characteristics and histological results of the 12 patients included are listed 
in Table 1. Median patient age was 58 years (range 17 – 78 years), median BMI was 
26 (range 18 – 34 kg/m2). Eleven patients were planned for surgery for primary 
hyperparathyroidism and 1 patient suffered from parathyromatosis.  Prior to the 
study, one patient underwent a total thyroid resection, one patient a parathyroid 
adenoma resection, and one patient had undergone previous parathyroid surgery 3 
times as well as a thymectomy. During the current study, a resection of the putative 
diseased tissue was performed in all patients. Histopathological examination 
showed a solitary parathyroid adenoma in 7 patients, two parathyroid adenomas 
in 1 patient, small parathyroid fragments in 1 patient, a parathyroid carcinoma in 
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1 patient and a thyroid carcinoma with a synchronous parathyroid adenoma in 2 
patients. Average maximum diameter of the resected lesions was 15.7 ± 8.7 mm.
Preoperative Imaging
In all patients, a preoperative 99mTc-sestamibi-SPECT scan was performed which 
was combined with a low-dose CT-scan in 10 patients. In 8 of 12 patients, the 99mTc-
sestamibi-SPECT scan could identify the parathyroid adenoma. In 9 of 12 patients 
a preoperative ultrasonography was performed, which was positive in 4 patients. 
Preoperative imaging results are summarized in Table 2. 
Intraoperative NIR Fluorescence Imaging
Intraoperative NIR fluorescent guidance was provided by the Mini-FLARE imaging 
system and MB, which clearly identified a hyperparathyroid adenoma in 9 patients 
(Figs. 1 and 2). Of these patients, the average signal-to-background ratio (SBR) 
was 6.1 ± 4.1. Importantly, in 2 of these 9 NIR fluorescence-positive patients, the 
parathyroid adenoma was not identified using the 99mTc-sestamibi-SPECT scan or 
preoperative ultrasound. In 3 of 12 patients, no intraoperative fluorescent signal 
could be detected. In two of these patients, no parathyroid adenoma was found 
during histological examination (parathyromatosis and a necrotic parathyroid 
carcinoma). In one patient a normal parathyroid adenoma, which contained 
extensive fibrosis and bleeding, was identified. In other words, in 9 of 10 patients 
diagnosed with a parathyroid adenoma, the adenoma could be identified using 
NIR fluorescence. No significant difference was observed between parathyroid 
fluorescence and thyroid fluorescence (322.6 ± 272.1 vs. 220.2 ± 186.7, P = 0.25). 
During the course of the study, no adverse events were observed.  
 In 9 of 12 patients, preoperative results using 99mTc-sestamibi overlapped 
with intraoperative NIR fluorescence. In 1 patient in whom the 99mTc-sestamibi-
scan was positive, no fluorescent signal could be obtained. This patient was found 
to have a parathyroid carcinoma. In 2 patients in whom the 99mTc-sestamibi-scan 
was negative, NIR fluorescence could identify the parathyroid adenoma. In 3 of 9 
patients in whom an ultrasonography was performed, results overlapped with NIR 
fluorescence. The overlap between different imaging modalities and the location 
of the parathyroid glands is schematically shown in Figure 3.
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Figure 1 – Preoperative surgical planning and intraoperative NIR fluorescence-guided resection of a 
parathyroid adenoma located in the neck: 
A: 3D SPECT-CT image 2 h postinjection of 99mTc-sestamibi with visualization of a parathyroid adenoma 
located at the right side of the neck (arrow).
B: During minimally-invasive parathyroid surgery, a parathyroid adenoma is identified using NIR fluorescence 
imaging, 5 and 10 minutes postinjection of 0.5 mg/kg MB. T= thyroid tissue.
Figure 2 – Preoperative surgical planning and intraoperative NIR fluorescence-guided resection of a 
parathyroid adenoma located in the mediastinum:
A: 3D SPECT-CT image 2 h postinjection of 99mTc-sestamibi with visualization of a parathyroid adenoma 
located paratracheally in the mediastinum (arrow).
B: A parathyroid adenoma located paratracheally in the mediastinum is identified using NIR fluorescence 
imaging, 10 minutes postinjection of 0.5 mg/kg MB.
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Figure 3 – Schematic overview of parathyroid adenoma location and corresponding detection 
methods: Shown is the location of all parathyroid adenomas (N = 10) and one parathyroid carcinoma (N = 
1, Asterix) and corresponding imaging modalities with which they were identified. The patient with 
parathyromatosis was excluded from this scheme. 
Fluorescence Microscopy
700 NIR fluorescence signal of methylene blue was located within oncocytic cells 
as confirmed using H&E staining of the same specimen (Fig. 4).
Figure 4 – Histopathological evaluation and fluorescence microscopy: 
Shown are 40X H&E staining (left) of the resected specimen, which shows oncocytic cells with monotone 
round nuclei surrounding a blood vessel. The right image shows the same section stained with 4’,6-diamidino-
2-phenylindole (DAPI) nuclear staining (blue), with the 700 nm NIR fluorescence from MB pseudo-colored in 
yellow. The NIR fluorescent signal is located in the oncocytic cells.
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1 - - + + 5.48
2 + - + + 9.59
3 + - + + 4.37
4 - - - - n/a
5 + * NP + + 2.68
6 - + + - n/a
7 + * + + - n/a
8 + + + + 4.45
9 + + + + 5.50
10 - - + + 1.91
11 + NP + + 5.21
12 + NP + + 15.33
PTH: parathyroid hormone; n/a: not applicable; NIR: Near-infrared; NP: Not performed; SBR: signal-to-
background ratio; *: SPECT without CT was performed
DISCUSSION
 The primary objective of the current study was to test the feasibility of 
NIR fluorescence with low-dose MB (0.5 mg/kg; 15 times lower than the dose used 
for macroscopic identification) to identify parathyroid adenomas during surgery. 
Furthermore, concordance between 99mTc-sestamibi SPECT and intraoperative NIR 
fluorescence imaging results was assessed. Two patients were not diagnosed with 
a parathyroid adenoma. A clear identification of parathyroid adenomas using NIR 
fluorescence was found in 9 of 10 patients who were histologically diagnosed with 
a parathyroid adenoma. Furthermore, a high overlap between imaging results of 
99mTc-sestamibi SPECT and NIR fluorescence was observed.  
 In 3 of 12 patients, no clear identification of the lesion could be obtained 
using NIR fluorescence. In one of these patients, histopathological examination 
revealed a parathyroid carcinoma. This carcinoma was described as a highly 
necrotic lesion, which presumably hampered MB uptake in this lesion. Alternatively, 
carcinoma may not take up MB like benign lesions. One patient suffered from 
extended cervical parathyromatosis and in this patient all parathyroid glands were 
already surgically removed in the past. In this patient, the parathyroid tissue could 
not be demarcated from the surrounding tissue, however no adenomas were 
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present. In one patient with a large parathyroid adenoma, in whom no adequate 
SBR could be obtained, the adenoma contained extensive fibrosis and bleeding. 
The extensive fibrosis and bleeding could have hampered uptake of MB in the 
adenoma, which might also explain the negative 99mTc -sestamibi SPECT scan. 
 A potential pitfall using the technology we describe is the background 
signal in the thyroid gland. It is known from data acquired in patients undergoing 
99mTc-sestamibi radioscintigraphy that adenomatous and hyperplastic parathyroid 
tissue show more avid uptake of 99mTc-sestamibi, although initially this activity 
can be obscured by uptake from the adjacent thyroid gland. The observation that 
abnormal parathyroid tissue commonly retains 99mTc-sestamibi longer than thyroid 
gland tissue has led to the widespread use of delayed imaging.24 Therefore, an early 
(15-30 min.) and delayed (2-3 hr.) imaging sequence is performed. Furthermore, 
a window of 4 hours between administration and imaging was also used in the 
clinical studies that used ALA for parathyroid identification.13,15 In the current study, 
high thyroid gland uptake of MB was observed. We hypothesize that a similar 
delayed imaging protocol could improve the contrast between thyroid gland and 
parathyroid gland tissue. 
Although conventional preoperative imaging modalities (99mTc-sestamibi 
scan and US) achieve an accurate preoperative localization of the adenoma in 
most cases (sensitivity approximately 80% for both techniques), intraoperative 
identification can be challenging.25 In this perspective, time needed to 
intraoperatively localize the adenoma may decrease using NIR fluorescence and 
MB. The comparable biological characteristics of MB and sestamibi, both lipophilic 
and cationic, resulted in a high concordance between the outcome of 99mTc-
sestamibi scans and NIR fluorescence detection in 7 of 9 patients in the current 
study. The results of the 99mTc-sestamibi SPECT-CT may therefore help predict those 
patients that will most likely benefit from NIR fluorescence intraoperative imaging. 
 The current study was the first to show that low-dose MB and NIR 
fluorescence can be used for the intraoperative detection of parathyroid adenomas 
after a simple peripheral infusion. Though this technique will not replace the detailed 
and thorough anatomical knowledge and experience of surgeons, which are the 
key factors for successful parathyroidectomy. Due to the significantly lower doses 
MB that can be used, this technique can provide valuable additional information 
during surgery in a safe manner, provided that proper exclusion criteria are followed. 
However, optimization of MB dose, timing of injection, clinical outcome and patient 
benefit need to be studied in larger clinical trials.  
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A 67-year-old female presented with unexplained abdominal pain. A contrast-
enhanced CT scan of the abdomen incidentally revealed a mass in the uncinate 
process of the pancreas. This mass was resected and based on histopathological 
findings, diagnosed as a solitary fibrous tumor of the pancreas. A solitary fibrous 
tumor is an extremely rare benign mesenchymal tumor that in 65% of cases 
affects the visceral pleura but can also affect extra-pleural sites. The intraoperative 
demarcation of pancreatic tumors, such as a solitary fibrous tumor, can be 
challenging. In this report, the first clear intraoperative identification of a solitary 
fibrous tumor of the pancreas using near-infrared fluorescence and methylene blue 
in a human was shown. 
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INTRODUCTION
Pancreatic tumors are most often adenocarcinomas, but can also be rare 
neuroendocrine tumors and even rarer benign mesenchymal tumors. Diagnostic 
workup of pancreatic tumors is typically performed using contrast-enhanced 
Doppler ultrasound (US), helical computed tomography (CT), enhanced magnetic 
resonance imaging (MRI), and endoscopic US (EUS). However, during pancreatic 
surgery, tumor localization and assessment of the extent of disease is presently 
made using visual inspection and palpation, and in some cases, intraoperative US. 
Inadequate intraoperative tumor identification can lead to recurrent disease and/
or the need for re-exploration. 
Near-infrared (NIR) fluorescence imaging is a promising technique to 
facilitate intraoperative, real time, visual identification of tumors,1,2 which uses tumor-
specific fluorescent contrast agents.3-6 Although several targeted NIR fluorophores 
have shown promise in preclinical model systems, there are no tumor-specific 
contrast agents presently available for clinical use. In fact, the only 2 NIR fluorescent 
contrast agents available clinically, and approved for other indications, are the 700 
nm fluorophore methylene blue (MB) and the 800 nm fluorophore indocyanine 
green (ICG); both agents are classified as non-specific with respect to targeting. MB 
and ICG have been clinically used for decades. MB is used in parathyroid surgery7 
and for the treatment of septic shock8. ICG is used to assess the clearance capacity 
of the liver9 and for angiographies10 and has been used off label for NIR fluorescence 
sentinel lymph node mapping.11
Although the enhanced permeability and retention (EPR) effect can 
potentially be used to accumulate non-targeted contrast agents in tumors,12,13 a 
recent clinical study by our group suggested that intravenously injected ICG did 
not result in improved identification of adenocarcinoma of the pancreas from this 
effect.14 In a different preclinical study by our group, it appeared that intravenous 
injection of MB into transgenic mice resulted in high sensitivity detection of 
insulinomas and a pancreatic neuroendocrine tumor.15 The optimal dose of MB in 
that study was 1 to 2 mg/kg. Based on these results, a clinical study was initiated 
in which patients with a suspected neuroendocrine tumor of the pancreas were 
administered 1.0 mg/kg MB intraoperatively and the pancreas was imaged using 
an optimized NIR fluorescence imaging system. 




A 67-year-old female presented with unexplained abdominal pain. The 
patient did not have jaundice or other symptoms of obstruction. A contrast-
enhanced CT scan of the abdomen incidentally revealed a mass of 1.6 x 2.8 cm 
in the uncinate process of the pancreas (Fig. 1; dashed outline). The mass showed 
hyperattenuation during the arterial phase of contrast administration. Static total 
body and SPECT / low-dose CT scans using In-111-Octreotide showed a normal 
distribution in the body and no uptake in the pancreatic mass (data not shown). 
Moreover, no hormonal hypersecretion was observed. Family history of multiple 
endocrine neoplasia syndrome was negative. A non-functioning neuroendocrine 
tumor was suspected and the patient was planned for resection. During surgery, 
directly after exposure of the uncinate process, NIR fluorescence imaging of the 
pancreatic mass using MB was performed. Afterwards, the lesion was enucleated 
(Fig. 1) while sparing the pancreatic duct and processed for histology. No surgical 
complications or adverse events were reported and the patient was released from 
the hospital 7 days postoperatively. 
Intraoperative NIR Fluorescence Imaging System
NIR fluorescence imaging was performed using the Mini-FLARE™ image-guided 
surgery system as described in detail previously (Fig 2) 16. Briefly, the system consists 
of 2 wavelength separated light sources: a “white” LED light source, generating 
26,600 lx of 400 to 650 nm light to illuminate the surgical field and an NIR LED light 
source, generating 7.7 mW / cm2 of 670 nm fluorescence excitation light. White 
light and NIR fluorescence images are acquired simultaneously and displayed in 
real time, using custom designed optics and software. A pseudo-colored (neon 
red) image of NIR fluorescence superimposed over the white light image is also 
displayed, to provide the NIR fluorescence signal in the proper anatomical context.
Intraoperative NIR Fluorescence Imaging and Fluorescence Microscopy
The current study was approved by the Medical Ethics Committee of the Leiden 
University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. One patient with a suspected 
pancreatic neuroendocrine tumor was included and gave written informed 
consent. In this patient, a dose of 1.0 mg/kg MB (64 mg in 6.4 ml of water; 10 mg/
ml final stock solution concentration) was infused intravenously over 5 min directly 
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after exposure of the uncinate process. After the start of infusion, NIR fluorescence 
imaging of the pancreatic mass and the pancreas was performed approximately 
every 30 seconds for a period of 20 min. Ex vivo NIR fluorescence imaging of the 
sliced resection specimen was performed at the pathology department. NIR 
fluorescence imaging using the Mini-FLARE™ system enabled clear visualization 
of the pancreatic lesion (Fig. 3A). After the infusion time of 5 min, a tumor-to-
background ratio of ≈ 3 was reached and was stable for the next 15 min (Fig. 3B). 
No adverse effects occurred. 
Histopathology
Part of the excised tissue was fixed in formalin and embedded in paraffin for 
hematoxylin and eosin (H&E) and immunohistopathological staining, and part of 
the excised tissue was snap frozen for fluorescence microscopy. Macroscopically, a 
clearly defined well-circumscribed pale tan firm nodule was seen. Sections showed 
an unencapsulated, circumscribed tumor, consisting of a spindle cell proliferation 
with hypercellular areas alternating with hypocellular foci (Fig. 4A). The hypercellular 
areas are made up of spindle shaped cells without cytological atypia. There is no 
cellular pleomorphism, mitoses or necrosis. Furthermore, deposition of abundant 
hyalinized collagen was identified (sometimes keloid-like) and the stroma contained 
several vessels, a few of which were dilated and hemangiopericytic. Several normal 
pancreatic acinar elements are embedded within the mass. No islets of Langerhans 
were identified within the lesion. Additional, immunohistochemical staining shows 
that the tumor cells were positive for CD34, CD99, and Bcl2 (Fig. 4A). CD117 and 
b-catenin were negative (data not shown). Based on these histopathological 
findings the tumor was diagnosed as a solitary fibrous tumor (SFT) of the pancreas. 
Fluorescence Microscopy
Snap frozen tissue was sectioned at 6 µm for fluorescence microscopy and 
additionally stained with a blue 4’,6-diamidino-2-phenylindole (DAPI) nuclear 
staining. Fluorescence microscopy was performed on a Zeiss LSM 700 Confocal 
Laser Scanning Microscope and a Zeiss HBO 100 Microscope Illuminating System 
(Jena, Germany) using a 633 nm laser for excitation and a 650 nm high pass emission 
filter. Subsequently, tissue sections were stained with H&E and overlay images of 
NIR fluorescence were created. Fluorescence signal was located in remnants of the 
exocrine pancreatic tissue, encapsulated by the tumor tissue (Fig 4B). 
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Figure 1: Presurgical and intraoperative visualization of the pancreatic mass (dashed outline) 
Figure 2: The Mini-FLARE imaging sytem
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Figure 3A: Intraoperative near-infrared (NIR) fluorescence imaging
Figure 3B: Signal-to-background ratio of the solitary fibrous tumor
Figure 4A: Histopathological evaluation 
Figure 4B: Fluorescence microscopy




Despite the availability of many preoperative imaging modalities, 
intraoperative identification and demarcation of pancreatic tumors remains 
challenging. In this report, the first clear identification of a SFT of the pancreas 
using NIR fluorescence and MB in a human was shown. A SFT is an extremely rare 
benign mesenchymal tumor that in 65% of cases affects the visceral pleura but 
can also affect extra-pleural sites. Until now, 9 cases of a SFT affecting the pancreas 
have been reported.17-25 In these cases, patients were asymptomatic or complained 
of abdominal pain. 
Although the current study was initiated to assess the ability to 
intraoperatively detect neuroendocrine tumors using NIR fluorescence and MB, 
the unexpected findings in this patient with a SFT in the pancreas are encouraging. 
Although SFTs mimic neuroendocrine tumor radiologically, it remains unknown 
whether MB will provide strong contrast in other non-adenocarcinoma pancreatic 
tumors. SFTs, like neuroendocrine tumors, typically show a hypervascular, 
hyperenhancing mass using contrast-enhanced CT, and because MB is a 
phenothiazine derivative that acts as a perfusion tracer, it remains likely that future 
clinical testing will confirm what has been seen preclinically in neuroendocrine 
tumors.15 Our clinical study enrolling patients with a suspected neuroendocrine 
tumor remains open to accrual. Moreover, NIR fluorescence imaging using 
methylene blue could potentially be translated to patients with other diseases 
giving hypervascular lesions, such as hyperparathyroidism and angiodysplasia of 
the gut. A clinical trial in hyperparathyroidism patients using methylene blue and 
NIR fluorescence is currently ongoing in our center.
In conclusion, the current study demonstrated the first in human NIR 
fluorescence imaging of a SFT in the pancreas using MB, a registered and approved 
pharmaceutical. Larger series will be needed to confirm this result. 
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Complete surgical resection of a tumor still is the single most important prognostic 
factor in most types of cancer. Many preoperative imaging modalities are being used 
to diagnose and stage patients and to finalize the surgical planning. However, during 
surgery only a limited number of tools can be used to identify tumors, and more 
importantly to differentiate between normal tissue and tumor tissue. Since it can 
be extremely challenging to assess the resection margins during surgery, irradical 
resections unfortunately still occur in a substantial part of patients. Near-infrared 
(NIR) fluorescence imaging has the potential to be of major impact on surgical 
treatment and surgical treatment in surgical oncology in particular. Intraoperative 
real-time visualization of tumors and lymph nodes can hopefully decrease the 
number of irradical resections and improve surgical outcome parameters such as 
time of surgery and surgical complications (chapter 1).
This thesis focus on preclinical validation of novel fluorescent contrast agents for 
solid tumor imaging (Part I), the clinical introduction of NIR fluorescence sentinel 
lymph node imaging in several cancer types using indocyanine green (Part II) 
and the clinical translation of NIR fluorescence imaging using clinically available 
fluorescent contrast agents for solid tumor imaging (Part III).
Part 1: Pre-clinical validation of near-infrared image guided surgery
Chapter 2 describes the preclinical optimization of intraoperative visualization 
of colorectal liver metastases using NIR fluorescence and indocyanine green 
(ICG). ICG has shown to passively accumulate around liver metastases, however 
optimal conditions in terms of injection time and dose were never tested. Several 
different time-points of ICG administration prior to surgery and several different 
dose groups were tested in an experimental syngeneic liver metastases rat 
model. All metastases could be identified after ICG injection. The highest tumor-
to-liver ratio was obtained when ICG was administered 72 hours prior to surgery. 
 In head and neck surgery, positive resection margins severely impact patient 
outcome. Intraoperative assessment of resection margins could be of great value and 
has the potential to decrease the number of irradical resections. Since most head and 
neck cancers show high levels of EGFr expression, chapter 3 describes the successful 
use of the EGFr –targeting nanobody 7D12 in an experimental orthotopic tongue 
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cancer mouse model. All tumors could be clearly identified and most importantly, 
the negative control nanobody showed no fluorescent uptake in the tumor. 
 Chapter 4 describes the use of the zwitterionic fluorophore ZW800-1 
which was conjugated to the tumor specific peptide cRGD (targeting integrins) 
and to the a-specific peptide cRAD. These probes were injected in mice bearing 
subcutaneous and orthotopic HT-29 human colorectal tumors. Both subcutaneous 
and orthotopic tumors could be clearly identified using cRGD-ZW800-1. A 
significantly higher signal-to-background ratio (SBR) was observed in mice injected 
with cRGD-ZW800-1 compared to mice injected with cRAD-ZW800-1 or ZW800-
1 alone when measured at 24 h after probe administration. The clearance of 
cRGD-ZW800-1 permitted visualization of the ureters and also generated minimal 
background fluorescence in the gastrointestinal tract.
Part 2: Clinical translation: Sentinel lymph node imaging
In vulvar cancer patients, SLN mapping is standard of care to obtain nodal 
staging. Typically, a blue dye and radiocolloids are being used, which have certain 
disadvantages. In chapter 5, the use of NIR fluorescence imaging was tested 
in vulvar cancer patients using different doses of ICG premixed with human 
serum albumin (complex ICG:HSA). In this study, a high identification rate of 
100% was demonstrated. SLN mapping in vulvar cancer patients is in particular 
an interesting indication since the lymph nodes are often located superficially 
which enables NIR fluorescence imaging to percutaneously identify the SLN. 
  In cervical cancer, sentinel lymph node biopsies are not yet standard of care 
due to disappointing identification rates and high false-negative rates. In chapter 6, 
NIR fluorescence and ICG:HSA was used for sentinel lymph node mapping in cervical 
cancer patients. Three dose levels (1.6 ml of 500, 750 and 1000 μM ICG:HSA) were tested. 
A high intraoperative identification rate of 100% was observed, no false negative 
cases were observed and no significant differences between dose groups could be 
identified. NIR fluorescence therefore has the potential to be used for SLN mapping in 
cervical cancer patients and can thereby possibly prevent a total lymphadenectomy 
in a large number of patients. However, this has to be assessed in larger clinical trials. 
  In-vitro and preclinical studies showed that premixing ICG with HSA 
increased fluorescent yield and increased hydrodynamic diameter, which possibly 
results in better retention in the SLN.1 However, a randomized clinical study 
in breast cancer patients showed no differences between using ICG alone and 
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ICG:HSA.2 This can possibly be explained by the physiologically available proteins 
in lymph fluid, which eliminate the need of premixing with HSA. In chapter 7, 
a randomized study is described, which tested the need of premixing ICG with 
HSA in cervical cancer patients. Based on chapter 6, a dose level of 500μM 
ICG (1.6 ml) alone or ICG:HSA was used. No significant differences could be 
observed between the ICG alone group and the ICG:HSA group. These results 
show that ICG alone can be used for SLN mapping in cervical cancer patients. 
 In chapter 8, the use of NIR fluorescence and ICG:HSA at different 
dose levels was tested in a clinical trial in melanoma patients. In all patients (N 
= 15), the SLN could be identified using NIR fluorescence. Thereby, SLNs could 
be percutaneously identified using NIR fluorescence in several cases. Using NIR 
fluorescence in melanoma patients, time of surgery could possibly be decreased. 
Furthermore, NIR fluorescence outperformed blue dye staining and the 
benefit of using patent blue needs to be assessed in future larger clinical trials. 
 The SLN procedure is not standard of care in oral cavity and oropharynx 
cancer patients. NIR fluorescence imaging using ICG:HSA was tested in patients 
which were planned for surgery for oral cavity or oropharynx carcinoma in chapter 
9. Since standard of care in our center includes a complete neck dissection, a perfect 
platform is created to test the flow to higher tier lymph nodes using ICG:HSA. In all 
patients, a SLN could be identified during surgery and one false-negative case was 
observed. This can be explained by multiple drainage patterns, resulting in a subset 
of SLNs becoming fluorescent later, being incorrectly identified as higher tier lymph 
nodes. Future research should therefore be focused on fluorescent tracers that are 
retained in the first draining node(s), which makes it possible to perform imaging 
later after injection of the dye. 
 Previous clinical studies showed that SLN mapping in breast cancer 
patients can be performed using NIR fluorescence and that 1.6 ml 500uM of ICG 
alone is most optimal to use. In chapter 10, the need to use patent blue when 
using NIR fluorescence and radiocolloids has been assessed in a randomized 
trial. The results of this study show that patent blue can be omitted when NIR 
fluorescence and radiocolloids are used. In all cases, the SLN was identified with 
NIR fluorescence earlier than with patent blue. Furthermore, to preliminarily assess 
the needs of radiocolloids for SLN mapping in breast cancer patients the gamma 
probe was not used during the first 15 minutes of the operation. To identify the 
SLN, the gamma probe was still needed in 25% of patients. However, the body 
mass index of patients in whom the gamma probe was needed to identify the SLN 
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was significantly higher compared to the body mass index of patients in whom 
the SLN could be identified using only NIR fluorescence (33.1 ± 9.9 vs. 24.4 ± 5.4). 
These results suggest that BMI might be used eventually to select those patients 
in whom SLN mapping can be performed without the use of radiocolloids.  
  In summary, this thesis shows that a dose of 500μM of ICG administered 
as a volume of 1.6 ml without the need of premixing with HSA is optimal to 
use for the sentinel lymph node procedure in various cancer types that were 
studied in this thesis. Another recently developed approach is combining 
radioactive colloids with indocyanine green in one multimodal tracer.3,4 The 
advantage of this approach is the necessity of only one injection. Moreover, rather 
than visualizing lymph flow with fluorescence imaging, the hybrid approach 
individually illuminates the very nodes identified on lymphoscintigrams and 
SPECT/CT and thus combines preoperative results with intraoperative findings. 
Part 3: Clinical translation: Solid tumor imaging
Chapter 11 was performed to clinically translate the results from chapter 2. In 
this study, ICG was injected prior to surgery to intraoperatively identify colorectal 
liver metastases using NIR fluorescence imaging. In 40 patients, median tumor-
to-liver ratios of 7.0 (range 1.9-18.7) were observed. No differences in tumor-to-
liver ratios were observed between dose and time groups. Therefore, the lowest 
tested dose of 10 mg is recommended. In 12.5 % (95 % CI: 5.0 -26.6) of patients, 
additional metastases, which would otherwise be missed, could be identified 
and resected using NIR fluorescence. Furthermore, it was shown that ICG 
accumulated in CK7-positive immature hepatocytes. It is known that immature 
hepatocytes often have impaired expression of their organic anion transporters, 
which are essential for the transport of many organic anions, including ICG. 
Consequently, the biliary excretion of ICG in immature hepatocytes can be 
reduced by 90%. Therefore, the pattern of rim fluorescence could be explained 
by the presence of immature hepatocytes in the liver tissue surrounding 
the tumor that have taken up ICG, but exhibit impaired biliary clearance. 
 In chapter 12, an attempt was made to use ICG to explore the enhanced 
permeability and retention (EPR) effect to intraoperatively identify pancreatic 
tumors. Even after a macroscopically curative resection of pancreatic tumors, 
tumor cells might be observed by microscopy at one or more edges of the 
resected specimen in 17–74%.5-7 Better visualization of pancreatic tumors during 
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surgery could therefore decrease the number of irradical resections. The EPR effect, 
which is based on leaky vessels and hampered lymphatic drainage and results in 
passive accumulation of agents in tumors has been described extensively. Since 
no tumor-specific contrast agents are yet available clinically, ICG was injected 
intravenously with the objective to explore the EPR effect in pancreatic cancer 
patients. However, no adequate contrast between tumor and normal pancreatic 
tissue could be observed in all but one patient, unfortunately. This is possibly the 
result of different tumor biology of pancreatic cancer when compared to other 
cancer types. Several earlier studies reported a lower perfusion of tumor tissue 
in comparison with healthy pancreas tissue, which might decrease availability of 
ICG for a potential EPR effect of the tumor.8,9 Concluding, pancreatic cancer is not 
a suitable tumor type to exploit the EPR effect. On the other hand, results will not 
be distorted by the EPR effect when using tumor-targeting fluorescent agents. 
 The intraoperative identification of parathyroid adenomas can be 
challenging, which results in surgical complications and reoperations. In the 
past, methylene blue has been used to macroscopically stain parathyroid 
glands during surgery. However, since high doses were necessary for visual 
identification and toxicity could occur, this was stopped. As methylene blue is a 
medium-strength fluorophore when diluted to doses invisible to the human eye, 
chapter 13 describes the use of NIR fluorescence and low-dose methylene blue 
in parathyroid surgery. In 10 of 12 patients, histology confirmed a parathyroid 
adenoma and in 9 of these patients, NIRF could clearly identify the parathyroid 
adenoma during surgery. Seven of these 9 patients had a positive preoperative 
99mTc-sestamibi SPECT scan. Importantly, in two patients, parathyroid adenomas 
could be identified only using NIRF. This is the first study to show that low-dose 
MB can be used as NIRF tracer for identification of parathyroid adenomas, and 
suggests a correlation with preoperative 99mTcsestamibi SPECT scanning.  
  As discussed in the chapter 13, based on an unknown mechanism, 
methylene blue accumulates in neuro-endocrine tissue. This mechanism could be 
used to identify neuro-endocrine tumors of the pancreas by injecting methylene 
blue during surgery. Chapter 14 describes a case study in which methylene blue was 
intravenously injected in a patient suffering from an extremely rare solitary fibrous 
tumor of the pancreas. In this case, the pancreatic tumor could be clearly identified 
during surgery and maximum tumor-to-background ratio of approximately 3 was 
observed.    
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FUTURE PERSPECTIVES
NIR fluorescent contrast agents
The clinical availability of the fluorescent contrast agents indocyanine green and 
methylene blue, which were used in part II and III of this thesis resulted in a fast 
introduction of NIR fluorescence imaging in cancer surgery. Thereby, it significantly 
contributed to the practical knowledge of using NIR fluorescence imaging during 
surgery. However, both these agents cannot be conjugated to other molecules 
without changing their chemical structure, which will result in the necessity to 
conduct phase 0 and 1 clinical trials. Moreover, fluorescent brightness of both ICG 
and MB are by far not optimal. In order to determine the true clinical benefit of 
this technique, development and clinical assessment of contrast agents tailored 
to specific applications are essential. In this perspective, the development of 
novel targeted probes starts with clinically-compatible fluorophores. Although 
several fluorophores have been studied and tested preclinically, to date only two 
fluorophores made it towards the process of clinical translation. IRDye 800CW 
(LI-COR Biosciences, Lincoln, NE) and ZW800-1 (The FLARE Foundation, Wayland, 
MA) are both small molecules which are easily conjugatable to targeting ligands. 
Initial toxicity studies of both compounds showed no toxicity and the purely renal 
clearance of ZW800-1, and the combined renal and hepatic clearance of IRDye 
800CW, enable these agents to be used for imaging of ureters and bile ducts. 
 Combining these NIR fluorophores with clinically available antibodies could 
usher in a new generation of NIR fluorescent contrast agents. As recently reviewed 
by Scheuer and colleagues10 clinically approved targeted antibodies are available 
for various tumors and tumor markers, for example bevacizumab (Genentech, San 
Francisco, CA) against the vascular endothelial growth factor A, cetuximab against 
the epidermal growth factor receptor (Bristol-Myers Squibb, New York City, NY, and Eli 
Lilly, Indianapolis, IN), and trastuzumab against the human epidermal growth factor 
receptor 2 (Genentech, San Francisco, CA). Indeed, van Dam and colleagues are 
currently accruing patients in the first clinical trial using bevacizumab conjugated to 
IRDye 800CW.11 Next to antibodies, which have several disadvantages such as their 
large size and long circulation time, other smaller targeting molecules have been 
advocated and even successfully translated into the clinic. Cyclic arginine-glycine-
aspartic acid (cRGD) has been extensively used clinically in positron emission 
tomography studies mostly in glioblastoma patients.12-14 cRGD conjugated to 
ZW800-1 (cRGD-ZW800-1) was first described by Choi et al15,16 and was preclinically 
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used to clearly visualize orthotopic colon tumors in mice (unpublished data). 
Another approach to overcome the drawbacks of intact antibodies is the use of 
smaller antigen binding fragments such as nanobodies (chapter 3 of this thesis).17 
Imaging system development and optimization
During the last decade, many different imaging systems, designed and developed 
by both academic and industry groups, for open, laparoscopic, thoracoscopic, 
and robotic surgery were used for NIR fluorescence imaging studies.4,18-24 The 
optics, usability, fluorescence excitation source and power and cost are key issues 
in imaging system design. There should be a balance between maximizing the 
fluence rate of the excitation light, which increases tissue penetration depth 
and minimizing undesirable effects such as skin/eye exposure, irreversible 
photochemical bleaching of the NIR fluorophore, and tissue heating. To avoid these 
issues and to avoid the need to wear laser goggles, fluence rates are mostly limited 
to the 10-25 mW/cm2 range. A few imaging systems are able to acquire multiple 
wavelengths of light at the same time.19,23 This enables the visualization of the 
targeted tissue in relation to the surrounding tissue anatomy. For example, tumor 
identification and nerve visualization in pelvic surgery for rectal cancer would be 
extremely beneficial. Furthermore, using software based correction techniques, it is 
also possible to discriminate between multiple contrast agents emitting at a nearly 
similar wavelength.25,26 NIR fluorescence imaging can also be of particular benefit 
in laparoscopic and robot assisted surgery, in which there exists diminished tactile 
feedback. NIR fluorescence-capable fiberscopic systems are now readily available 
for these applications.4,27,28 Further technical developments of these laparoscopic 
NIR imaging systems are in progress aiming to improve the real-time intraoperative 
display of NIR fluorophores. 
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Limitations and leverage
The major disadvantage of using NIR fluorescence and reason for it being a adjunct 
on rather than a substitute of other imaging modalities is the limited penetration 
depth. NIR fluorescence imaging (which uses reflectance-based systems) is not 
able to visualize structures that are located more than 5 mm to 1 cm beneath 
the tissue surface. Therefore, the field of intraoperative imaging is moving towards 
combining imaging modalities. Imaging modalities based on radioactive tracers, 
such as preoperative PET and SPECT, and intraoperative gamma probes and 
gamma cameras, have depth sensitivity to several cm but cannot provide real-
time and precise visualization. Intraoperative ultrasound imaging also has superior 
depth penetration when compared with NIR fluorescence, but requires tissue 
contact and has problems visualizing smaller and superficial lesions. Combining 
NIR fluorescence imaging with these modalities leverages the key benefits, whilst 
overcoming the limited penetration depth of NIR light. 
Conclusion and path to routine patient care
NIR fluorescence image-guidance during cancer surgery has the potential to change 
patient management by visualizing tissue demarcation in real-time, thereby increasing 
the completeness of surgery and decreasing the morbidity associated with damage 
to normal structures. As stated before, the limited penetration depth will make NIR 
fluorescence imaging complementary to existing techniques rather than replacing 
them. However, results of studies using the first generation imaging systems and 
clinically available contrast agents are extremely promising and feasibility has been 
proven in many clinical studies. That leaves the main question, when will it become 
part of routine patient care?  As we know from other promising imaging techniques 
that made it to wide clinical implementation, such as magnetic resonance imaging 
and computed tomography, adaptation had to satisfy two major criteria; changing 
patient management and being clinically realistic. Thus, it needs to have a significant 
impact on patient care and it cannot disrupt normal workflow. Thereby, since insurance 
companies and governments try to streamline (reign in) health care, a novel imaging 
modality also needs to make patient care faster, better, and cheaper. NIR fluorescence 
imaging has the ability to meet all criteria as the surgeon can possibly identify the 
targeted tissue faster and it will not disrupt normal workflow, as the surgical field will not 
be hampered. If NIR fluorescence imaging will increase the number of radical resections 
and decrease complication rates, then healthcare costs can and will be significantly 
reduced, but most importantly, patient care and prognosis will be improved. 




 1.  Ohnishi S, Lomnes SJ, Laurence RG et al. Organic alternatives to quantum dots for intraoperative near-
infrared fluorescent sentinel lymph node mapping. Mol Imaging 2005; 4:172-181.
 2.  Hutteman M, Mieog JS, van der Vorst JR et al. Randomized, double-blind comparison of indocyanine 
green with or without albumin premixing for near-infrared fluorescence imaging of sentinel lymph 
nodes in breast cancer patients. Breast Cancer Res Treat 2011; 127:163-170.
 3.  Brouwer OR, Klop WM, Buckle T et al. Feasibility of Sentinel Node Biopsy in Head and Neck Melanoma 
Using a Hybrid Radioactive and Fluorescent Tracer. Ann Surg Oncol 2011; 19:1988-1994.
 4.  van der Poel HG, Buckle T, Brouwer OR et al. Intraoperative laparoscopic fluorescence guidance to the 
sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional 
imaging approach using a multimodal tracer. Eur Urol 2011; 60:826-833.
 5.  Jamieson NB, Foulis AK, Oien KA et al. Positive mobilization margins alone do not influence survival 
following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010; 
251:1003-1010.
 6.  Raut CP, Tseng JF, Sun CC et al. Impact of resection status on pattern of failure and survival after 
pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246:52-60.
 7.  Verbeke CS. Resection margins in pancreatic cancer. Surg Clin North Am 2013; 93:647-662.
 8.  Reuter SR, Redman HC, Bookstein JJ. Differential problems in the angiographic diagnosis of carcinoma 
of the pancreas. Radiology 1970; 96:93-99.
 9.  Komar G, Kauhanen S, Liukko K et al. Decreased blood flow with increased metabolic activity: a novel 
sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009; 15:5511-5517.
 10.  Scheuer W, van Dam GM, Dobosz M et al. Drug-based optical agents: infiltrating clinics at lower risk. Sci 
Transl Med 2012; 4:134ps11.
 11.  US National Library of Medicine. VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer. 
Clinicaltrials.gov [online] NCT01508572.  2014. 
 12.  Beer AJ, Haubner R, Goebel M et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective 
tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005; 46:1333-1341.
 13.  Beer AJ, Niemeyer M, Carlsen J et al. Patterns of alphavbeta3 expression in primary and metastatic 
human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008; 49:255-259.
 14.  Beer AJ, Kessler H, Wester HJ et al. PET Imaging of Integrin alphaVbeta3 Expression. Theranostics 2011; 
1:48-57.
 15.  Choi HS, Nasr K, Alyabyev S et al. Synthesis and in vivo fate of zwitterionic near-infrared fluorophores. 
Angew Chem Int Ed Engl 2011; 50:6258-6263.
 16.  Choi HS, Gibbs SL, Lee JH et al. Targeted zwitterionic near-infrared fluorophores for improved optical 
imaging. Nat Biotechnol 2013; 31:148-153.
 17.  Sabrina Oliveira, Guus A.M.S.van Dongen, Marijke Stigter-van Walsum et al. Rapid Visualization of 
Human Tumor Xenografts through Optical Imaging with a Near-infrared Fluorescent Anti–Epidermal 
Growth Factor Receptor Nanobody. Molecular Imaging 2011.
 18.  Hirche C, Engel H, Kolios L et al. An experimental study to evaluate the fluobeam 800 imaging system 
for fluorescence-guided lymphatic imaging and sentinel node biopsy. Surg Innov 2013; 20:516-523.
 19.  Troyan SL, Kianzad V, Gibbs-Strauss SL et al. The FLARE intraoperative near-infrared fluorescence 
imaging system: a first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg 
Oncol 2009; 16:2943-2952.
 20.  Yamauchi K, Nagafuji H, Nakamura T et al. Feasibility of ICG fluorescence-guided sentinel node biopsy 
in animal models using the HyperEye Medical System. Ann Surg Oncol 2011; 18:2042-2047.
 21.  Spinoglio G, Priora F, Bianchi PP et al. Real-time near-infrared (NIR) fluorescent cholangiography in 
single-site robotic cholecystectomy (SSRC): a single-institutional prospective study. Surg Endosc 2013; 
27:2156-2162.
 22.  Mieog JS, Hutteman M, van der Vorst JR et al. Image-guided tumor resection using real-time near-
infrared fluorescence in a syngeneic rat model of primary breast cancer. Breast Cancer Res Treat 2010.
28456 Vorst NW.indd   226 13-03-14   12:30
Summary and Future Perspectives
227
 23.  Crane LM, Themelis G, Pleijhuis RG et al. Intraoperative multispectral fluorescence imaging for the de-
tection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol 2011; 13:1043-
1049.
 24.  Yamashita S, Tokuishi K, Anami K et al. Video-assisted thoracoscopic indocyanine green fluorescence 
imaging system shows sentinel lymph nodes in non-small-cell lung cancer. J Thorac Cardiovasc Surg 
2011; 141:141-144.
 25.  Themelis G, Yoo JS, Ntziachristos V. Multispectral imaging using multiple-bandpass filters. Opt Lett 
2008; 33:1023-1025.
 26.  Kumar AT, Chung E, Raymond SB et al. Feasibility of in vivo imaging of fluorescent proteins using 
lifetime contrast. Opt Lett 2009; 34:2066-2068.
 27.  Borofsky MS, Gill IS, Hemal AK et al. Near-infrared fluorescence imaging to facilitate super-selective 
arterial clamping during zero-ischaemia robotic partial nephrectomy. BJU Int 2013; 111:604-610.
 28.  van der Pas MH, Ankersmit M, Stockmann HB et al. Laparoscopic sentinel lymph node identification in 
patients with colon carcinoma using a near-infrared dye: description of a new technique and feasibility 
study. J Laparoendosc Adv Surg Tech A 2013; 23:367-371.
28456 Vorst NW.indd   227 13-03-14   12:30









Complete chirurgische resectie van een tumor is nog steeds de belangrijkste 
prognostische factor in de meeste typen kanker. Beeldvormende technieken 
worden preoperatief vaak ingezet om patiënten te diagnosticeren, te stadiëren 
en om een chirurgisch plan te maken. Echter, tijdens de operatie kan maar een 
zeer beperkt aantal hulpmiddelen gebruikt worden om tumoren op te sporen en 
nog belangrijker, de grens tussen tumor en normaal weefsel aan te duiden. Daar 
het vaak erg lastig is om de resectiemarges tijdens de operatie te bepalen komen 
irradicale resecties helaas nog in een substantieel deel van patiënten voor. Nabij-
infrarood (NIR) fluorescentie zou in potentie een grote impact kunnen hebben 
op de chirurgische behandeling van tumoren. Intraoperatieve beeldvorming van 
tumoren en lymfeklieren in real-time kan het aantal irradicale resectie hopelijk 
verminderen en de chirurgische outcome verbeteren. 
Dit proefschrift richt zich op de preklinische validatie van nieuwe fluorescente 
contrastmiddelen voor intraoperatieve imaging van solide tumoren (Deel 1), 
de klinische introductie van NIR fluorescentie binnen de schildwachtklier (SLN) 
procedure in verschillende kankertypen met indocyanine groen (ICG) (Deel 2) en 
de klinische translatie van NIR fluorescente beeldvorming van solide tumoren met 
klinisch beschikbare contrastmiddelen (Deel 3).
Deel 1: preklinische validatie van nabij-infrarood fluorescente beeldgeleide 
chirurgie
Hoofdstuk 2 beschrijft de preklinische optimalisatie van intraoperatieve visualisatie 
van colorectale levermetastasen met NIR fluorescentie en indocyanine groen. ICG 
accumuleert passief rondom levermetastasen, echter de optimale condities wat 
betreft tijdstip van injecteren en dosis werden nooit onderzocht. In een syngeen 
levermetastasen ratmodel werden verschillende momenten van injecteren en 
verschillende dosisgroepen met elkaar vergeleken. Alle metastasen werden 
geïdentificeerd middels NIR fluorescentie en ICG. De hoogste tumor-lever ratio 
werd bereikt in de groep waar ICG 72 uur voor de operatie werd geïnjecteerd. 
Tussen verschillende dosisgroepen werd geen significant verschil gevonden.
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In de hoofd-halschirurgie hebben positieve resectiemarges een enorme invloed op 
de overleving van patiënten. Intraoperatieve beoordeling van resectievlakken zou 
van grote waarde zijn en zou het aantal irradicale resecties kunnen verminderen. Daar 
tumoren in het hoofd-halsgebied vaak een hoge epithelial growth factor receptor 
(EGFr) expressie vertonen werd in hoofdstuk 3 het EGFr-targeting nanobody 7D12 
getest in een orthotopisch tongcarcinoom muismodel. Alle tumoren konden 
duidelijk worden geïdentificeerd het negatieve controle nanobody vertoonde 
geen opname in de tumor. 
 Hoofdstuk 4 beschrijft het gebruik van de fluorescente stof ZW800-1, 
welke werd geconjugeerd aan het tumorspecifieke peptide cRGD (target integrines) 
en het aspecifieke cRAD. Deze probes werden geïnjecteerd in muizen met 
humane subcutane en orthotopische HT-29 colontumoren. Zowel de subcutane 
als orthotopische tumoren konden duidelijk worden geïdentificeerd met cRGD-
ZW800-1. Een significant hogere signaal-tot-achtergrond ratio werd gemeten in 
muizen geïnjecteerd met cRGD-ZW800-1 vergeleken met muizen geïnjecteerd 
met cRAD-ZW800-1 of ZW800-1 alleen. Deze metingen werden verricht na 24 
uur. De renale klaring van cRGD-ZW800-1 maakte het mogelijk om de ureteren 
intraoperatief te identificeren met NIR fluorescentie. 
Deel 2: klinische translatie: schildwachtklier procedure
 In patiënten met en vulvacarcinoom wordt de SLN procedure standaard 
uitgevoerd. De conventionele techniek beschrijft het gebruik van een blauwe 
kleurstof en radiocolloiden. Hoofdstuk 5 beschrijft het gebruik van NIR fluorescentie 
in vulvacarcinoom patiënten met verschillende doseringen ICG gemixt met 
humaan serum albumine (complex: ICG:HSA). In deze studie werd een hoge 
identificatieratio van 100% bereikt. De SLN procedure is in deze patiëntenpopulatie 
bij uitstek interessant daar de klieren meestal oppervlakkig gelegen zijn en veelal 
percutaan gedetecteerd konden worden. 
 In patiënten met een cervixcarcinoom wordt de SLN procedure niet 
standaard uitgevoerd wegens tegenvallende identificatie percentages en hoge 
percentages fout-negatieve patiënten.  In hoofdstuk 6 werd NIR fluorescentie en 
ICG:HSA (in drie dosis groepen) gebruikt voor de SLN procedure in patiënten met 
een cervixcarcinoom. Een hoog intraoperatief identificatie percentage van 100% en 
geen fout-negatieve patiënten werden geobserveerd. Er werden geen significante 
verschillen tussen dosisgroepen gevonden. Hoewel het nog onderzocht moet 
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worden in grotere studies zou NIR fluorescentie gebruikt kunnen worden voor de 
SLN procedure in patiënten met cervixcarcinoom en zou hiermee in de toekomst 
veel patiënten een complete lymfadenectomie bespaard kunnen worden. 
 In-vitro en preklinische studies laten zien dat het mixen van ICG met 
HSA de fluorescente eigenschappen verbetert en de hydrodynamische diameter 
vergroot. Hierdoor wordt wellicht een betere retentie in de eerste echilon lymfeklier 
bewerkstelligt. In hoofdstuk 7 wordt een gerandomiseerde studie beschreven 
die het nut van het mixen van ICG met HSA onderzoekt in patiënten met een 
cervixcarcinoom. Op data verkregen uit hoofdstuk 6 werd een dosis van 500μM 
ICG (1.6 ml) gebruikt. Er werden geen significante verschillen tussen de ICG alleen 
groep en de ICG gemixt met HSA groep gevonden. 
 In hoofdstuk 8 werd het gebruik van NIR fluorescentie en ICG:HSA in 
verschillende doseringen getest in patiënten met een melanoom.  In alle 15 patiënten 
kon de SLN (vaak percutaan) geïdentificeerd worden. Verder liet het gebruik van NIR 
fluorescentie et ICG:HSA betere resultaten zien dan het gebruik van patent blauw. 
 De SLN procedure wordt niet standaard uitgevoerd in patiënten met 
tumoren in de mondholte of oropharynx. NIR fluorescentie met behulp van ICG:HSA 
werd getest in patiënten die werden geopereerd aan een tumor in de mondholte of 
oropharynx in hoofdstuk 9. Omdat deze patiëntenpopulatie standaard een volledige 
halsklierdissectie ondergaat ontstond er een ideaal platform om doorstroming van 
ICG:HSA naar hogere echilon klieren te testen. In alle patiënten werd tenminste 1 SLN 
geïdentificeerd waarbij 1 fout-negatieve patiënt geobserveerd werd. Daarbij werd 
geobserveerd dat ICG:HSA relatief snel doorstroomde naar hogere echilon klieren. 
 Eerdere studies lieten zien dat de SLN procedure in borstkanker patiënten 
uitgevoerd kan worden met NIR fluorescentie en dat het gebruik van 1.6 ml 500μM 
ICG alleen de meest optimale condities creëert. In hoofdstuk 10 werd het nut van het 
gebruik van patent blauw naast NIR fluorescentie en het radiocolloid onderzocht in 
een gerandomiseerde studie. Deze studie laat zien dat patent blauw weggelaten kan 
worden wanneer het radiocolloid in combinatie met ICG:HSA gebruikt wordt. Verder 
werd de gammaprobe in deze studie de eerste 15 minuten niet gebruikt om de 
noodzaak van het gebruik van radiocolloiden te testen. Om de SLN te vinden was de 
gammaprobe nog noodzakelijk in 25% van de patiënten. Wel bleken deze patiënten 
een significant hogere body-mass index te hebben, iets wat in de toekomst zou 
kunnen helpen bij de selectie van patiënten waarbij het gebruik van radiocolloiden 
niet meer nodig is. 
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Samengevat beschrijft dit proefschrift dat een dosis van 500μM ICG toegediend 
als een volume van 1.6 ml zonder het premixen van HSA optimaal is voor de SLN 
procedure in verschillende typen kanker. Een andere recentelijk ontwikkelde 
aanpak is het combineren van de radiocolloiden met ICG in 1 multimodale tracer. 
Het voordeel van deze aanpak is de noodzaak van enkel een injectie in plaats van 
twee. Daarnaast kan de data van preoperatieve beeldvormende modaliteiten als 
de lymfoscintigrafiën en de SPECT/CT gerelateerd worden met intraoperatieve 
bevindingen. 
Deel 3: Klinische translatie: beeldvorming van solide tumoren
Hoofdstuk 11 beschrijft de klinische translatie van hoofdstuk 2. In deze studie werd 
ICG voor de operatie intraveneus toegediend om colorectale levermetastasen 
intraoperatief te identificeren middels NIR fluorescentie. In 40 patiënten werd een 
mediane ratio tussen signaal in de tumor en signaal in de lever van 7.0 (bereik 1.9 
– 18.7) geobserveerd. Er werden geen verschillen gevonden tussen dosisgroepen 
en het moment van injectie had geen invloed op de resultaten. Hierdoor werd 
de laagst geteste dosis van 10mg ICG aanbevolen.  In 12.5% van de patiënten 
werd een additionele metastasen gevonden, welke anders gemist zou zijn. 
Immunohistochemische kleuringen lieten zien dat ICG ophoopt in immature 
hepatocyten gelegen rondom de metastasen. 
 In hoofdstuk 12 werd getracht het enhanced-permeability and retention 
(EPR) effect te gebruiken en met ICG en NIR fluorescentie pancreas tumoren te 
identificeren. Het EPR-effect is gebaseerd op lekkende bloedvaten en verminderde 
lymfe afvloed, waardoor er passieve accumulatie in tumoren ontstaat. Helaas bleek 
het met ICG niet mogelijk een adequaat contrast tussen tumor en omliggend 
pancreasweefsel te bereiken. 
 De intraoperatieve identificatie van bijschildklieradenomen kan erg 
uitdagend zijn en resulteert soms in chirurgische complicaties en re-operaties. In het 
verleden werd methyleen blauw (MB) gebruikt voor macroscopische identificatie 
van bijschildklieradenomen. Echter, omdat er hoge doseringen nodig voor een 
goed signaal in het adenoom en dit een risico op toxiciteit met zich mee bracht is 
het gebruik van MB gestopt. Omdat MB een gemiddeld sterke fluorescente stof is 
wanneer verdund tot doses die onzichtbaar zijn met blote oog werd in hoofdstuk 13 
het gebruik hiervan in patiënten met een bijschildklieradenoom onderzocht. In 10 
van de 12 patiënten bevestigde histologisch onderzoek een bijschildklieradenoom. 
28456 Vorst NW.indd   233 13-03-14   12:30
Chapter 16
234
In 9 van deze 10 patiënten kon MB en NIR fluorescentie het bijschildklieradenoom 
intraoperatief duidelijk identificeren. Zeven van deze 9 patiënten had een positieve 
preoperatieve 99mTc-sestamibi SPECT scan. In 2 patiënten in deze studie werd het 
bijschilklieradenoom enkel met NIR fluorescentie gevonden. 
 Zoals besproken in hoofdstuk 13, gebaseerd op een onbekend 
mechanisme, hoopt MB zich op in neuro-endocrien weefsel. Hoofdstuk 14 
beschrijft het succesvol gebruik van MB en NIR fluorescentie in een patiënt met 
een solitaire fibreuze tumor van het pancreas. 
CONCLUSIE
NIR fluorescentie geleide chirurgie heeft de potentie patiëntenzorg te verbeteren 
door de demarcatie van tumor en normaal weefsel tijdens de operatie in beeld te 
brengen. Hiermee zou het aantal irradicale resecties verminderd en de morbiditeit 
geassocieerd met schade aan vitale structuren beperkt kunnen worden. Dan 
rest nog 1 vraag, wanneer zal het deel uit gaan maken van de standaard zorg? 
Zoals we weten van andere veelbelovende beelvormende technieken die brede 
klinische implementatie hebben gekend, zoals de magnetic resonance imaging 
(MRI) en computed tomography (CT), zal moeten voldaan worden aan 2 criteria: 
het kunnen veranderen van patiëntenzorg en klinisch realistisch zijn. Dus, impact 
op patiëntenzorg zonder de normale workflow te beïnvloeden. Daar overheden en 
verzekeringsmaatschappijen voortdurend bezig zijn de zorg te ‘stroomlijnen’ dient 
een nieuwe techniek daarnaast patiëntenzorg ook snelle, effectiever, goedkoper 
en beter te maken. Mijns inziens heeft NIR fluorescentie de potentie aan al deze 
criteria te voldoen en ik verwacht dat de techniek spoedig breed geïmplementeerd 
zal worden. 
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Allereerst ben ik alle patiënten die hebben meegewerkt aan de klinische studies 
zeer dankbaar. De realisatie van dit proefschrift is een team-effort geweest en ik wil 
iedereen die hierbij geholpen heeft hartelijk danken. Er is bij de totstandkoming 
van dit proefschrift een aantal mensen die ik in het bijzonder wil noemen. 
Prof. van de Velde, vanaf onze eerste kennismaking in 2009 was ik onder de 
indruk van uw drive en doortastendheid. Ondanks de ‘hatrick’ van afspraken die ik 
vergeten ben dank ik u voor uw begeleiding, geduld en de vele deuren die u voor 
me geopend heeft. 
Dr. Vahrmeijer, beste Alexander, je rust, zakelijk inzicht en mensenkennis zijn 
uitzonderlijk, jij leerde me dat het soms (lees: vaak) verstandiger en effectiever is 
om om de muur heen te lopen dan er doorheen te willen gaan. Ik blijf me verbazen 
over hoe je een groep jonge, ongeremde honden elke dag weer op een natuurlijke 
wijze in het gareel houdt. 
Prof. Frangioni, dear John, thank you for the warm welcome and the guidance 
you gave me during my research fellowship at your lab in Boston, it was a great 
experience which I will never forget. 
Dan bedank ik het Green Team, een begrip in het LUMC, een dynamische groep 
mannen die ervoor zorgde dat het promoveren voor mij zelfs nog een paar jaar 
langer had mogen duren. 
Sven, pater familias, je energie en vrolijkheid werkte aanstekelijk, dank voor je 
altijd teambuildende initiatieven. Dat wij samen een nieuw ESSO-hoofdstuk zijn 
begonnen vind ik schitterend! 
Merlijn, Hut, ik heb je zien evolueren van oermens tot uomo universale, in slechts 3 
jaar! Dat we beiden geen ‘normale’ promotie hebben gehad en dat dit onze band 
enkel heeft versterkt ben je ongetwijfeld met me eens. Wat hebben we samen een 
mooie tijd gehad, dank daarvoor! 
Bob, hoewel we totaal verschillende persoonlijkheden zijn, vulden we elkaar 
uitstekend aan en hebben we jarenlang zij aan zij het fort bewaakt. Ik heb enorm 
met je gelachen, een hoop prijzen met je uitgedeeld en vond het prachtig om ook 
in de kliniek een tijd met je te werken.
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Mark, korporaal, chef pre-kliniek, met jouw vechtlust weet ik zeker dat de pre-kliniek 
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Noor, Charlotte en Hein, alle ogen zijn op jullie gericht nu! Ik vind het mooi om te 
zien dat de trein onder jullie leiding net zo hard doordendert als toen. 
Dit proefschrift is alleen tot stand kunnen komen dankzij hulp van velen. Graag 
wil ik de volgende groepen mensen bedanken voor hun inzet en hulp: chirurgen, 
gynaecologen, urologen, KNO-artsen en hun arts-assistenten van het LUMC. Verder 
dank ik het Heelkunde research lab, mede-promovendi, de proefdierverzorgers, 
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op je terug kan vallen is iets dat ik koester. Rick van de Langenberg, Face, de knapste 
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Vrienden, jullie zorgen ervoor dat ik altijd met een lach opsta en met een lach ga 
slapen. Wappie Semi’s, Nondejuke, 2003, Koninkies, MELT ‘13, De échte Boston, 44, 
Tiki wiki, Lalalalorentz, de Javakade en de ZA posse; ik prijs mezelf elke dag heel 
gelukkig met zo’n mooie groep mensen om me heen.
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altijd al in je hebt gehad, ben enorm trots op wat je hebt bereikt. 
Papa en mama, het creëren van een veilige thuishaven, waar alles kan en niets 
teveel is geeft me nog steeds veel rust.  Jullie onvoorwaardelijke liefde, steun en 
vertrouwen betekenen alles voor me. Zonder jullie was ik nooit zo ver gekomen. 
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